| 1 |
Shi JT, Chen N, Xu J, Goyal H, Wu ZQ, Zhang JX, Xu HG. Diagnostic Accuracy of Fecal Calprotectin for Predicting Relapse in Inflammatory Bowel Disease: A Meta-Analysis. J Clin Med 2023;12. [PMID: 36769850 DOI: 10.3390/jcm12031206] [Reference Citation Analysis]
|
| 2 |
D'Amico F, Magro F, Caron B, Dignass A, Jairath V, Hart A, Kotze PG, Paridaens K, Awadhi SA, Kobayashi T, Siegmund B, Peyrin-Biroulet L, Danese S. iSTART-II: An Update on the i Support Therapy-Access to Rapid Treatment (iSTART) Approach for Patient-Centered Therapy in Mild-to-Moderate Ulcerative Colitis. J Clin Med 2023;12. [PMID: 36769791 DOI: 10.3390/jcm12031142] [Reference Citation Analysis]
|
| 3 |
Ramos L, Teo-Loy J, Barreiro-de Acosta M. Disease clearance in ulcerative colitis: Setting the therapeutic goals for future in the treatment of ulcerative colitis. Front Med (Lausanne) 2022;9:1102420. [PMID: 36698823 DOI: 10.3389/fmed.2022.1102420] [Reference Citation Analysis]
|
| 4 |
Niklinska-schirtz B, Sauer CG. Fecal Markers in Inflammatory Bowel Disease. Pediatric Inflammatory Bowel Disease 2023. [DOI: 10.1007/978-3-031-14744-9_19] [Reference Citation Analysis]
|
| 5 |
Otley A, Day AS, Zachos M. Nutritional Management of Inflammatory Bowel Disease. Pediatric Inflammatory Bowel Disease 2023. [DOI: 10.1007/978-3-031-14744-9_27] [Reference Citation Analysis]
|
| 6 |
Brand S. Phänotypen und extraintestinale Manifestationen. Pflege bei chronisch-entzündlichen Darmerkrankungen 2023. [DOI: 10.1007/978-3-662-64938-1_5] [Reference Citation Analysis]
|
| 7 |
Liu L, Ouyang H, Su J, Lin Y, Hu Y, Shi H, Xie C. Increased modified DUBLIN scores are associated with serious ulcerative colitis and treatment failure. Therap Adv Gastroenterol 2022;15:17562848221142671. [PMID: 36545387 DOI: 10.1177/17562848221142671] [Reference Citation Analysis]
|
| 8 |
Chilay A, Mehra N, Misra M, Almeida F, Chadha K, Jatale R, Ramchandran S. ROLE OF FECAL CALPROTECTIN FOR ASSESSMENT OF INFLAMMATORY BOWEL DISEASE ACTIVITY, 4-YEAR STUDY DONE IN INDIAN REFERENCE LABORATORY. IJAR 2022. [DOI: 10.36106/ijar/4101226] [Reference Citation Analysis]
|
| 9 |
Cifarelli V, Peche VS, Abumrad NA. Vascular and lymphatic regulation of gastrointestinal function and disease risk. Biochim Biophys Acta Mol Cell Biol Lipids 2022;1867:159207. [PMID: 35882297 DOI: 10.1016/j.bbalip.2022.159207] [Reference Citation Analysis]
|
| 10 |
Puolanne AM, Qadri S, Vesterinen T, Hiltunen S, Mustonen A, Kurki S, Kolho KL, Arola J, Färkkilä M. Can dysplasia surveillance be better targeted in ulcerative colitis by using faecal calprotectin? Scand J Gastroenterol 2022;57:1304-11. [PMID: 35697499 DOI: 10.1080/00365521.2022.2084345] [Reference Citation Analysis]
|
| 11 |
O'Meara D, Duyzend M, Harper B, Silverstein J. Severe, Recurrent Anemia in a 17-Year-Old Female. Clin Pediatr (Phila) 2022;61:659-63. [PMID: 35678025 DOI: 10.1177/00099228221101732] [Reference Citation Analysis]
|
| 12 |
Enderle LL, Köller G, Heilmann RM. Verification of the fCAL turbo immunoturbidimetric assay for measurement of the fecal calprotectin concentration in dogs and cats. J Vet Diagn Invest 2022;:10406387221114031. [PMID: 35879875 DOI: 10.1177/10406387221114031] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 13 |
Fairbrass KM, Gracie DJ, Ford AC. Relative Contribution of Disease Activity and Psychological Health to Prognosis of Inflammatory Bowel Disease During 6.5 Years of Longitudinal Follow-Up. Gastroenterology 2022;163:190-203.e5. [PMID: 35339461 DOI: 10.1053/j.gastro.2022.03.014] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 14 |
Kakiuchi T, Yoshiura M. Vedolizumab as the First-Line of Biologicals for Pediatric Patients With Ulcerative Colitis. Clin Ther 2022:S0149-2918(22)00216-8. [PMID: 35779956 DOI: 10.1016/j.clinthera.2022.06.004] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 15 |
Jun S, Jie L, Ren M, Zhihua R. Secondary Indicators for an Evaluation and Guidance System for Quality of Care in Inflammatory Bowel Disease Centers: A Critical Review of the Inflammatory Bowel Disease Quality of Care Center. Inflammatory Bowel Diseases 2022;28:S3-S8. [DOI: 10.1093/ibd/izac009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 16 |
Bergqvist V, Holmgren J, Klintman D, Marsal J. Real-world data on switching from intravenous to subcutaneous vedolizumab treatment in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2022;55:1389-401. [PMID: 35470449 DOI: 10.1111/apt.16927] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 17 |
Bosch S, Wintjens DSJ, Wicaksono A, Pierik M, Covington JA, de Meij TGJ, de Boer NKH. Prediction of Inflammatory Bowel Disease Course Based on Fecal Scent. Sensors (Basel) 2022;22. [PMID: 35336485 DOI: 10.3390/s22062316] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 18 |
Sturm A, Atreya R, Bettenworth D, Bokemeyer B, Dignaß A, Ehehalt R, Germer C, Grunert PC, Helwig U, Herrlinger K, Kienle P, Kreis ME, Kucharzik T, Langhorst J, Maaser C, Ockenga J, Ott C, Siegmund B, Zeißig S, Stallmach A; Collaborators:. Aktualisierte S3-Leitlinie „Diagnostik und Therapie des Morbus Crohn“ der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) – August 2021 – AWMF-Registernummer: 021-004. Z Gastroenterol 2022;60:332-418. [PMID: 35263784 DOI: 10.1055/a-1713-3941] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 19 |
Kitai T, Nemet I, Engelman T, Morales R, Chaikijurajai T, Morales K, Hazen SL, Tang WHW. Intestinal barrier dysfunction is associated with elevated right atrial pressure in patients with advanced decompensated heart failure. Am Heart J 2022;245:78-80. [PMID: 34929195 DOI: 10.1016/j.ahj.2021.11.014] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 20 |
Salama RI, Ahmed MH. Can Fecal Calprotectin Reflect Your Colonic Status? Journal of Coloproctology. [DOI: 10.1055/s-0041-1739351] [Reference Citation Analysis]
|
| 21 |
Sasidharan S, Sasson AN, Shannon KM, Ananthakrishnan AN. Fecal Calprotectin Is a Predictor of Need for Rescue Therapy in Hospitalized Severe Colitis. Inflamm Bowel Dis 2022;28:1833-7. [PMID: 35134899 DOI: 10.1093/ibd/izac011] [Reference Citation Analysis]
|
| 22 |
Jose SK, Simon B, Simon EG, Eapen A, John RA, Putta T, Dutta AK, Pulimood AB. Comparison of Magnetic Resonance Enterography Global Score (MEGS) with indices of Crohn's disease activity in South Asian population. Abdom Radiol (NY) 2022;47:547-53. [PMID: 34958408 DOI: 10.1007/s00261-021-03381-5] [Reference Citation Analysis]
|
| 23 |
Thuy-Boun PS, Wang AY, Crissien-Martinez A, Xu JH, Chatterjee S, Stupp GS, Su AI, Coyle WJ, Wolan DW. Quantitative metaproteomics and activity-based protein profiling of patient fecal microbiome identifies host and microbial serine-type endopeptidase activity associated with ulcerative colitis. Mol Cell Proteomics 2022;:100197. [PMID: 35033677 DOI: 10.1016/j.mcpro.2022.100197] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 24 |
Pavlidis P, Joshi D, El Sherif Y, Warner B, Gulati S, Alexander J, Cross G, Dew T, Arqoub HA, Devlin J, Heneghan M, Dubois P, Bjarnason I, Powell N, Hayee B. Faecal calprotectin is a surrogate marker of biliary inflammation in primary sclerosing cholangitis associated inflammatory bowel disease. Frontline Gastroenterol 2022;13:497-502. [PMID: 36250171 DOI: 10.1136/flgastro-2021-102053] [Reference Citation Analysis]
|
| 25 |
Fukuchi T, Kawashima K, Koga H, Utsunomiya R, Sugiyama K, Shimazu K, Eguchi T, Ishihara S. Induction of mucosal healing by intensive granulocyte/monocyte adsorptive apheresis (GMA) without use of corticosteroids in patients with ulcerative colitis: long-term remission maintenance after induction by GMA and efficacy of GMA re-treatment upon relapse. J Clin Biochem Nutr . [DOI: 10.3164/jcbn.21-112] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 26 |
Wetwittayakhlang P, Lontai L, Gonczi L, Golovics PA, Hahn GD, Bessissow T, Lakatos PL. Treatment Targets in Ulcerative Colitis: Is It Time for All In, including Histology? J Clin Med 2021;10:5551. [PMID: 34884252 DOI: 10.3390/jcm10235551] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 27 |
Cassinotti A, Corona A, Duca P, Nebuloni M, Maconi G, Fociani P, Ardizzone S. Noninvasive Monitoring After Azathioprine Withdrawal in Patients With Inflammatory Bowel Disease in Deep Remission. Clin Gastroenterol Hepatol 2021;19:2293-2301.e1. [PMID: 34139332 DOI: 10.1016/j.cgh.2021.06.014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 28 |
Kruchinina MV, Svetlova IO, Azgaldyan AV, Gromov AA, Generalov VM, Yakovina IN, Shestov AA. Electrical and viscoelastic parameters of erythrocytes as predictors of exacerbation in inflammatory bowel diseases. Sibirskij nauchnyj medicinskij zhurnal 2021;41:96-112. [DOI: 10.18699/ssmj20210513] [Reference Citation Analysis]
|
| 29 |
Bots S, De Voogd F, De Jong M, Ligtvoet V, Löwenberg M, Duijvestein M, Ponsioen CY, D'Haens G, Gecse KB. Point-of-care Intestinal Ultrasound in IBD Patients: Disease Management and Diagnostic Yield in a Real-world Cohort and Proposal of a Point-of-care Algorithm. J Crohns Colitis 2022;16:606-15. [PMID: 34636839 DOI: 10.1093/ecco-jcc/jjab175] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 30 |
Linares R, Francés R, Gutiérrez A, Juanola O. Bacterial Translocation as Inflammatory Driver in Crohn's Disease. Front Cell Dev Biol 2021;9:703310. [PMID: 34557484 DOI: 10.3389/fcell.2021.703310] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 31 |
Nijakowski K, Rutkowski R, Eder P, Simon M, Korybalska K, Witowski J, Surdacka A. Potential Salivary Markers for Differential Diagnosis of Crohn's Disease and Ulcerative Colitis. Life (Basel) 2021;11:943. [PMID: 34575091 DOI: 10.3390/life11090943] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 32 |
Chen F, Hu Y, Fan YH, Lv B. Clinical Value of Fecal Calprotectin in Predicting Mucosal Healing in Patients With Ulcerative Colitis. Front Med (Lausanne) 2021;8:679264. [PMID: 34414201 DOI: 10.3389/fmed.2021.679264] [Reference Citation Analysis]
|
| 33 |
Yamashita T, Tai S, Tsukahara T, Inoue R. Fusobacterium nucleatum impedes remission of colitis in a mouse model. Biosci Biotechnol Biochem 2021;85:1235-42. [PMID: 33674867 DOI: 10.1093/bbb/zbab029] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 34 |
Brescia P, Rescigno M. The gut vascular barrier: a new player in the gut-liver-brain axis. Trends Mol Med 2021:S1471-4914(21)00154-4. [PMID: 34229973 DOI: 10.1016/j.molmed.2021.06.007] [Cited by in Crossref: 15] [Cited by in F6Publishing: 19] [Article Influence: 7.5] [Reference Citation Analysis]
|
| 35 |
Vidova V, Benesova E, Klanova J, Thon V, Spacil Z. Simultaneous quantitative profiling of clinically relevant immune markers in neonatal stool swabs to reveal inflammation. Sci Rep 2021;11:10222. [PMID: 33986356 DOI: 10.1038/s41598-021-89384-0] [Reference Citation Analysis]
|
| 36 |
Ferdinando D'Amico, David T. Rubin, Paulo Gustavo Kotze, Fernando Magro, Britta Siegmund, Taku Kobayashi, Pablo A. Olivera, Peter Bossuyt, Lieven Pouillon, Edouard Louis, Eugeni Domènech, Subrata Ghosh, Silvio Danese, Laurent Peyrin‐Biroulet. International consensus on methodological issues in standardization of fecal calprotectin measurement in inflammatory bowel diseases. United European Gastroenterol J 2021;9. [PMID: 33961734 DOI: 10.1002/ueg2.12069] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 7.5] [Reference Citation Analysis]
|
| 37 |
Marafini I, Stolfi C, Troncone E, Lolli E, Onali S, Paoluzi OA, Fantini MC, Biancone L, Calabrese E, Di Grazia A, Monteleone I, Lenti MV, Di Sabatino A, Monteleone G. A Pharmacological Batch of Mongersen that Downregulates Smad7 is Effective as Induction Therapy in Active Crohn's Disease: A Phase II, Open-Label Study. BioDrugs 2021;35:325-36. [PMID: 33871807 DOI: 10.1007/s40259-021-00482-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 38 |
Turner D, Ricciuto A, Lewis A, D'Amico F, Dhaliwal J, Griffiths AM, Bettenworth D, Sandborn WJ, Sands BE, Reinisch W, Schölmerich J, Bemelman W, Danese S, Mary JY, Rubin D, Colombel JF, Peyrin-Biroulet L, Dotan I, Abreu MT, Dignass A; International Organization for the Study of IBD. STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD. Gastroenterology 2021;160:1570-83. [PMID: 33359090 DOI: 10.1053/j.gastro.2020.12.031] [Cited by in Crossref: 473] [Cited by in F6Publishing: 458] [Article Influence: 236.5] [Reference Citation Analysis]
|
| 39 |
Labarta-Bajo L, Nilsen SP, Humphrey G, Schwartz T, Sanders K, Swafford A, Knight R, Turner JR, Zúñiga EI. Type I IFNs and CD8 T cells increase intestinal barrier permeability after chronic viral infection. J Exp Med 2020;217:e20192276. [PMID: 32880630 DOI: 10.1084/jem.20192276] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 6.5] [Reference Citation Analysis]
|
| 40 |
Maric V, Jovanovic M, Zdravkovic N, Jovanovic M, Gajovic N, Jurisevic M, Jovanovic M, Jovanovic I. Increased IL-33 and IL-17 in Colorectal Carcinoma Patients with Severe Disease. Serbian Journal of Experimental and Clinical Research 2020;21:239-45. [DOI: 10.2478/sjecr-2018-0034] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 41 |
Liu F, Lee SA, Riordan SM, Zhang L, Zhu L. Global Studies of Using Fecal Biomarkers in Predicting Relapse in Inflammatory Bowel Disease. Front Med (Lausanne) 2020;7:580803. [PMID: 33392214 DOI: 10.3389/fmed.2020.580803] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
|
| 42 |
Muehler A, Slizgi JR, Kohlhof H, Groeppel M, Peelen E, Vitt D. Clinical relevance of intestinal barrier dysfunction in common gastrointestinal diseases. World J Gastrointest Pathophysiol 2020; 11(6): 114-130 [PMID: 33362939 DOI: 10.4291/wjgp.v11.i6.114] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 43 |
Roca M, Rodriguez Varela A, Carvajal E, Donat E, Cano F, Armisen A, Vaya MJ, Ekoff H, Hervas D, Rydell N, Ribes-Koninckx C. Fecal calprotectin in healthy children aged 4-16 years. Sci Rep 2020;10:20565. [PMID: 33239728 DOI: 10.1038/s41598-020-77625-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 44 |
Thuy-boun PS, Wang AY, Crissien-martinez A, Xu JH, Chatterjee S, Stupp GS, Su AI, Coyle WJ, Wolan DW. Quantitative metaproteomics of patient fecal microbiota identifies host and microbial proteins associated with ulcerative colitis.. [DOI: 10.1101/2020.11.11.378836] [Reference Citation Analysis]
|
| 45 |
Jafri L, Siddiqui A, Sidddique S, Parkash O, Kausar R, Majid H. Clinical Spectrum in a Cohort of Patients With High Fecal Calprotectin Levels. Cureus 2020;12:e11314. [PMID: 33282590 DOI: 10.7759/cureus.11314] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 46 |
Armuzzi A, Bouhnik Y, Cummings F, Bettey M, Pieper B, Kang T. Enhancing treatment success in inflammatory bowel disease: Optimising the use of anti-TNF agents and utilising their biosimilars in clinical practice. Dig Liver Dis 2020;52:1259-65. [PMID: 32601035 DOI: 10.1016/j.dld.2020.06.008] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 47 |
Khaki-Khatibi F, Qujeq D, Kashifard M, Moein S, Maniati M, Vaghari-Tabari M. Calprotectin in inflammatory bowel disease. Clin Chim Acta 2020;510:556-65. [PMID: 32818491 DOI: 10.1016/j.cca.2020.08.025] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 9.7] [Reference Citation Analysis]
|
| 48 |
Soleymani S, Moradkhani A, Eftekhari M, Rahmanian F, Moosavy SH. Correlation between Clinical Symptoms and Lab Tests with Endoscopic Severity Indexes in Patients with Inflammatory Bowel Diseases. Middle East J Dig Dis 2020;12:162-70. [PMID: 33062221 DOI: 10.34172/mejdd.2020.178] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 49 |
Nijakowski K, Surdacka A. Salivary Biomarkers for Diagnosis of Inflammatory Bowel Diseases: A Systematic Review. Int J Mol Sci 2020;21:E7477. [PMID: 33050496 DOI: 10.3390/ijms21207477] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 50 |
Kang EA, Chun J, Im JP, Lee HJ, Han K, Soh H, Park S, Kim JS. Anemia is associated with the risk of Crohn's disease, not ulcerative colitis: A nationwide population-based cohort study. PLoS One 2020;15:e0238244. [PMID: 32898174 DOI: 10.1371/journal.pone.0238244] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 51 |
Bertani L, Mumolo MG, Tapete G, Albano E, Baiano Svizzero G, Zanzi F, Ceccarelli L, Bellini M, Marchi S, Costa F. Fecal calprotectin: current and future perspectives for inflammatory bowel disease treatment. Eur J Gastroenterol Hepatol 2020;32:1091-8. [PMID: 32282400 DOI: 10.1097/MEG.0000000000001731] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 7.3] [Reference Citation Analysis]
|
| 52 |
Ishida N, Miyazu T, Matsuura T, Takano R, Tamura S, Kagami T, Tani S, Yamade M, Hamaya Y, Iwaizumi M, Osawa S, Furuta T, Sugimoto K. Effect of ulcerative colitis duration on the usefulness of immunochemical fecal occult blood test result as a disease activity biomarker. Int J Colorectal Dis 2020;35:1729-39. [PMID: 32472230 DOI: 10.1007/s00384-020-03636-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 53 |
Pai YC, Weng LT, Wei SC, Wu LL, Shih DQ, Targan SR, Turner JR, Yu LC. Gut microbial transcytosis induced by tumor necrosis factor-like 1A-dependent activation of a myosin light chain kinase splice variant contributes to IBD. J Crohns Colitis 2020;15:258-72. [PMID: 32770194 DOI: 10.1093/ecco-jcc/jjaa165] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
|
| 54 |
Martos L, Oto J, Fernández-Pardo Á, Plana E, Solmoirago MJ, Cana F, Hervás D, Bonanad S, Ferrando F, España F, Navarro S, Medina P. Increase of Neutrophil Activation Markers in Venous Thrombosis-Contribution of Circulating Activated Protein C. Int J Mol Sci 2020;21:E5651. [PMID: 32781781 DOI: 10.3390/ijms21165651] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 3.7] [Reference Citation Analysis]
|
| 55 |
Laserna-Mendieta EJ, Lucendo AJ. Faecal calprotectin in inflammatory bowel diseases: a review focused on meta-analyses and routine usage limitations. Clin Chem Lab Med 2019;57:1295-307. [PMID: 30785706 DOI: 10.1515/cclm-2018-1063] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 56 |
Dai C, Jiang M, Sun MJ, Cao Q. Fecal Lactoferrin for Assessment of Inflammatory Bowel Disease Activity: A Systematic Review and Meta-Analysis. J Clin Gastroenterol 2020;54:545-53. [PMID: 30994521 DOI: 10.1097/MCG.0000000000001212] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
|
| 57 |
Langhorst J, Kairey L, Oberle A, Boone J, Dobos G, Juette H, Tannapfel A, Rueffer A. Assessing Histological Inflammatory Activity in Patients With Ulcerative Colitis: A Diagnostic Accuracy Study Testing Fecal Biomarkers Lactoferrin and Calprotectin. Crohns Colitis 360 2020;2:otaa053. [PMID: 36776494 DOI: 10.1093/crocol/otaa053] [Reference Citation Analysis]
|
| 58 |
Li Y, Khamou M, Schaarschmidt BM, Umutlu L, Forsting M, Demircioglu A, Haubold J, Koch AK, Bruckmann NM, Sawicki LM, Herrmann K, Boone JH, Langhorst J. Comparison of 18F-FDG PET-MR and fecal biomarkers in the assessment of disease activity in patients with ulcerative colitis. Br J Radiol 2020;93:20200167. [PMID: 32579403 DOI: 10.1259/bjr.20200167] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 59 |
Matsuda Y, Ozawa N, Shinozaki T, Wakabayashi KI, Suzuki K, Kawano Y, Ohtsu I, Tatebayashi Y. Ergothioneine, a metabolite of the gut bacterium Lactobacillus reuteri, protects against stress-induced sleep disturbances. Transl Psychiatry 2020;10:170. [PMID: 32467627 DOI: 10.1038/s41398-020-0855-1] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 8.3] [Reference Citation Analysis]
|
| 60 |
Matsuda Y, Ozawa N, Shinozaki T, Wakabayashi K, Suzuki K, Kawano Y, Ohtsu I, Tatebayashi Y. Ergothioneine, a metabolite of the gut bacterium Lactobacillus reuteri, protects against stress-induced sleep disturbances.. [DOI: 10.1101/2020.03.26.009423] [Reference Citation Analysis]
|
| 61 |
Pai YC, Yu LC. Is "Cholinergic" Stimulus Useful for Ulcerative Colitis Treatment? Dig Dis Sci 2020;65:6-8. [PMID: 31696383 DOI: 10.1007/s10620-019-05933-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 62 |
Abedin N, Seemann T, Kleinfeld S, Ruehrup J, Röseler S, Trautwein C, Streetz K, Sellge G. Fecal Eosinophil Cationic Protein Is a Diagnostic and Predictive Biomarker in Young Adults with Inflammatory Bowel Disease. J Clin Med 2019;8:E2025. [PMID: 31756948 DOI: 10.3390/jcm8122025] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 63 |
Cremer A, Ku J, Amininejad L, Bouvry MR, Brohet F, Liefferinckx C, Devière J, van Gossum A, Smet J, Stordeur P, Franchimont D. Variability of Faecal Calprotectin in Inflammatory Bowel Disease Patients: An Observational Case-control Study. J Crohns Colitis 2019;13:1372-9. [PMID: 30944925 DOI: 10.1093/ecco-jcc/jjz069] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 64 |
Sathananthan D, Rajagopalan A, Van De Ven L, Martin S, Fon J, Costello S, Bryant RV. Point-of-care gastrointestinal ultrasound in inflammatory bowel disease: An accurate alternative for disease monitoring. JGH Open 2020;4:273-9. [PMID: 32280777 DOI: 10.1002/jgh3.12269] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 65 |
Berinstein JA, Steiner CA, Bousvaros A, Tiongco FP, Greenberg E, Hardi R, Lembo AJ, Friedenberg K, Sedghi S, Fint A, Florez DA, Kumar A, Arsenescu R, Park KT, Kupchak P, Grob A, Leavitt J, Higgins PDR. The Clinical Accuracy of the BÜHLMANN fCAL ELISA in the Differentiation of Inflammatory Bowel Disease From Irritable Bowel Syndrome: A Multicenter Prospective Case–Control Study. Crohn's & Colitis 360 2019;1:otz037. [DOI: 10.1093/crocol/otz037] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 66 |
Af Björkesten CG, Jussila A, Kemppainen H, Hallinen T, Soini E, Mankinen P, Valgarðsson S, Veckman V, Nissinen R, Naessens D, Molander P. Relationship of faecal calprotectin and long-term outcomes in Finnish patients with Crohn's disease: retrospective multi-centre chart review study. Scand J Gastroenterol 2019;54:1226-32. [PMID: 31532265 DOI: 10.1080/00365521.2019.1667426] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 67 |
Wang C, Baer HM, Gaya DR, Nibbs RJB, Milling S. Can molecular stratification improve the treatment of inflammatory bowel disease? Pharmacol Res 2019;148:104442. [PMID: 31491469 DOI: 10.1016/j.phrs.2019.104442] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 68 |
Engström J, Lönnkvist M, Befrits R, Ljung T, Diaz-Tartera H, Holst M, Hellström PM. Comparison of fecal calprotectin and serum C-reactive protein in early prediction of outcome to infliximab induction therapy. Scand J Gastroenterol 2019;54:1081-8. [PMID: 31499013 DOI: 10.1080/00365521.2019.1660402] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 69 |
Cai J, Chen H, Weng M, Jiang S, Gao J. Diagnostic and Clinical Significance of Serum Levels of D-Lactate and Diamine Oxidase in Patients with Crohn's Disease. Gastroenterol Res Pract 2019;2019:8536952. [PMID: 31531016 DOI: 10.1155/2019/8536952] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 70 |
Majster M, Almer S, Boström EA. Salivary calprotectin is elevated in patients with active inflammatory bowel disease. Arch Oral Biol 2019;107:104528. [PMID: 31442931 DOI: 10.1016/j.archoralbio.2019.104528] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 71 |
Lee HJ, Kim JH, Hong S, Hwang I, Park SJ, Kim TI, Kim WH, Yu JW, Kim SW, Cheon JH. Proteomics-based functional studies reveal that galectin-3 plays a protective role in the pathogenesis of intestinal Behçet's disease. Sci Rep 2019;9:11716. [PMID: 31406212 DOI: 10.1038/s41598-019-48291-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 72 |
Puolanne AM, Kolho KL, Alfthan H, Färkkilä M. Is home monitoring of inflammatory bowel disease feasible? A randomized controlled study. Scand J Gastroenterol 2019;54:849-54. [PMID: 31264494 DOI: 10.1080/00365521.2019.1618910] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 73 |
Ricciuto A, Griffiths AM. Clinical value of fecal calprotectin. Crit Rev Clin Lab Sci 2019;56:307-20. [PMID: 31088326 DOI: 10.1080/10408363.2019.1619159] [Cited by in Crossref: 37] [Cited by in F6Publishing: 30] [Article Influence: 9.3] [Reference Citation Analysis]
|
| 74 |
Scaioli E, Belluzzi A, Ricciardiello L, Del Rio D, Rotondo E, Mena P, Derlindati E, Danesi F. Pomegranate juice to reduce fecal calprotectin levels in inflammatory bowel disease patients with a high risk of clinical relapse: Study protocol for a randomized controlled trial. Trials 2019;20:327. [PMID: 31171016 DOI: 10.1186/s13063-019-3321-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 75 |
Mahdipour M, Shafaghi A, Mansour-ghanaei F, Hojati A, Joukar F, Mavaddati S. Fecal calprotectin role in diagnosis of ulcerative colitis and treatment follow-up. Journal of Coloproctology 2019;39:115-120. [DOI: 10.1016/j.jcol.2018.10.012] [Reference Citation Analysis]
|
| 76 |
F. Csáki K, Sebestyén É. Who will carry out the tests that would be necessary for proper safety evaluation of food emulsifiers? Food Science and Human Wellness 2019;8:126-35. [DOI: 10.1016/j.fshw.2019.04.001] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 77 |
Bjarnason I, Sission G, Hayee B. A randomised, double-blind, placebo-controlled trial of a multi-strain probiotic in patients with asymptomatic ulcerative colitis and Crohn's disease. Inflammopharmacology 2019;27:465-73. [PMID: 31054010 DOI: 10.1007/s10787-019-00595-4] [Cited by in Crossref: 60] [Cited by in F6Publishing: 46] [Article Influence: 15.0] [Reference Citation Analysis]
|
| 78 |
Jones GR, Fascì-Spurio F, Kennedy NA, Plevris N, Jenkinson P, Lyons M, Wong L, MacLean P, Glancy S, Lees CW. Faecal Calprotectin and Magnetic Resonance Enterography in Ileal Crohn's Disease: Correlations Between Disease Activity and Long-Term Follow-Up. J Crohns Colitis 2019;13:442-50. [PMID: 30452618 DOI: 10.1093/ecco-jcc/jjy187] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 79 |
Zhang P, Jiao H, Wang C, Lin Y, You S. Chlorogenic Acid Ameliorates Colitis and Alters Colonic Microbiota in a Mouse Model of Dextran Sulfate Sodium-Induced Colitis. Front Physiol 2019;10:325. [PMID: 30971953 DOI: 10.3389/fphys.2019.00325] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 80 |
Aluzaite K, Al-Mandhari R, Osborne H, Ho C, Williams M, Sullivan MM, Hobbs CE, Schultz M. Detailed Multi-Dimensional Assessment of Fatigue in Inflammatory Bowel Disease. Inflamm Intest Dis. 2019;3:192-201. [PMID: 31111036 DOI: 10.1159/000496054] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 81 |
Simon EG, Wardle R, Thi AA, Eldridge J, Samuel S, Moran GW. Does fecal calprotectin equally and accurately measure disease activity in small bowel and large bowel Crohn's disease? - a systematic review. Intest Res. 2019;. [PMID: 30704158 DOI: 10.5217/ir.2018.00114] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 5.8] [Reference Citation Analysis]
|
| 82 |
Lynn AM, Loftus EV. Luminal Crohn’s Disease. Biomarkers in Inflammatory Bowel Diseases 2019. [DOI: 10.1007/978-3-030-11446-6_6] [Reference Citation Analysis]
|
| 83 |
Navaneethan U. Diagnosis of Pouch Disorders: Laboratory Tests. Pouchitis and Ileal Pouch Disorders 2019. [DOI: 10.1016/b978-0-12-809402-0.00019-8] [Reference Citation Analysis]
|
| 84 |
Monteiro S, Dias de Castro F, Leite S, Moreira MJ, Cotter J. Low fecal calprotectin predicts clinical remission in Crohn's disease patients: the simple answer to a challenging question. Scand J Gastroenterol 2019;54:49-54. [PMID: 30663515 DOI: 10.1080/00365521.2018.1549683] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 85 |
Iwamoto F, Matsuoka K, Motobayashi M, Takenaka K, Kuno T, Tanaka K, Tsukui Y, Kobayashi S, Yoshida T, Fujii T, Saito E, Yamaguchi T, Nagahori M, Sato T, Ohtsuka K, Enomoto N, Watanabe M. Prediction of disease activity of Crohn's disease through fecal calprotectin evaluated by balloon-assisted endoscopy. J Gastroenterol Hepatol 2018;33:1984-9. [PMID: 29889986 DOI: 10.1111/jgh.14310] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 86 |
Yu LC. Microbiota dysbiosis and barrier dysfunction in inflammatory bowel disease and colorectal cancers: exploring a common ground hypothesis. J Biomed Sci 2018;25:79. [PMID: 30413188 DOI: 10.1186/s12929-018-0483-8] [Cited by in Crossref: 167] [Cited by in F6Publishing: 174] [Article Influence: 33.4] [Reference Citation Analysis]
|
| 87 |
Kim DJ, Jeoun YM, Lee DW, Koo JS, Lee SW. Usefulness of fecal immunochemical test and fecal calprotectin for detection of active ulcerative colitis. Intest Res 2018;16:563-70. [PMID: 30301335 DOI: 10.5217/ir.2018.00020] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 88 |
Guardiola J, Lobatón T, Cerrillo E, Ferreiro-iglesias R, Gisbert JP, Domènech E, Chaparro M, Esteve M, Rodríguez-moranta F. Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on the utility of the determination of faecal calprotectin in inflammatory bowel disease. Gastroenterología y Hepatología (English Edition) 2018;41:514-29. [DOI: 10.1016/j.gastre.2018.05.018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 89 |
Guardiola J, Lobatón T, Cerrillo E, Ferreiro-iglesias R, Gisbert JP, Domènech E, Chaparro M, Esteve M, Rodríguez-moranta F. Recomendaciones del Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU) sobre la utilidad de la determinación de calprotectina fecal en la enfermedad inflamatoria intestinal. Gastroenterología y Hepatología 2018;41:514-29. [DOI: 10.1016/j.gastrohep.2018.05.029] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 4.8] [Reference Citation Analysis]
|
| 90 |
Mumolo MG, Bertani L, Ceccarelli L, Laino G, Di Fluri G, Albano E, Tapete G, Costa F. From bench to bedside: Fecal calprotectin in inflammatory bowel diseases clinical setting. World J Gastroenterol 2018; 24(33): 3681-3694 [PMID: 30197475 DOI: 10.3748/wjg.v24.i33.3681] [Cited by in CrossRef: 101] [Cited by in F6Publishing: 104] [Article Influence: 20.2] [Reference Citation Analysis]
|
| 91 |
Libertucci J, Dutta U, Kaur S, Jury J, Rossi L, Fontes ME, Shajib MS, Khan WI, Surette MG, Verdu EF, Armstrong D. Inflammation-related differences in mucosa-associated microbiota and intestinal barrier function in colonic Crohn's disease. Am J Physiol Gastrointest Liver Physiol 2018;315:G420-31. [PMID: 29848021 DOI: 10.1152/ajpgi.00411.2017] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 6.4] [Reference Citation Analysis]
|
| 92 |
Jha AK, Chaudhary M, Dayal VM, Kumar A, Jha SK, Jha P, Purkayastha S, Ranjan R. Optimal cut-off value of fecal calprotectin for the evaluation of ulcerative colitis: An unsolved issue? JGH Open 2018;2:207-13. [PMID: 30483591 DOI: 10.1002/jgh3.12074] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 93 |
Turner D, Ruemmele FM, Orlanski-Meyer E, Griffiths AM, de Carpi JM, Bronsky J, Veres G, Aloi M, Strisciuglio C, Braegger CP, Assa A, Romano C, Hussey S, Stanton M, Pakarinen M, de Ridder L, Katsanos K, Croft N, Navas-López V, Wilson DC, Lawrence S, Russell RK. Management of Paediatric Ulcerative Colitis, Part 1: Ambulatory Care-An Evidence-based Guideline From European Crohn's and Colitis Organization and European Society of Paediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 2018;67:257-91. [PMID: 30044357 DOI: 10.1097/MPG.0000000000002035] [Cited by in Crossref: 210] [Cited by in F6Publishing: 157] [Article Influence: 42.0] [Reference Citation Analysis]
|
| 94 |
Buisson A, Vazeille E, Minet-Quinard R, Goutte M, Bouvier D, Goutorbe F, Pereira B, Barnich N, Bommelaer G. Fecal Matrix Metalloprotease-9 and Lipocalin-2 as Biomarkers in Detecting Endoscopic Activity in Patients With Inflammatory Bowel Diseases. J Clin Gastroenterol 2018;52:e53-62. [PMID: 28723856 DOI: 10.1097/MCG.0000000000000837] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 95 |
Shimoyama T, Yamamoto T, Umegae S, Matsumoto K. Faecal calprotectin level for assessing endoscopic activity and predicting future clinical course in patients with moderately active ulcerative colitis undergoing granulomonocytapheresis: a prospective cohort study. BMC Gastroenterol 2018;18:120. [PMID: 30068300 DOI: 10.1186/s12876-018-0853-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 96 |
Kim ES. Optimal Usage of Fecal Calprotectin for Intestinal Diseases. Korean J Med 2018;93:364-368. [DOI: 10.3904/kjm.2018.93.4.364] [Reference Citation Analysis]
|
| 97 |
Uspenskaya YB, Belogubova SJ. DIAGNOSTIC POSSIBILITIES OF FECAL CALPROTECTIN APPLICATION IN PATIENTS WITH INFLAMMATORY DOWEL DISEASES DURING PREGNANCY (literature review and clinical observations). Koloproktologiâ 2018. [DOI: 10.33878/2073-7556-2018-0-2-95-101] [Reference Citation Analysis]
|
| 98 |
Chami B, Martin NJ, Dennis JM, Witting PK. Myeloperoxidase in the inflamed colon: A novel target for treating inflammatory bowel disease. Archives of Biochemistry and Biophysics 2018;645:61-71. [DOI: 10.1016/j.abb.2018.03.012] [Cited by in Crossref: 101] [Cited by in F6Publishing: 104] [Article Influence: 20.2] [Reference Citation Analysis]
|
| 99 |
Dai C, Jiang M, Sun MJ, Cao Q. Fecal immunochemical test for predicting mucosal healing in ulcerative colitis patients: A systematic review and meta-analysis. J Gastroenterol Hepatol 2018;33:990-7. [PMID: 29427297 DOI: 10.1111/jgh.14121] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 100 |
Jovanovic M, Gajovic N, Zdravkovic N, Jovanovic M, Jurisevic M, Vojvodic D, Maric V, Arsenijevic A, Jovanovic I. Fecal Galectin-3: A New Promising Biomarker for Severity and Progression of Colorectal Carcinoma. Mediators Inflamm. 2018;2018:8031328. [PMID: 29849497 DOI: 10.1155/2018/8031328] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 101 |
Brookes MJ, Whitehead S, Gaya DR, Hawthorne AB. Practical guidance on the use of faecal calprotectin. Frontline Gastroenterol 2018;9:87-91. [PMID: 29588834 DOI: 10.1136/flgastro-2016-100762] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 4.4] [Reference Citation Analysis]
|
| 102 |
Velikova TV, Spassova ZA, Milatchkov LM, Panova DG, Ivanova - Todorova EI, Tumangelova - Yuzeir KD, Kurteva EK, Kyurkchiev DS, Deredjan SA, Nikolov RK, Altankova IP, Vladimirova LM. Dynamics of Some Routine Immunological Parameters During Anti - TNF Therapy in Patients with Crohn’s Disease. Ann Colorectal Res 2018;6. [DOI: 10.5812/acr.68674] [Reference Citation Analysis]
|
| 103 |
Kaymak T, Moriconi F, Niess JH, Beglinger C, Hruz P. Low Discontinuation Rate of Infliximab Treatment in Steroid-Dependent/Refractory Crohn's Disease Patients. Inflamm Intest Dis 2018;2:171-9. [PMID: 30018967 DOI: 10.1159/000486676] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 104 |
Yamamoto T, Shimoyama T, Umegae S, Matsumoto K. Endoscopic score vs. fecal biomarkers for predicting relapse in patients with ulcerative colitis after clinical remission and mucosal healing. Clin Transl Gastroenterol 2018;9:136. [PMID: 29491393 DOI: 10.1038/s41424-018-0006-7] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 105 |
Choden T, Mandaliya R, Charabaty A, Mattar MC. Monitoring inflammatory bowel disease during pregnancy: Current literature and future challenges. World J Gastrointest Pharmacol Ther 2018;9:1-7. [PMID: 29430322 DOI: 10.4292/wjgpt.v9.i1.1] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 106 |
Doherty G, Katsanos KH, Burisch J, Allez M, Papamichael K, Stallmach A, Mao R, Berset IP, Gisbert JP, Sebastian S, Kierkus J, Lopetuso L, Szymanska E, Louis E. European Crohn's and Colitis Organisation Topical Review on Treatment Withdrawal ['Exit Strategies'] in Inflammatory Bowel Disease. J Crohns Colitis 2018;12:17-31. [PMID: 28981623 DOI: 10.1093/ecco-jcc/jjx101] [Cited by in Crossref: 105] [Cited by in F6Publishing: 104] [Article Influence: 21.0] [Reference Citation Analysis]
|
| 107 |
Nakarai A, Hiraoka S, Takahashi S, Inaba T, Higashi R, Mizuno M, Takashima S, Inokuchi T, Sugihara Y, Takahara M, Harada K, Kato J, Okada H. Simultaneous Measurements of Faecal Calprotectin and the Faecal Immunochemical Test in Quiescent Ulcerative Colitis Patients Can Stratify Risk of Relapse. J Crohns Colitis 2018;12:71-6. [PMID: 28961792 DOI: 10.1093/ecco-jcc/jjx118] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 4.6] [Reference Citation Analysis]
|
| 108 |
Ghweil A, Khodeary A, Aziz SP. Diagnostic Value of Fecal Calprotectin and Serum MMP-9 in Diagnosing Disease Activity of Ulcerative Colitis. OJGas 2018;08:234-244. [DOI: 10.4236/ojgas.2018.86026] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 109 |
Ma TY, Nighot P, Al-sadi R. Tight Junctions and the Intestinal Barrier. Physiology of the Gastrointestinal Tract 2018. [DOI: 10.1016/b978-0-12-809954-4.00025-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 110 |
Chew TS, Mansfield JC. Can faecal calprotectin predict relapse in inflammatory bowel disease: a mini review. Frontline Gastroenterol 2018;9:23-8. [PMID: 29484157 DOI: 10.1136/flgastro-2016-100686] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 111 |
Ayling RM, Kok K. Fecal Calprotectin. Adv Clin Chem 2018;87:161-90. [PMID: 30342711 DOI: 10.1016/bs.acc.2018.07.005] [Cited by in Crossref: 70] [Cited by in F6Publishing: 72] [Article Influence: 14.0] [Reference Citation Analysis]
|
| 112 |
Colombel JF, Panaccione R, Bossuyt P, Lukas M, Baert F, Vaňásek T, Danalioglu A, Novacek G, Armuzzi A, Hébuterne X, Travis S, Danese S, Reinisch W, Sandborn WJ, Rutgeerts P, Hommes D, Schreiber S, Neimark E, Huang B, Zhou Q, Mendez P, Petersson J, Wallace K, Robinson AM, Thakkar RB, D'Haens G. Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet 2017;390:2779-89. [PMID: 29096949 DOI: 10.1016/S0140-6736(17)32641-7] [Cited by in Crossref: 501] [Cited by in F6Publishing: 381] [Article Influence: 83.5] [Reference Citation Analysis]
|
| 113 |
Aggarwal V, Day AS, Connor S, Leach ST, Brown G, Singh R, Friedman A, Zekry A, Craig PI. Role of capsule endoscopy and fecal biomarkers in small-bowel Crohn's disease to assess remission and predict relapse. Gastrointest Endosc 2017;86:1070-8. [PMID: 28947363 DOI: 10.1016/j.gie.2017.09.011] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 114 |
Kostas A, Siakavellas SI, Kosmidis C, Takou A, Nikou J, Maropoulos G, Vlachogiannakos J, Papatheodoridis GV, Papaconstantinou I, Bamias G. Fecal calprotectin measurement is a marker of short-term clinical outcome and presence of mucosal healing in patients with inflammatory bowel disease. World J Gastroenterol 2017; 23(41): 7387-7396 [PMID: 29151692 DOI: 10.3748/wjg.v23.i41.7387] [Cited by in CrossRef: 50] [Cited by in F6Publishing: 50] [Article Influence: 8.3] [Reference Citation Analysis]
|
| 115 |
Puolanne AM, Kolho KL, Alfthan H, Ristimäki A, Mustonen H, Färkkilä M. Rapid Fecal Calprotectin Test and Symptom Index in Monitoring the Disease Activity in Colonic Inflammatory Bowel Disease. Dig Dis Sci 2017;62:3123-30. [PMID: 28948412 DOI: 10.1007/s10620-017-4770-0] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 116 |
Kristensen V, Røseth A, Ahmad T, Skar V, Moum B. Fecal Calprotectin: A Reliable Predictor of Mucosal Healing after Treatment for Active Ulcerative Colitis. Gastroenterol Res Pract 2017;2017:2098293. [PMID: 29225617 DOI: 10.1155/2017/2098293] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 117 |
Sawada K. Cytapheresis (CAP) with leukocyte removal filter/bead column as one therapeutic option for inflammatory bowel disease. Transfus Apher Sci 2017;56:689-97. [PMID: 28986009 DOI: 10.1016/j.transci.2017.08.016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 118 |
Yamamoto T, Shimoyama T. Monitoring and detection of disease recurrence after resection for Crohn's disease: the role of non-invasive fecal biomarkers. Expert Rev Gastroenterol Hepatol 2017;11:899-909. [PMID: 28708427 DOI: 10.1080/17474124.2017.1356226] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 119 |
Ye L, Chen BQ, Wang SD, Shi H, Yang Z, Wang FY. Fecal calprotectin is a strong predictive marker of relapse in Chinese patients with Crohn's disease: a two-year prospective study. Scand J Gastroenterol 2017;52:1113-9. [PMID: 28675068 DOI: 10.1080/00365521.2017.1346704] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 120 |
Fischer S, Neurath MF. Precision Medicine in Inflammatory Bowel Diseases. Clin Pharmacol Ther 2017;102:623-32. [DOI: 10.1002/cpt.793] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 121 |
Day AS, Leach ST, Lemberg DA. An update on diagnostic and prognostic biomarkers in inflammatory bowel disease. Expert Rev Mol Diagn. 2017;17:835-843. [PMID: 28770636 DOI: 10.1080/14737159.2017.1364160] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 122 |
Shimoyama T, Yamamoto T, Umegae S, Matsumoto K. Faecal biomarkers for screening small bowel inflammation in patients with Crohn's disease: a prospective study. Therap Adv Gastroenterol 2017;10:577-87. [PMID: 28835772 DOI: 10.1177/1756283X17717683] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 123 |
Buisson A, Gonzalez F, Poullenot F, Nancey S, Sollellis E, Fumery M, Pariente B, Flamant M, Trang-Poisson C, Bonnaud G, Mathieu S, Thevenin A, Duruy M, Filippi J, Lʼhopital F, Luneau F, Michalet V, Genès J, Achim A, Cruzille E, Bommelaer G, Laharie D, Peyrin-Biroulet L, Pereira B, Nachury M, Bouguen G; ACCEPT study group. Comparative Acceptability and Perceived Clinical Utility of Monitoring Tools: A Nationwide Survey of Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis 2017;23:1425-33. [PMID: 28570431 DOI: 10.1097/MIB.0000000000001140] [Cited by in Crossref: 107] [Cited by in F6Publishing: 87] [Article Influence: 17.8] [Reference Citation Analysis]
|
| 124 |
Kwapisz L, Gregor J, Chande N, Yan B, Ponich T, Mosli M. The utility of fecal calprotectin in predicting the need for escalation of therapy in inflammatory bowel disease. Scand J Gastroenterol 2017;52:846-50. [PMID: 28423962 DOI: 10.1080/00365521.2017.1315740] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 125 |
Maione F, Giglio MC, Luglio G, Rispo A, D'Armiento M, Manzo B, Cassese G, Schettino P, Gennarelli N, Siciliano S, D'Armiento FP, De Palma GD. Confocal laser endomicroscopy in ulcerative colitis: beyond endoscopic assessment of disease activity. Tech Coloproctol 2017;21:531-40. [PMID: 28674950 DOI: 10.1007/s10151-017-1654-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 126 |
Wędrychowicz A, Tomasik P, Zając A, Fyderek K. Prognostic value of assessment of stool and serum IL-1β, IL-1ra and IL-6 concentrations in children with active and inactive ulcerative colitis. Arch Med Sci 2018;14:107-14. [PMID: 29379540 DOI: 10.5114/aoms.2017.68696] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 127 |
Wei SC, Chang TA, Chao TH, Chen JS, Chou JW, Chou YH, Chuang CH, Hsu WH, Huang TY, Hsu TC, Lin CC, Lin HH, Lin JK, Lin WC, Ni YH, Shieh MJ, Shih IL, Shun CT, Tsang YM, Wang CY, Wang HY, Weng MT, Wu DC, Wu WC, Yen HH, Wong JM. Management of ulcerative colitis in Taiwan: consensus guideline of the Taiwan Society of Inflammatory Bowel Disease.Intest Res. 2017;15:266-284. [PMID: 28670225 DOI: 10.5217/ir.2017.15.3.266] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 128 |
Wei SC, Chang TA, Chao TH, Chen JS, Chou JW, Chou YH, Chuang CH, Hsu WH, Huang TY, Hsu TC, Lin CC, Lin HH, Lin JK, Lin WC, Ni YH, Shieh MJ, Shih IL, Shun CT, Tsang YM, Wang CY, Wang HY, Weng MT, Wu DC, Wu WC, Yen HH, Wong JM. Management of Crohn's disease in Taiwan: consensus guideline of the Taiwan Society of Inflammatory Bowel Disease. Intest Res 2017;15:285-310. [PMID: 28670226 DOI: 10.5217/ir.2017.15.3.285] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 3.7] [Reference Citation Analysis]
|
| 129 |
Yamaguchi Y, Noda H, Okaniwa N, Adachi K, Shinmura T, Nakagawa S, Ebi M, Ogasawara N, Funaki Y, Zhuo L, Kimata K, Sasaki M, Kasugai K. Serum-Derived Hyaluronan-Associated Protein Is a Novel Biomarker for Inflammatory Bowel Diseases. Digestion 2017;95:146-55. [PMID: 28161704 DOI: 10.1159/000456071] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 130 |
Cabriada J, Rodríguez-lago I. Granulocitoaféresis en 2017. Puesta al día. Enfermedad Inflamatoria Intestinal al Día 2017;16:62-69. [DOI: 10.1016/j.eii.2016.12.001] [Reference Citation Analysis]
|
| 131 |
Katsumata R, Shiotani A, Murao T, Ishii M, Fujita M, Matsumoto H, Haruma K. Gender Differences in Serotonin Signaling in Patients with Diarrhea-predominant Irritable Bowel Syndrome. Intern Med 2017;56:993-9. [PMID: 28458330 DOI: 10.2169/internalmedicine.56.7674] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 132 |
Smolinska A, Bodelier AG, Dallinga JW, Masclee AA, Jonkers DM, van Schooten FJ, Pierik MJ. The potential of volatile organic compounds for the detection of active disease in patients with ulcerative colitis. Aliment Pharmacol Ther 2017;45:1244-54. [PMID: 28239876 DOI: 10.1111/apt.14004] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 4.8] [Reference Citation Analysis]
|
| 133 |
Gerçeker E, Yüceyar H, Kasap E, Demirci U, Ekti BC, Aydoğdu İ, Miskioğlu M. Treatment of inflammatory bowel disease by leukocytapheresis. Transfus Apher Sci 2017;56:421-6. [PMID: 28454883 DOI: 10.1016/j.transci.2017.03.016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 134 |
Lee J. [Fecal Calprotectin in Inflammatory Bowel Disease]. Korean J Gastroenterol 2016;67:233-7. [PMID: 27206433 DOI: 10.4166/kjg.2016.67.5.233] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 135 |
Angelison L, Marsal J, Hertervig E. Letter: how to define remission in ulcerative colitis - histological remission should be considered. Authors' reply. Aliment Pharmacol Ther 2017;45:1177-8. [PMID: 28326579 DOI: 10.1111/apt.14003] [Reference Citation Analysis]
|
| 136 |
Guirgis M, Wendt E, Wang LM, Walsh A, Burger D, Bryant RV, Kent A, Adamson R, Brain O, Travis SPL, Keshav S. Beyond Histological Remission: Intramucosal Calprotectin as a Potential Predictor of Outcomes in Ulcerative Colitis. J Crohns Colitis 2017;11:460-7. [PMID: 27856523 DOI: 10.1093/ecco-jcc/jjw174] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 137 |
Diederen K, Hoekman DR, Leek A, Wolters VM, Hummel TZ, de Meij TG, Koot BG, Tabbers MM, Benninga MA, Kindermann A. Raised faecal calprotectin is associated with subsequent symptomatic relapse, in children and adolescents with inflammatory bowel disease in clinical remission. Aliment Pharmacol Ther 2017;45:951-60. [PMID: 28138990 DOI: 10.1111/apt.13950] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
|
| 138 |
Tyler CJ, McCarthy NE, Lindsay JO, Stagg AJ, Moser B, Eberl M. Antigen-Presenting Human γδ T Cells Promote Intestinal CD4+ T Cell Expression of IL-22 and Mucosal Release of Calprotectin. J Immunol 2017;198:3417-25. [PMID: 28330898 DOI: 10.4049/jimmunol.1700003] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 5.2] [Reference Citation Analysis]
|
| 139 |
Manceau H, Chicha-Cattoir V, Puy H, Peoc'h K. Fecal calprotectin in inflammatory bowel diseases: update and perspectives. Clin Chem Lab Med. 2017;55:474-483. [PMID: 27658156 DOI: 10.1515/cclm-2016-0522] [Cited by in Crossref: 56] [Cited by in F6Publishing: 58] [Article Influence: 9.3] [Reference Citation Analysis]
|
| 140 |
Bar-Gil Shitrit A, Koslowsky B, Livovsky DM, Shitrit D, Paz K, Adar T, Adler SN, Goldin E. A prospective study of fecal calprotectin and lactoferrin as predictors of small bowel Crohn's disease in patients undergoing capsule endoscopy. Scand J Gastroenterol 2017;52:328-33. [PMID: 27841040 DOI: 10.1080/00365521.2016.1253769] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 141 |
Amcoff K, Stridsberg M, Lampinen M, Magnuson A, Carlson M, Halfvarson J. Clinical implications of assay specific differences in f-calprotectin when monitoring inflammatory bowel disease activity over time. Scand J Gastroenterol 2017;52:344-50. [PMID: 27881032 DOI: 10.1080/00365521.2016.1256424] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 142 |
Lopez RN, Leach ST, Lemberg DA, Duvoisin G, Gearry RB, Day AS. Fecal biomarkers in inflammatory bowel disease. J Gastroenterol Hepatol 2017;32:577-82. [PMID: 27723123 DOI: 10.1111/jgh.13611] [Cited by in Crossref: 40] [Cited by in F6Publishing: 39] [Article Influence: 6.7] [Reference Citation Analysis]
|
| 143 |
Kristensen V, Lauritzen T, Jelsness-Jørgensen LP, Frigstad SO, Corwin C, Moum B. Patient-performed extraction of faecal calprotectin. Clin Chem Lab Med 2016;54:1357-63. [PMID: 26812797 DOI: 10.1515/cclm-2015-1037] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 144 |
Panes J, Jairath V, Levesque BG. Advances in Use of Endoscopy, Radiology, and Biomarkers to Monitor Inflammatory Bowel Diseases. Gastroenterology 2017;152:362-373.e3. [PMID: 27751880 DOI: 10.1053/j.gastro.2016.10.005] [Cited by in Crossref: 59] [Cited by in F6Publishing: 60] [Article Influence: 9.8] [Reference Citation Analysis]
|
| 145 |
McCann RK, Smith K, Gaya DR. A prospective single centre pilot evaluation of a serum calprotectin assay in unselected GI patients. Clin Biochem 2017;50:533-6. [PMID: 28093196 DOI: 10.1016/j.clinbiochem.2017.01.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 146 |
Otley AR, Day AS, Zachos M. Nutritional Management of Inflammatory Bowel Disease. Pediatric Inflammatory Bowel Disease 2017. [DOI: 10.1007/978-3-319-49215-5_27] [Reference Citation Analysis]
|
| 147 |
Odenwald MA, Turner JR. The intestinal epithelial barrier: a therapeutic target? Nat Rev Gastroenterol Hepatol 2017;14:9-21. [PMID: 27848962 DOI: 10.1038/nrgastro.2016.169] [Cited by in Crossref: 514] [Cited by in F6Publishing: 505] [Article Influence: 85.7] [Reference Citation Analysis]
|
| 148 |
Kanai T. Leukocytapheresis Therapy of Inflammatory Bowel Disease. Crohn's Disease and Ulcerative Colitis 2017. [DOI: 10.1007/978-3-319-33703-6_49] [Reference Citation Analysis]
|
| 149 |
Arai T, Takeuchi K, Miyamura M, Ishikawa R, Yamada A, Katsumata M, Igarashi Y, Suzuki Y. Level of Fecal Calprotectin Correlates With Severity of Small Bowel Crohn's Disease, Measured by Balloon-assisted Enteroscopy and Computed Tomography Enterography. Clin Gastroenterol Hepatol 2017;15:56-62. [PMID: 27565523 DOI: 10.1016/j.cgh.2016.08.015] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 6.3] [Reference Citation Analysis]
|
| 150 |
Galgut BJ, Lemberg DA, Day AS, Leach ST. The Value of Fecal Markers in Predicting Relapse in Inflammatory Bowel Diseases. Front Pediatr 2017;5:292. [PMID: 29404311 DOI: 10.3389/fped.2017.00292] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 151 |
Hassan EA, Ramadan HK, Ismael AA, Mohamed KF, El-Attar MM, Alhelali I. Noninvasive biomarkers as surrogate predictors of clinical and endoscopic remission after infliximab induction in patients with refractory ulcerative colitis. Saudi J Gastroenterol 2017;23:238-45. [PMID: 28721978 DOI: 10.4103/sjg.SJG_599_16] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
|
| 152 |
Damman J, Park KT. Fecal Biomarkers in Inflammatory Bowel Disease. Pediatric Inflammatory Bowel Disease 2017. [DOI: 10.1007/978-3-319-49215-5_19] [Reference Citation Analysis]
|
| 153 |
Shinzaki S, Matsuoka K, Iijima H, Mizuno S, Serada S, Fujimoto M, Arai N, Koyama N, Morii E, Watanabe M, Hibi T, Kanai T, Takehara T, Naka T. Leucine-rich Alpha-2 Glycoprotein is a Serum Biomarker of Mucosal Healing in Ulcerative Colitis. J Crohns Colitis 2017;11:84-91. [PMID: 27466171 DOI: 10.1093/ecco-jcc/jjw132] [Cited by in Crossref: 69] [Cited by in F6Publishing: 70] [Article Influence: 11.5] [Reference Citation Analysis]
|
| 154 |
Smythe M. Orally Delivered Peptides for Treatment of Inflammatory Bowel Disease. Comprehensive Medicinal Chemistry III 2017. [DOI: 10.1016/b978-0-12-409547-2.12417-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 155 |
Ryu DG, Kim HW, Park SB, Kang DH, Choi CW, Kim SJ, Nam HS. Assessment of disease activity by fecal immunochemical test in ulcerative colitis. World J Gastroenterol 2016; 22(48): 10617-10624 [PMID: 28082814 DOI: 10.3748/wjg.v22.i48.10617] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 156 |
Heuschkel R. Synergy Between Immunosuppressive Therapy and Enteral Nutrition in the Management of Childhood Crohn's Disease. JPEN J Parenter Enteral Nutr 2016;29:S160-5. [DOI: 10.1177/01486071050290s4s160] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 157 |
Keppner A, Malsure S, Nobile A, Auberson M, Bonny O, Hummler E. Altered Prostasin (CAP1/Prss8) Expression Favors Inflammation and Tissue Remodeling in DSS-induced Colitis. Inflamm Bowel Dis 2016;22:2824-39. [PMID: 27755216 DOI: 10.1097/MIB.0000000000000940] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 158 |
Barnes EL, Burakoff R. New Biomarkers for Diagnosing Inflammatory Bowel Disease and Assessing Treatment Outcomes. Inflamm Bowel Dis 2016;22:2956-65. [PMID: 27763951 DOI: 10.1097/MIB.0000000000000903] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 3.1] [Reference Citation Analysis]
|
| 159 |
Pavlidis P, Gulati S, Dubois P, Chung-Faye G, Sherwood R, Bjarnason I, Hayee B. Early change in faecal calprotectin predicts primary non-response to anti-TNFα therapy in Crohn's disease. Scand J Gastroenterol 2016;51:1447-52. [PMID: 27400728 DOI: 10.1080/00365521.2016.1205128] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 160 |
Aydemir Y, Pınar A, Hızal G, Demir H, Saltık Temizel İN, Özen H, Akbıyık F, Yüce A. Neutrophil volume distribution width as a new marker in detecting inflammatory bowel disease activation. Int Jnl Lab Hem 2017;39:51-7. [DOI: 10.1111/ijlh.12574] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 161 |
Kristensen V, Malmstrøm GH, Skar V, Røseth A, Moum B. Clinical importance of faecal calprotectin variability in inflammatory bowel disease: intra-individual variability and standardisation of sampling procedure. Scand J Gastroenterol 2016;51:548-55. [PMID: 26634305 DOI: 10.3109/00365521.2015.1117650] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 4.6] [Reference Citation Analysis]
|
| 162 |
Mendall MA, Chan D, Patel R, Kumar D. Faecal calprotectin: factors affecting levels and its potential role as a surrogate marker for risk of development of Crohn's Disease. BMC Gastroenterol 2016;16:126. [PMID: 27717310 DOI: 10.1186/s12876-016-0535-z] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
|
| 163 |
Connelly TM, Devane L, Kelly JC, Wrafter P, Messaris E. The 100 classic papers in ulcerative colitis: a bibliometric analysis. Expert Rev Gastroenterol Hepatol 2016;10:1187-95. [PMID: 27531253 DOI: 10.1080/17474124.2016.1216786] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 164 |
Camilleri M, Katzka DA. Enhancing High Value Care in Gastroenterology Practice. Clin Gastroenterol Hepatol 2016;14:1376-84. [PMID: 27215366 DOI: 10.1016/j.cgh.2016.05.022] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 165 |
Mirsepasi-Lauridsen HC, Halkjaer SI, Mortensen EM, Lydolph MC, Nordgaard-Lassen I, Krogfelt KA, Petersen AM. Extraintestinal pathogenic Escherichia coli are associated with intestinal inflammation in patients with ulcerative colitis. Sci Rep 2016;6:31152. [PMID: 27686530 DOI: 10.1038/srep31152] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 166 |
Chatzikonstantinou M, Konstantopoulos P, Stergiopoulos S, Kontzoglou K, Verikokos C, Perrea D, Dimitroulis D. Calprotectin as a diagnostic tool for inflammatory bowel diseases. Biomed Rep 2016;5:403-7. [PMID: 27699005 DOI: 10.3892/br.2016.751] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 167 |
Zhulina Y, Cao Y, Amcoff K, Carlson M, Tysk C, Halfvarson J. The prognostic significance of faecal calprotectin in patients with inactive inflammatory bowel disease. Aliment Pharmacol Ther 2016;44:495-504. [PMID: 27402063 DOI: 10.1111/apt.13731] [Cited by in Crossref: 51] [Cited by in F6Publishing: 33] [Article Influence: 7.3] [Reference Citation Analysis]
|
| 168 |
Ronaghan NJ, Shang J, Iablokov V, Zaheer R, Colarusso P, Dion S, Désilets A, Leduc R, Turner JR, MacNaughton WK. The serine protease-mediated increase in intestinal epithelial barrier function is dependent on occludin and requires an intact tight junction. Am J Physiol Gastrointest Liver Physiol 2016;311:G466-79. [PMID: 27492333 DOI: 10.1152/ajpgi.00441.2015] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 2.9] [Reference Citation Analysis]
|
| 169 |
Lopes S, Andrade P, Afonso J, Rodrigues-Pinto E, Dias CC, Macedo G, Magro F. Correlation Between Calprotectin and Modified Rutgeerts Score. Inflamm Bowel Dis 2016;22:2173-81. [PMID: 27482974 DOI: 10.1097/MIB.0000000000000850] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 3.4] [Reference Citation Analysis]
|
| 170 |
Cappello M, Morreale GC. The Role of Laboratory Tests in Crohn's Disease. Clin Med Insights Gastroenterol. 2016;9:51-62. [PMID: 27656094 DOI: 10.4137/cgast.s38203] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 171 |
Garg A, Zhao A, Erickson SL, Mukherjee S, Lau AJ, Alston L, Chang TK, Mani S, Hirota SA. Pregnane X Receptor Activation Attenuates Inflammation-Associated Intestinal Epithelial Barrier Dysfunction by Inhibiting Cytokine-Induced Myosin Light-Chain Kinase Expression and c-Jun N-Terminal Kinase 1/2 Activation. J Pharmacol Exp Ther 2016;359:91-101. [PMID: 27440420 DOI: 10.1124/jpet.116.234096] [Cited by in Crossref: 43] [Cited by in F6Publishing: 43] [Article Influence: 6.1] [Reference Citation Analysis]
|
| 172 |
Wagner M, Sjöberg K, Vigren L, Olesen M, Benoni C, Toth E, Carlson M. Elevated fecal levels of eosinophil granule proteins predict collagenous colitis in patients referred to colonoscopy due to chronic non-bloody diarrhea. Scand J Gastroenterol 2016;51:835-41. [PMID: 26854205 DOI: 10.3109/00365521.2016.1141432] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 173 |
Rutka M, Bor R, Bálint A, Fábián A, Milassin Á, Nagy F, Szepes Z, Szűcs M, Tiszlavicz L, Farkas K, Molnár T. Diagnostic Accuracy of Five Different Fecal Markers for the Detection of Precancerous and Cancerous Lesions of the Colorectum. Mediators Inflamm 2016;2016:2492081. [PMID: 27413251 DOI: 10.1155/2016/2492081] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 174 |
Wong C, Harris PJ, Ferguson LR. Potential Benefits of Dietary Fibre Intervention in Inflammatory Bowel Disease. Int J Mol Sci 2016;17:E919. [PMID: 27314323 DOI: 10.3390/ijms17060919] [Cited by in Crossref: 68] [Cited by in F6Publishing: 72] [Article Influence: 9.7] [Reference Citation Analysis]
|
| 175 |
Nakarai A, Kato J, Hiraoka S, Takashima S, Takei D, Inokuchi T, Sugihara Y, Takahara M, Harada K, Okada H. Ulcerative colitis patients in clinical remission demonstrate correlations between fecal immunochemical test results, mucosal healing, and risk of relapse. World J Gastroenterol 2016; 22(21): 5079-5087 [PMID: 27275100 DOI: 10.3748/wjg.v22.i21.5079] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 176 |
Ramphul P. Faecal calprotectin - the Crohn's disease activity predictor of the future. Clin Med (Lond) 2016;16 Suppl 3:s28. [PMID: 27252331 DOI: 10.7861/clinmedicine.16-3-s28] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 177 |
Musci JO, Cornish JS, Däbritz J. Utility of surrogate markers for the prediction of relapses in inflammatory bowel diseases. J Gastroenterol 2016;51:531-47. [PMID: 26975751 DOI: 10.1007/s00535-016-1191-3] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 178 |
Elsaadany HM, Almaghraby MF, Edrees AA, Elsherbiny YM, Kumar RK. Utility of fecal calprotectin as a discriminative biomarker between ulcerative colitis and irritable bowel syndrome and its ability to be used for the assessment of the remission stage of ulcerative colitis. Egypt J Intern Med 2016;28:21-7. [DOI: 10.4103/1110-7782.182956] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 179 |
Ikhtaire S, Shajib MS, Reinisch W, Khan WI. Fecal calprotectin: its scope and utility in the management of inflammatory bowel disease. J Gastroenterol 2016;51:434-46. [PMID: 26897740 DOI: 10.1007/s00535-016-1182-4] [Cited by in Crossref: 48] [Cited by in F6Publishing: 48] [Article Influence: 6.9] [Reference Citation Analysis]
|
| 180 |
Theede K, Holck S, Ibsen P, Kallemose T, Nordgaard-Lassen I, Nielsen AM. Fecal Calprotectin Predicts Relapse and Histological Mucosal Healing in Ulcerative Colitis. Inflamm Bowel Dis 2016;22:1042-8. [PMID: 26919460 DOI: 10.1097/MIB.0000000000000736] [Cited by in Crossref: 96] [Cited by in F6Publishing: 76] [Article Influence: 13.7] [Reference Citation Analysis]
|
| 181 |
Buisson A, Vazeille E, Minet-Quinard R, Goutte M, Bouvier D, Goutorbe F, Pereira B, Barnich N, Bommelaer G. Faecal chitinase 3-like 1 is a reliable marker as accurate as faecal calprotectin in detecting endoscopic activity in adult patients with inflammatory bowel diseases. Aliment Pharmacol Ther 2016;43:1069-79. [PMID: 26953251 DOI: 10.1111/apt.13585] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 4.4] [Reference Citation Analysis]
|
| 182 |
Wright EK, Kamm MA, De Cruz P, Hamilton AL, Ritchie KJ, Keenan JI, Leach S, Burgess L, Aitchison A, Gorelik A, Liew D, Day AS, Gearry RB. Comparison of Fecal Inflammatory Markers in Crohn's Disease. Inflamm Bowel Dis 2016;22:1086-94. [PMID: 26818420 DOI: 10.1097/MIB.0000000000000671] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 183 |
Inokuchi T, Kato J, Hiraoka S, Takashima S, Nakarai A, Takei D, Sugihara Y, Takahara M, Kawano S, Harada K, Okada H. Fecal Immunochemical Test Versus Fecal Calprotectin for Prediction of Mucosal Healing in Crohn's Disease. Inflamm Bowel Dis 2016;22:1078-85. [PMID: 26891256 DOI: 10.1097/MIB.0000000000000728] [Cited by in Crossref: 40] [Cited by in F6Publishing: 35] [Article Influence: 5.7] [Reference Citation Analysis]
|
| 184 |
von Arnim U, Wex T, Ganzert C, Schulz C, Malfertheiner P. Fecal calprotectin: a marker for clinical differentiation of microscopic colitis and irritable bowel syndrome. Clin Exp Gastroenterol 2016;9:97-103. [PMID: 27147826 DOI: 10.2147/CEG.S97701] [Cited by in Crossref: 37] [Cited by in F6Publishing: 39] [Article Influence: 5.3] [Reference Citation Analysis]
|
| 185 |
Rogler G, Biedermann L. Clinical Utility of Biomarkers in IBD. Curr Gastroenterol Rep. 2015;17:26. [PMID: 26122247 DOI: 10.1007/s11894-015-0449-x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 186 |
Zittan E, Kelly OB, Kirsch R, Milgrom R, Burns J, Nguyen GC, Croitoru K, Van Assche G, Silverberg MS, Steinhart AH. Low Fecal Calprotectin Correlates with Histological Remission and Mucosal Healing in Ulcerative Colitis and Colonic Crohn's Disease. Inflamm Bowel Dis 2016;22:623-30. [PMID: 26829408 DOI: 10.1097/MIB.0000000000000652] [Cited by in Crossref: 113] [Cited by in F6Publishing: 85] [Article Influence: 16.1] [Reference Citation Analysis]
|
| 187 |
Kucharski M, Karczewski J, Mańkowska-Wierzbicka D, Karmelita-Katulska K, Kaczmarek E, Iwanik K, Rzymski P, Grzymisławski M, Linke K, Dobrowolska A. Usefulness of Endoscopic Indices in Determination of Disease Activity in Patients with Crohn's Disease. Gastroenterol Res Pract 2016;2016:7896478. [PMID: 26997952 DOI: 10.1155/2016/7896478] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 188 |
Vinding KK, Elsberg H, Thorkilgaard T, Belard E, Pedersen N, Elkjaer M, Marker D, Carlsen K, Burisch J, Munkholm P. Fecal Calprotectin Measured By Patients at Home Using Smartphones--A New Clinical Tool in Monitoring Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis 2016;22:336-44. [PMID: 26535869 DOI: 10.1097/MIB.0000000000000619] [Cited by in Crossref: 67] [Cited by in F6Publishing: 54] [Article Influence: 9.6] [Reference Citation Analysis]
|
| 189 |
Walsham NE, Sherwood RA. Fecal calprotectin in inflammatory bowel disease. Clin Exp Gastroenterol. 2016;9:21-29. [PMID: 26869808 DOI: 10.2147/ceg.s51902] [Cited by in Crossref: 37] [Cited by in F6Publishing: 68] [Article Influence: 5.3] [Reference Citation Analysis]
|
| 190 |
Liverani E, Scaioli E, Digby RJ, Bellanova M, Belluzzi A. How to predict clinical relapse in inflammatory bowel disease patients. World J Gastroenterol 2016; 22(3): 1017-1033 [PMID: 26811644 DOI: 10.3748/wjg.v22.i3.1017] [Cited by in CrossRef: 76] [Cited by in F6Publishing: 85] [Article Influence: 10.9] [Reference Citation Analysis]
|
| 191 |
Ding NS, Hart A, De Cruz P. Systematic review: predicting and optimising response to anti-TNF therapy in Crohn's disease - algorithm for practical management. Aliment Pharmacol Ther 2016;43:30-51. [PMID: 26515897 DOI: 10.1111/apt.13445] [Cited by in Crossref: 194] [Cited by in F6Publishing: 145] [Article Influence: 27.7] [Reference Citation Analysis]
|
| 192 |
Rendek Z, Falk M, Grodzinsky E, Wahlin K, Kechagias S, Svernlöv R, Hjortswang H. Effect of oral diclofenac intake on faecal calprotectin. Scand J Gastroenterol 2016;51:28-32. [PMID: 26200803 DOI: 10.3109/00365521.2015.1066421] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 3.9] [Reference Citation Analysis]
|
| 193 |
Khaleghi S, Ju JM, Lamba A, Murray JA. The potential utility of tight junction regulation in celiac disease: focus on larazotide acetate. Therap Adv Gastroenterol 2016;9:37-49. [PMID: 26770266 DOI: 10.1177/1756283X15616576] [Cited by in Crossref: 72] [Cited by in F6Publishing: 74] [Article Influence: 10.3] [Reference Citation Analysis]
|
| 194 |
Sandborn WJ, Panés J, Zhang H, Yu D, Niezychowski W, Su C. Correlation Between Concentrations of Fecal Calprotectin and Outcomes of Patients With Ulcerative Colitis in a Phase 2 Trial. Gastroenterology 2016;150:96-102. [PMID: 26376350 DOI: 10.1053/j.gastro.2015.09.001] [Cited by in Crossref: 72] [Cited by in F6Publishing: 73] [Article Influence: 10.3] [Reference Citation Analysis]
|
| 195 |
Yamaguchi S, Takeuchi Y, Arai K, Fukuda K, Kuroki Y, Asonuma K, Takahashi H, Saruta M, Yoshida H. Fecal calprotectin is a clinically relevant biomarker of mucosal healing in patients with quiescent ulcerative colitis. J Gastroenterol Hepatol 2016;31:93-8. [PMID: 26212346 DOI: 10.1111/jgh.13061] [Cited by in Crossref: 44] [Cited by in F6Publishing: 37] [Article Influence: 6.3] [Reference Citation Analysis]
|
| 196 |
Morreale GC, Cappello M, Craxì A. Laboratory Tests in Crohn’s Disease. Crohn’s Disease 2016. [DOI: 10.1007/978-3-319-23066-5_3] [Reference Citation Analysis]
|
| 197 |
Burisch J, Munkholm P. Telemonitoring and Self-Care in Patients with IBD. Telemanagement of Inflammatory Bowel Disease 2016. [DOI: 10.1007/978-3-319-22285-1_7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 198 |
Lin WC, Wong JM, Tung CC, Lin CP, Chou JW, Wang HY, Shieh MJ, Chang CH, Liu HH, Wei SC, Taiwan Society of Inflammatory Bowel Disease Multicenter Study. Fecal calprotectin correlated with endoscopic remission for Asian inflammatory bowel disease patients. World J Gastroenterol 2015; 21(48): 13566-13573 [PMID: 26730169 DOI: 10.3748/wjg.v21.i48.13566] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 32] [Article Influence: 3.9] [Reference Citation Analysis]
|
| 199 |
Scaioli E, Scagliarini M, Cardamone C, Liverani E, Ugolini G, Festi D, Bazzoli F, Belluzzi A. Clinical application of faecal calprotectin in ulcerative colitis patients. Eur J Gastroenterol Hepatol 2015;27:1418-24. [PMID: 26308711 DOI: 10.1097/MEG.0000000000000461] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 200 |
Goutorbe F, Goutte M, Minet-Quinard R, Boucher AL, Pereira B, Bommelaer G, Buisson A. Endoscopic Factors Influencing Fecal Calprotectin Value in Crohn's Disease. J Crohns Colitis 2015;9:1113-9. [PMID: 26351383 DOI: 10.1093/ecco-jcc/jjv150] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 201 |
Humes DJ, Spiller RC. Diverticular Disease of the Colon. Yamada' s Textbook of Gastroenterology 2015. [DOI: 10.1002/9781118512074.ch76] [Reference Citation Analysis]
|
| 202 |
Hanauer SB, Podolsky DK. Ulcerative Colitis. Yamada' s Textbook of Gastroenterology 2015. [DOI: 10.1002/9781118512074.ch71] [Reference Citation Analysis]
|
| 203 |
Benítez JM, García-Sánchez V. Faecal calprotectin: Management in inflammatory bowel disease. World J Gastrointest Pathophysiol 2015; 6(4): 203-209 [PMID: 26600978 DOI: 10.4291/wjgp.v6.i4.203] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
|
| 204 |
Chang S, Malter L, Hudesman D. Disease monitoring in inflammatory bowel disease. World J Gastroenterol 2015; 21(40): 11246-11259 [PMID: 26523100 DOI: 10.3748/wjg.v21.i40.11246] [Cited by in CrossRef: 102] [Cited by in F6Publishing: 104] [Article Influence: 12.8] [Reference Citation Analysis]
|
| 205 |
Kotze LM, Nisihara RM, Marion SB, Cavassani MF, Kotze PG. Fecal Calprotectin: levels for the ethiological diagnosis in Brazilian patients with gastrointestinal symptoms. Arq Gastroenterol. 2015;52:50-54. [PMID: 26017083 DOI: 10.1590/S0004-28032015000100011] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 206 |
Bressler B, Panaccione R, Fedorak RN, Seidman EG. Clinicians' guide to the use of fecal calprotectin to identify and monitor disease activity in inflammatory bowel disease. Can J Gastroenterol Hepatol 2015;29:369-72. [PMID: 26125109 DOI: 10.1155/2015/852723] [Cited by in Crossref: 50] [Cited by in F6Publishing: 52] [Article Influence: 6.3] [Reference Citation Analysis]
|
| 207 |
Onal IK, Beyazit Y, Altinbas A, Kurt M, Arhan M. Maintenance therapy for Crohn's disease: should it be indefinite? Eur J Gastroenterol Hepatol 2015;27:1115-25. [PMID: 26181109 DOI: 10.1097/MEG.0000000000000433] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 208 |
Viennois E, Zhao Y, Merlin D. Biomarkers of Inflammatory Bowel Disease: From Classical Laboratory Tools to Personalized Medicine. Inflamm Bowel Dis 2015;21:2467-74. [PMID: 25985250 DOI: 10.1097/MIB.0000000000000444] [Cited by in Crossref: 10] [Cited by in F6Publishing: 17] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 209 |
Jeon HJ, Kim JM, Cho CK, Lee YW, Yoo HS. Wheel Balanced Cancer Therapy for Longer Than 21 Days Can Have a Positive Effect on the Survival of Patients with Stage IV Cancer. J Pharmacopuncture 2015;18:19-31. [PMID: 26388999 DOI: 10.3831/KPI.2015.18.021] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 210 |
Novak K, Tanyingoh D, Petersen F, Kucharzik T, Panaccione R, Ghosh S, Kaplan GG, Wilson A, Kannengiesser K, Maaser C. Clinic-based Point of Care Transabdominal Ultrasound for Monitoring Crohn's Disease: Impact on Clinical Decision Making. J Crohns Colitis 2015;9:795-801. [PMID: 26079723 DOI: 10.1093/ecco-jcc/jjv105] [Cited by in Crossref: 53] [Cited by in F6Publishing: 54] [Article Influence: 6.6] [Reference Citation Analysis]
|
| 211 |
Yamamoto T, Shimoyama T, Matsumoto K. Consecutive monitoring of faecal calprotectin during mesalazine suppository therapy for active rectal inflammation in ulcerative colitis. Aliment Pharmacol Ther 2015;42:549-58. [PMID: 26140337 DOI: 10.1111/apt.13308] [Cited by in Crossref: 37] [Cited by in F6Publishing: 28] [Article Influence: 4.6] [Reference Citation Analysis]
|
| 212 |
Pedersen N, Munkholm P. Reply to Methodological Approach to Mesalazine Treatment in Patients with Mild-to-moderate Ulcerative Colitis. Inflamm Bowel Dis 2015;21:E15-6. [PMID: 26111214 DOI: 10.1097/MIB.0000000000000484] [Reference Citation Analysis]
|
| 213 |
Bodelier AG, Smolinska A, Baranska A, Dallinga JW, Mujagic Z, Vanhees K, van den Heuvel T, Masclee AA, Jonkers D, Pierik MJ, van Schooten FJ. Volatile Organic Compounds in Exhaled Air as Novel Marker for Disease Activity in Crohn's Disease: A Metabolomic Approach. Inflamm Bowel Dis 2015;21:1776-85. [PMID: 26199990 DOI: 10.1097/MIB.0000000000000436] [Cited by in Crossref: 42] [Cited by in F6Publishing: 42] [Article Influence: 5.3] [Reference Citation Analysis]
|
| 214 |
David L, Surdea-blaga T, Dumitrascu D. Semiquantitative fecal calprotectin test in postinfectious and non-postinfectious irritable bowel syndrome: cross-sectional study. Sao Paulo Med J 2014;133:343-349. [DOI: 10.1590/1516-3180.2014.8000815] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 215 |
Gecse KB, Brandse JF, van Wilpe S, Löwenberg M, Ponsioen C, van den Brink G, D'Haens G. Impact of disease location on fecal calprotectin levels in Crohn's disease. Scand J Gastroenterol 2015;50:841-7. [PMID: 25636819 DOI: 10.3109/00365521.2015.1008035] [Cited by in Crossref: 77] [Cited by in F6Publishing: 75] [Article Influence: 9.6] [Reference Citation Analysis]
|
| 216 |
Billiet T, Ferrante M, Van Assche G. The use of prognostic factors in inflammatory bowel diseases. Curr Gastroenterol Rep. 2014;16:416. [PMID: 25262067 DOI: 10.1007/s11894-014-0416-y] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 217 |
Tursi A, Elisei W, Picchio M, Giorgetti G, Brandimarte G. Accuracy of Rapid Fecal Calprotectin Test in Monitoring Inflammatory Bowel Diseases Under Treatment with TNFα Antagonists. Dig Dis Sci 2015;60:1406-13. [PMID: 25445163 DOI: 10.1007/s10620-014-3459-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 218 |
Wright EK, Kamm MA, De Cruz P, Hamilton AL, Ritchie KJ, Krejany EO, Leach S, Gorelik A, Liew D, Prideaux L, Lawrance IC, Andrews JM, Bampton PA, Jakobovits SL, Florin TH, Gibson PR, Debinski H, Macrae FA, Samuel D, Kronborg I, Radford-Smith G, Selby W, Johnston MJ, Woods R, Elliott PR, Bell SJ, Brown SJ, Connell WR, Day AS, Desmond PV, Gearry RB. Measurement of fecal calprotectin improves monitoring and detection of recurrence of Crohn's disease after surgery. Gastroenterology 2015;148:938-947.e1. [PMID: 25620670 DOI: 10.1053/j.gastro.2015.01.026] [Cited by in Crossref: 198] [Cited by in F6Publishing: 207] [Article Influence: 24.8] [Reference Citation Analysis]
|
| 219 |
Stawczyk-Eder K, Eder P, Lykowska-Szuber L, Krela-Kazmierczak I, Klimczak K, Szymczak A, Szachta P, Katulska K, Linke K. Is faecal calprotectin equally useful in all Crohn’s disease locations? A prospective, comparative study. Arch Med Sci. 2015;11:353-361. [PMID: 25995752 DOI: 10.5114/aoms.2014.43672] [Cited by in Crossref: 29] [Cited by in F6Publishing: 33] [Article Influence: 3.6] [Reference Citation Analysis]
|
| 220 |
Kristensen V, Lauritzen T, Jelsness-JØrgensen LP, Moum B. Validation of a new extraction device for measuring faecal calprotectin in inflammatory bowel disease, and comparison to established extraction methods. Scand J Clin Lab Invest 2015;75:355-61. [PMID: 25856663 DOI: 10.3109/00365513.2015.1030765] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 221 |
Reinisch W, Reinink AR, Higgins PD. Factors associated with poor outcomes in adults with newly diagnosed ulcerative colitis. Clin Gastroenterol Hepatol 2015;13:635-42. [PMID: 24887059 DOI: 10.1016/j.cgh.2014.03.037] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 3.9] [Reference Citation Analysis]
|
| 222 |
Sacco R, Tanaka T, Yamamoto T, Bresci G, Saniabadi AR. Adacolumn leucocytapheresis for ulcerative colitis: clinical and endoscopic features of responders and unresponders. Expert Rev Gastroenterol Hepatol 2015;9:327-33. [PMID: 25160857 DOI: 10.1586/17474124.2014.953060] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 223 |
Farkas K, Bálint A, Bor R, Földesi I, Szűcs M, Nagy F, Szepes Z, Annaházi A, Róka R, Molnár T. Faecal matrix metalloprotease-9 is a more sensitive marker for diagnosing pouchitis than faecal calprotectin: results from a pilot study. Expert Rev Gastroenterol Hepatol 2015;9:387-92. [PMID: 25264031 DOI: 10.1586/17474124.2015.965144] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 224 |
Lasson A, Öhman L, Stotzer PO, Isaksson S, Überbacher O, Ung KA, Strid H. Pharmacological intervention based on fecal calprotectin levels in patients with ulcerative colitis at high risk of a relapse: A prospective, randomized, controlled study. United European Gastroenterol J. 2015;3:72-79. [PMID: 25653861 DOI: 10.1177/2050640614560785] [Cited by in Crossref: 39] [Cited by in F6Publishing: 40] [Article Influence: 4.9] [Reference Citation Analysis]
|
| 225 |
Kristensen V, Klepp P, Cvancarova M, Røseth A, Skar V, Moum B. Prediction of endoscopic disease activity in ulcerative colitis by two different assays for fecal calprotectin. J Crohns Colitis 2015;9:164-9. [PMID: 25518057 DOI: 10.1093/ecco-jcc/jju015] [Cited by in Crossref: 42] [Cited by in F6Publishing: 42] [Article Influence: 5.3] [Reference Citation Analysis]
|
| 226 |
Burri E, Beglinger C, von Felten S, Lehmann FS. Fecal calprotectin and the clinical activity index are both useful to monitor medical treatment in patients with ulcerative colitis. Dig Dis Sci 2015;60:485-91. [PMID: 25344905 DOI: 10.1007/s10620-014-3383-0] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 227 |
Sipponen T, Kolho KL. Fecal calprotectin in diagnosis and clinical assessment of inflammatory bowel disease. Scand J Gastroenterol 2015;50:74-80. [PMID: 25523558 DOI: 10.3109/00365521.2014.987809] [Cited by in Crossref: 84] [Cited by in F6Publishing: 87] [Article Influence: 10.5] [Reference Citation Analysis]
|
| 228 |
Kwapisz L, Mosli M, Chande N, Yan B, Beaton M, Micsko J, Mennill PW, Barnett W, Bax K, Ponich T, Howard J, Tirolese A, Lannigan R, Gregor J. Rapid fecal calprotectin testing to assess for endoscopic disease activity in inflammatory bowel disease: A diagnostic cohort study. Saudi J Gastroenterol 2015;21:360-6. [PMID: 26655130 DOI: 10.4103/1319-3767.170948] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 229 |
Lehmann FS, Burri E, Beglinger C. The role and utility of faecal markers in inflammatory bowel disease. Therap Adv Gastroenterol 2015;8:23-36. [PMID: 25553077 DOI: 10.1177/1756283X14553384] [Cited by in Crossref: 109] [Cited by in F6Publishing: 110] [Article Influence: 13.6] [Reference Citation Analysis]
|
| 230 |
Molander P, Färkkilä M, Ristimäki A, Salminen K, Kemppainen H, Blomster T, Koskela R, Jussila A, Rautiainen H, Nissinen M, Haapamäki J, Arkkila P, Nieminen U, Kuisma J, Punkkinen J, Kolho KL, Mustonen H, Sipponen T. Does fecal calprotectin predict short-term relapse after stopping TNFα-blocking agents in inflammatory bowel disease patients in deep remission? J Crohns Colitis 2015;9:33-40. [PMID: 25052347 DOI: 10.1016/j.crohns.2014.06.012] [Cited by in Crossref: 19] [Cited by in F6Publishing: 33] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 231 |
Mooiweer E, Severs M, Schipper ME, Fidder HH, Siersema PD, Laheij RJ, Oldenburg B. Low fecal calprotectin predicts sustained clinical remission in inflammatory bowel disease patients: a plea for deep remission. J Crohns Colitis 2015;9:50-5. [PMID: 25518048 DOI: 10.1093/ecco-jcc/jju003] [Cited by in Crossref: 91] [Cited by in F6Publishing: 85] [Article Influence: 11.4] [Reference Citation Analysis]
|
| 232 |
Lasson A, Stotzer PO, Öhman L, Isaksson S, Sapnara M, Strid H. The intra-individual variability of faecal calprotectin: a prospective study in patients with active ulcerative colitis. J Crohns Colitis 2015;9:26-32. [PMID: 25008478 DOI: 10.1016/j.crohns.2014.06.002] [Cited by in Crossref: 37] [Cited by in F6Publishing: 57] [Article Influence: 4.6] [Reference Citation Analysis]
|
| 233 |
Tursi A, Elisei W, Picchio M, Giorgetti G, Brandimarte G. Accuracy of Rapid Fecal Calprotectin Test in Monitoring Inflammatory Bowel Diseases Under Treatment with TNFα Antagonists. Dig Dis Sci 2015;60:1406-13. [PMID: 25445163 DOI: 10.1007/s10620-014-3459-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 234 |
Taghvaei T, Maleki I, Nagshvar F, Fakheri H, Hosseini V, Valizadeh SM, Neishaboori H. Fecal calprotectin and ulcerative colitis endoscopic activity index as indicators of mucosal healing in ulcerative colitis. Intern Emerg Med 2015;10:321-8. [DOI: 10.1007/s11739-014-1144-x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 235 |
Guidi L, Marzo M, Andrisani G, Felice C, Pugliese D, Mocci G, Nardone O, De Vitis I, Papa A, Rapaccini G, Forni F, Armuzzi A. Faecal calprotectin assay after induction with anti-Tumour Necrosis Factor α agents in inflammatory bowel disease: Prediction of clinical response and mucosal healing at one year. Dig Liver Dis 2014;46:974-9. [PMID: 25096964 DOI: 10.1016/j.dld.2014.07.013] [Cited by in Crossref: 51] [Cited by in F6Publishing: 51] [Article Influence: 5.7] [Reference Citation Analysis]
|
| 236 |
Hedin CR, McCarthy NE, Louis P, Farquharson FM, McCartney S, Taylor K, Prescott NJ, Murrells T, Stagg AJ, Whelan K, Lindsay JO. Altered intestinal microbiota and blood T cell phenotype are shared by patients with Crohn's disease and their unaffected siblings. Gut 2014;63:1578-86. [PMID: 24398881 DOI: 10.1136/gutjnl-2013-306226] [Cited by in Crossref: 98] [Cited by in F6Publishing: 101] [Article Influence: 10.9] [Reference Citation Analysis]
|
| 237 |
Wright EK, De Cruz P, Gearry R, Day AS, Kamm MA. Fecal biomarkers in the diagnosis and monitoring of Crohn's disease. Inflamm Bowel Dis 2014;20:1668-77. [PMID: 24918319 DOI: 10.1097/MIB.0000000000000087] [Cited by in Crossref: 40] [Cited by in F6Publishing: 31] [Article Influence: 4.4] [Reference Citation Analysis]
|
| 238 |
Naismith GD, Smith LA, Barry SJ, Munro JI, Laird S, Rankin K, Morris AJ, Winter JW, Gaya DR. A prospective evaluation of the predictive value of faecal calprotectin in quiescent Crohn's disease. J Crohns Colitis 2014;8:1022-9. [PMID: 24566170 DOI: 10.1016/j.crohns.2014.01.029] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 239 |
Saniabadi AR, Tanaka T, Ohmori T, Sawada K, Yamamoto T, Hanai H. Treating inflammatory bowel disease by adsorptive leucocytapheresis: A desire to treat without drugs. World J Gastroenterol 2014; 20(29): 9699-9715 [PMID: 25110409 DOI: 10.3748/wjg.v20.i29.9699] [Cited by in CrossRef: 54] [Cited by in F6Publishing: 57] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 240 |
Tursi A, Elisei W, Picchio M, Brandimarte G. Increased faecal calprotectin predicts recurrence of colonic diverticulitis. Int J Colorectal Dis 2014;29:931-5. [PMID: 24798630 DOI: 10.1007/s00384-014-1884-0] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 241 |
Lasson A, Strid H, Ohman L, Isaksson S, Olsson M, Rydström B, Ung KA, Stotzer PO. Fecal calprotectin one year after ileocaecal resection for Crohn's disease--a comparison with findings at ileocolonoscopy. J Crohns Colitis 2014;8:789-95. [PMID: 24418661 DOI: 10.1016/j.crohns.2013.12.015] [Cited by in Crossref: 43] [Cited by in F6Publishing: 44] [Article Influence: 4.8] [Reference Citation Analysis]
|
| 242 |
Prager M, Büning C. Klinik, CRP, Calprotectin, MRT oder Endoskopie? coloproctology 2014;36:250-258. [DOI: 10.1007/s00053-014-0464-7] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 243 |
Jauregui-Amezaga A, López-Cerón M, Aceituno M, Jimeno M, Rodríguez de Miguel C, Pinó-Donnay S, Zabalza M, Sans M, Ricart E, Ordás I, González-Suárez B, Cuatrecasas M, Llach J, Panés J, Pellise M. Accuracy of advanced endoscopy and fecal calprotectin for prediction of relapse in ulcerative colitis: a prospective study. Inflamm Bowel Dis 2014;20:1187-93. [PMID: 24874457 DOI: 10.1097/MIB.0000000000000069] [Cited by in Crossref: 46] [Cited by in F6Publishing: 39] [Article Influence: 5.1] [Reference Citation Analysis]
|
| 244 |
Yamamoto T, Shiraki M, Bamba T, Umegae S, Matsumoto K. Faecal calprotectin and lactoferrin as markers for monitoring disease activity and predicting clinical recurrence in patients with Crohn’s disease after ileocolonic resection: A prospective pilot study. United European Gastroenterol J. 2013;1:368-374. [PMID: 24917985 DOI: 10.1177/2050640613501818] [Cited by in Crossref: 48] [Cited by in F6Publishing: 55] [Article Influence: 5.3] [Reference Citation Analysis]
|
| 245 |
Goepp J, Fowler E, McBride T, Landis D. Frequency of abnormal fecal biomarkers in irritable bowel syndrome. Glob Adv Health Med. 2014;3:9-15. [PMID: 24891989 DOI: 10.7453/gahmj.2013.099] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 246 |
Piras C, Soggiu A, Greco V, Cassinotti A, Maconi G, Ardizzone S, Amoresano A, Porro GB, Bonizzi L, Roncada P. Serum protein profiling of early and advanced stage Crohn's disease. EuPA Open Proteomics 2014;3:48-59. [DOI: 10.1016/j.euprot.2014.02.010] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 247 |
Prell C, Nagel D, Freudenberg F, Schwarzer A, Koletzko S. Comparison of three tests for faecal calprotectin in children and young adults: a retrospective monocentric study. BMJ Open. 2014;4:e004558. [PMID: 24793248 DOI: 10.1136/bmjopen-2013-004558] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 248 |
Gerich ME, McGovern DP. Towards personalized care in IBD. Nat Rev Gastroenterol Hepatol 2014;11:287-99. [PMID: 24345887 DOI: 10.1038/nrgastro.2013.242] [Cited by in Crossref: 45] [Cited by in F6Publishing: 32] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 249 |
Gaya DR. Delivering optimal care for inflammatory bowel disease patients in Scotland in 2014. Scott Med J 2014;59:130-5. [PMID: 24728818 DOI: 10.1177/0036933014531540] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 250 |
Yamamoto T, Shiraki M, Bamba T, Umegae S, Matsumoto K. Fecal calprotectin and lactoferrin as predictors of relapse in patients with quiescent ulcerative colitis during maintenance therapy. Int J Colorectal Dis 2014;29:485-91. [PMID: 24343276 DOI: 10.1007/s00384-013-1817-3] [Cited by in Crossref: 51] [Cited by in F6Publishing: 52] [Article Influence: 5.7] [Reference Citation Analysis]
|
| 251 |
Buda A, Hatem G, Neumann H, D' Incà R, Mescoli C, Piselli P, Jackson J, Bruno M, Sturniolo GC. Confocal laser endomicroscopy for prediction of disease relapse in ulcerative colitis: A pilot study. Journal of Crohn's and Colitis 2014;8:304-311. [DOI: 10.1016/j.crohns.2013.09.005] [Cited by in Crossref: 56] [Cited by in F6Publishing: 53] [Article Influence: 6.2] [Reference Citation Analysis]
|
| 252 |
Kopylov U, Rosenfeld G, Bressler B, Seidman E. Clinical utility of fecal biomarkers for the diagnosis and management of inflammatory bowel disease. Inflamm Bowel Dis 2014;20:742-56. [PMID: 24562174 DOI: 10.1097/01.MIB.0000442681.85545.31] [Cited by in Crossref: 112] [Cited by in F6Publishing: 92] [Article Influence: 12.4] [Reference Citation Analysis]
|
| 253 |
Yoshino T, Nakase H, Minami N, Yamada S, Matsuura M, Yazumi S, Chiba T. Efficacy and safety of granulocyte and monocyte adsorption apheresis for ulcerative colitis: a meta-analysis. Dig Liver Dis 2014;46:219-26. [PMID: 24268950 DOI: 10.1016/j.dld.2013.10.011] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 3.1] [Reference Citation Analysis]
|
| 254 |
Burri E, Beglinger C. The use of fecal calprotectin as a biomarker in gastrointestinal disease. Expert Rev Gastroenterol Hepatol 2014;8:197-210. [PMID: 24345070 DOI: 10.1586/17474124.2014.869476] [Cited by in Crossref: 61] [Cited by in F6Publishing: 59] [Article Influence: 6.8] [Reference Citation Analysis]
|
| 255 |
Abraham BP, Sellin JH. Fecal calprotectin: controlling the cost of care. Clin Gastroenterol Hepatol 2014;12:263-4. [PMID: 24055986 DOI: 10.1016/j.cgh.2013.09.018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 256 |
Weiss GA, Chassard C, Hennet T. Selective proliferation of intestinal Barnesiella under fucosyllactose supplementation in mice. Br J Nutr 2014;111:1602-10. [PMID: 24411010 DOI: 10.1017/S0007114513004200] [Cited by in Crossref: 59] [Cited by in F6Publishing: 58] [Article Influence: 6.6] [Reference Citation Analysis]
|
| 257 |
Leach ST, Day AS. S100 proteins in the pathogenesis and diagnosis of inflammatory bowel disease. Expert Review of Clinical Immunology 2014;2:471-80. [DOI: 10.1586/1744666x.2.3.471] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 258 |
Ghosh S. Management of Crohn’s disease from efficacy, quality of life and health economic perspectives. Expert Review of Pharmacoeconomics & Outcomes Research 2014;3:587-98. [DOI: 10.1586/14737167.3.5.587] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 259 |
Rondonotti E, Pennazio M. Timing and Protocols of Endoscopic Follow-Up in Operated Patients After Small Bowel Surgery. Endoscopic Follow-up of Digestive Anastomosis 2014. [DOI: 10.1007/978-88-470-5370-0_6] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 260 |
Pang T, Leach ST, Katz T, Day AS, Ooi CY. Fecal biomarkers of intestinal health and disease in children. Front Pediatr 2014;2:6. [PMID: 24479111 DOI: 10.3389/fped.2014.00006] [Cited by in Crossref: 40] [Cited by in F6Publishing: 39] [Article Influence: 4.4] [Reference Citation Analysis]
|
| 261 |
Benitez JM, Meuwis MA, Reenaers C, Van Kemseke C, Meunier P, Louis E. Role of endoscopy, cross-sectional imaging and biomarkers in Crohn's disease monitoring. Gut 2013;62:1806-16. [PMID: 24203056 DOI: 10.1136/gutjnl-2012-303957] [Cited by in Crossref: 78] [Cited by in F6Publishing: 81] [Article Influence: 7.8] [Reference Citation Analysis]
|
| 262 |
Sipponen T. Diagnostics and prognostics of inflammatory bowel disease with fecal neutrophil-derived biomarkers calprotectin and lactoferrin. Dig Dis 2013;31:336-44. [PMID: 24246984 DOI: 10.1159/000354689] [Cited by in Crossref: 41] [Cited by in F6Publishing: 45] [Article Influence: 4.1] [Reference Citation Analysis]
|
| 263 |
Szczepański M, Dądalski M, Wiernicka A, Oracz G, Ryżko J, Kierkuś J. Nieinwazyjna diagnostyka zmian zapalnych błony śluzowej jelita w nieswoistych zapaleniach jelit u dzieci. Pediatria Polska 2013;88:548-554. [DOI: 10.1016/j.pepo.2013.07.004] [Reference Citation Analysis]
|
| 264 |
Molander P, Sipponen T, Kemppainen H, Jussila A, Blomster T, Koskela R, Nissinen M, Rautiainen H, Kuisma J, Kolho KL, Färkkilä M. Achievement of deep remission during scheduled maintenance therapy with TNFα-blocking agents in IBD. J Crohns Colitis 2013;7:730-5. [PMID: 23182163 DOI: 10.1016/j.crohns.2012.10.018] [Cited by in Crossref: 85] [Cited by in F6Publishing: 83] [Article Influence: 8.5] [Reference Citation Analysis]
|
| 265 |
Bamba T, Yamamoto T, Umegae S, Matsumoto K. Effects of preoperative leukocytapheresis on inflammatory cytokines following surgery for ulcerative colitis: a prospective randomized study. J Clin Apher. 2014;29:107-112. [PMID: 24000140 DOI: 10.1002/jca.21299] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 266 |
De Vos M, Louis EJ, Jahnsen J, Vandervoort JG, Noman M, Dewit O, Dʼhaens GR, Franchimont D, Baert FJ, Torp RA, Henriksen M, Potvin PM, Van Hootegem PP, Hindryckx PM, Moreels TG, Collard A, Karlsen LN, Kittang E, Lambrecht G, Grimstad T, Koch J, Lygren I, Coche JC, Mana F, Van Gossum A, Belaiche J, Cool MR, Fontaine F, Maisin JM, Muls V, Neuville B, Staessen DA, Van Assche GA, de Lange T, Solberg IC, Vander Cruyssen BJ, Vermeire SA. Consecutive fecal calprotectin measurements to predict relapse in patients with ulcerative colitis receiving infliximab maintenance therapy. Inflamm Bowel Dis 2013;19:2111-7. [PMID: 23883959 DOI: 10.1097/MIB.0b013e31829b2a37] [Cited by in Crossref: 151] [Cited by in F6Publishing: 118] [Article Influence: 15.1] [Reference Citation Analysis]
|
| 267 |
Papay P, Ignjatovic A, Karmiris K, Amarante H, Milheller P, Feagan B, D'Haens G, Marteau P, Reinisch W, Sturm A, Steinwurz F, Egan L, Panés J, Louis E, Colombel JF, Panaccione R. Optimising monitoring in the management of Crohn's disease: a physician's perspective. J Crohns Colitis 2013;7:653-69. [PMID: 23562672 DOI: 10.1016/j.crohns.2013.02.005] [Cited by in Crossref: 82] [Cited by in F6Publishing: 86] [Article Influence: 8.2] [Reference Citation Analysis]
|
| 268 |
Brusca I. Biomarcatori nelle malattie infiammatorie intestinali. Riv Ital Med Lab 2013;9:123-130. [DOI: 10.1007/s13631-013-0012-4] [Reference Citation Analysis]
|
| 269 |
Huckins DS, Simon HK, Copeland K, Spiro DM, Gogain J, Wandell M. A novel biomarker panel to rule out acute appendicitis in pediatric patients with abdominal pain. The American Journal of Emergency Medicine 2013;31:1368-75. [DOI: 10.1016/j.ajem.2013.06.016] [Cited by in Crossref: 36] [Cited by in F6Publishing: 40] [Article Influence: 3.6] [Reference Citation Analysis]
|
| 270 |
Moghadam AR, Mohajeri D, Namvaran-abbas-abad A, Manafi H, Shahi D, Mazani M. Protective effect of turmeric extract on ethotrexate-induced intestinal damage and oxidative stress. Chinese Journal of Natural Medicines 2013;11:477-83. [DOI: 10.1016/s1875-5364(13)60087-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 271 |
Rogler G, Aldeguer X, Kruis W, Lasson A, Mittmann U, Nally K, Peyrin-Biroulet L, Schoepfer A, Vatn M, Vavricka S, Logan R. Concept for a rapid point-of-care calprotectin diagnostic test for diagnosis and disease activity monitoring in patients with inflammatory bowel disease: expert clinical opinion. J Crohns Colitis 2013;7:670-7. [PMID: 23517932 DOI: 10.1016/j.crohns.2013.02.014] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 272 |
Tanaka T, Sugiyama S, Goishi H, Kajihara T, Akagi M, Miura T. Treatment of children and adolescents with ulcerative colitis by adsorptive depletion of myeloid lineage leucocytes as monotherapy or in combination with low dose prednisolone after failure of first-line medications. BMC Gastroenterol. 2013;13:130. [PMID: 23961883 DOI: 10.1186/1471-230x-13-130] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 273 |
Tanaka T, Sugiyama S, Goishi H, Kajihara T, Akagi M, Miura T. Treatment of children and adolescents with ulcerative colitis by adsorptive depletion of myeloid lineage leucocytes as monotherapy or in combination with low dose prednisolone after failure of first-line medications. BMC Gastroenterol. 2013;13:130. [PMID: 23961883 DOI: 10.1016/s1873-9946(13)60351-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 274 |
Shiotani A, Kusunoki H, Kimura Y, Ishii M, Imamura H, Tarumi K, Manabe N, Kamada T, Hata J, Haruma K. S100A expression and interleukin-10 polymorphisms are associated with ulcerative colitis and diarrhea predominant irritable bowel syndrome. Dig Dis Sci 2013;58:2314-23. [PMID: 23595519 DOI: 10.1007/s10620-013-2677-y] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 275 |
Miheller P, Kiss LS, Juhasz M, Mandel M, Lakatos PL. Recommendations for identifying Crohn’s disease patients with poor prognosis. Expert Rev Clin Immunol. 2013;9:65-75; quiz 76. [PMID: 23256765 DOI: 10.1586/eci.12.86] [Cited by in Crossref: 15] [Cited by in F6Publishing: 19] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 276 |
Rodríguez-moranta F, Lobatón T, Rodríguez-alonso L, Guardiola J. Calprotectina fecal en el diagnóstico de enfermedades inflamatorias. Gastroenterología y Hepatología 2013;36:400-6. [DOI: 10.1016/j.gastrohep.2012.10.008] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 277 |
Seeley EH, Washington MK, Caprioli RM, M'Koma AE. Proteomic patterns of colonic mucosal tissues delineate Crohn's colitis and ulcerative colitis. Proteomics Clin Appl. 2013;7:541-549. [PMID: 23382084 DOI: 10.1002/prca.201200107] [Cited by in Crossref: 40] [Cited by in F6Publishing: 45] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 278 |
Däbritz J, Langhorst J, Lügering A, Heidemann J, Mohr M, Wittkowski H, Krummenerl T, Foell D. Improving relapse prediction in inflammatory bowel disease by neutrophil-derived S100A12. Inflamm Bowel Dis 2013;19:1130-8. [PMID: 23377171 DOI: 10.1097/MIB.0b013e318280b1cd] [Cited by in Crossref: 51] [Cited by in F6Publishing: 52] [Article Influence: 5.1] [Reference Citation Analysis]
|
| 279 |
Cury DB, Mizsputen SJ, Versolato C, Miiji LO, Pereira E, Delboni MA, Schor N, Moss AC. Serum calprotectin levels correlate with biochemical and histological markers of disease activity in TNBS colitis. Cell Immunol 2013;282:66-70. [PMID: 23685388 DOI: 10.1016/j.cellimm.2013.04.004] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 280 |
Gwee K. Gut Inflammation in Irritable Bowel Syndrome. Irritable Bowel Syndrome 2013. [DOI: 10.1002/9781118444689.ch9] [Reference Citation Analysis]
|
| 281 |
Prager M, Büning C. Klinik, CRP, Calprotectin, MRT oder Endoskopie? Gastroenterologe 2013;8:187-196. [DOI: 10.1007/s11377-012-0723-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 282 |
Lahiff C, Safaie P, Awais A, Akbari M, Gashin L, Sheth S, Lembo A, Leffler D, Moss AC, Cheifetz AS. The Crohn's disease activity index (CDAI) is similarly elevated in patients with Crohn's disease and in patients with irritable bowel syndrome. Aliment Pharmacol Ther 2013;37:786-94. [PMID: 23432394 DOI: 10.1111/apt.12262] [Cited by in Crossref: 74] [Cited by in F6Publishing: 50] [Article Influence: 7.4] [Reference Citation Analysis]
|
| 283 |
Toya Y, Chiba T, Mizutani T, Sato K, Kasugai S, Matsuda N, Orikasa S, Shibata S, Abiko Y, Akasaka R. The effect of granulocyte and monocyte adsorptive apheresis on serum cytokine levels in patients with ulcerative colitis. Cytokine. 2013;62:146-150. [PMID: 23465691 DOI: 10.1016/j.cyto.2013.01.019] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 284 |
Lasson A, Simrén M, Stotzer PO, Isaksson S, Ohman L, Strid H. Fecal calprotectin levels predict the clinical course in patients with new onset of ulcerative colitis. Inflamm Bowel Dis 2013;19:576-81. [PMID: 23377170 DOI: 10.1097/MIB.0b013e31827e78be] [Cited by in Crossref: 46] [Cited by in F6Publishing: 36] [Article Influence: 4.6] [Reference Citation Analysis]
|
| 285 |
Tominaga K, Nakano M, Hoshino M, Kanke K, Hiraishi H. Efficacy, safety and cost analyses in ulcerative colitis patients undergoing granulocyte and monocyte adsorption or receiving prednisolone. BMC Gastroenterol. 2013;13:41. [PMID: 23452668 DOI: 10.1186/1471-230x-13-41] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 286 |
Naismith GD, Smith LA, Barry SJ, Munro JI, Laird S, Rankin K, Morris AJ, Winter JW, Gaya DR. A prospective single-centre evaluation of the intra-individual variability of faecal calprotectin in quiescent Crohn's disease. Aliment Pharmacol Ther 2013;37:613-21. [PMID: 23347334 DOI: 10.1111/apt.12221] [Cited by in Crossref: 58] [Cited by in F6Publishing: 38] [Article Influence: 5.8] [Reference Citation Analysis]
|
| 287 |
De Cruz P, Kamm MA, Prideaux L, Allen PB, Moore G. Mucosal healing in Crohn's disease: a systematic review. Inflamm Bowel Dis 2013;19:429-44. [PMID: 22539420 DOI: 10.1002/ibd.22977] [Cited by in Crossref: 111] [Cited by in F6Publishing: 88] [Article Influence: 11.1] [Reference Citation Analysis]
|
| 288 |
Schoepfer AM, Beglinger C, Straumann A, Safroneeva E, Romero Y, Armstrong D, Schmidt C, Trummler M, Pittet V, Vavricka SR. Fecal calprotectin more accurately reflects endoscopic activity of ulcerative colitis than the Lichtiger Index, C-reactive protein, platelets, hemoglobin, and blood leukocytes. Inflamm Bowel Dis 2013;19:332-41. [PMID: 23328771 DOI: 10.1097/MIB.0b013e3182810066] [Cited by in Crossref: 191] [Cited by in F6Publishing: 167] [Article Influence: 19.1] [Reference Citation Analysis]
|
| 289 |
Røseth A, Chapman R, Ramachandran R, Sheehan C. Gastrointestinal Tract. The Immunoassay Handbook 2013. [DOI: 10.1016/b978-0-08-097037-0.00070-1] [Reference Citation Analysis]
|
| 290 |
Otley A, Day AS, Zachos M. Nutritional Management of Inflammatory Bowel Disease. Pediatric Inflammatory Bowel Disease 2013. [DOI: 10.1007/978-1-4614-5061-0_28] [Reference Citation Analysis]
|
| 291 |
Smith LA, Gaya DR. Utility of faecal calprotectin analysis in adult inflammatory bowel disease. World J Gastroenterol 2012; 18(46): 6782-6789 [PMID: 23239916 DOI: 10.3748/wjg.v18.i46.6782] [Cited by in CrossRef: 43] [Cited by in F6Publishing: 46] [Article Influence: 3.9] [Reference Citation Analysis]
|
| 292 |
Goodhand JR, Wahed M, Mawdsley JE, Farmer AD, Aziz Q, Rampton DS. Mood disorders in inflammatory bowel disease: relation to diagnosis, disease activity, perceived stress, and other factors. Inflamm Bowel Dis 2012;18:2301-9. [PMID: 22359369 DOI: 10.1002/ibd.22916] [Cited by in Crossref: 149] [Cited by in F6Publishing: 131] [Article Influence: 13.5] [Reference Citation Analysis]
|
| 293 |
Whitehead SJ, French J, Brookes MJ, Ford C, Gama R. Between-assay variability of faecal calprotectin enzyme-linked immunosorbent assay kits. Ann Clin Biochem. 2013;50:53-61. [PMID: 23129721 DOI: 10.1258/acb.2012.011272] [Cited by in Crossref: 72] [Cited by in F6Publishing: 77] [Article Influence: 6.5] [Reference Citation Analysis]
|
| 294 |
Molander P, af Björkesten CG, Mustonen H, Haapamäki J, Vauhkonen M, Kolho KL, Färkkilä M, Sipponen T. Fecal calprotectin concentration predicts outcome in inflammatory bowel disease after induction therapy with TNFα blocking agents. Inflamm Bowel Dis 2012;18:2011-7. [PMID: 22223566 DOI: 10.1002/ibd.22863] [Cited by in Crossref: 130] [Cited by in F6Publishing: 108] [Article Influence: 11.8] [Reference Citation Analysis]
|
| 295 |
van Rheenen PF. Role of fecal calprotectin testing to predict relapse in teenagers with inflammatory bowel disease who report full disease control. Inflamm Bowel Dis 2012;18:2018-25. [PMID: 22275341 DOI: 10.1002/ibd.22896] [Cited by in Crossref: 34] [Cited by in F6Publishing: 26] [Article Influence: 3.1] [Reference Citation Analysis]
|
| 296 |
Vaiopoulou A, Gazouli M, Theodoropoulos G, Zografos G. Current advantages in the application of proteomics in inflammatory bowel disease. Dig Dis Sci 2012;57:2755-64. [PMID: 22740064 DOI: 10.1007/s10620-012-2291-4] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 297 |
Chen CC, Huang JL, Chang CJ, Kong MS. Fecal calprotectin as a correlative marker in clinical severity of infectious diarrhea and usefulness in evaluating bacterial or viral pathogens in children. J Pediatr Gastroenterol Nutr 2012;55:541-7. [PMID: 22699836 DOI: 10.1097/MPG.0b013e318262a718] [Cited by in Crossref: 70] [Cited by in F6Publishing: 73] [Article Influence: 6.4] [Reference Citation Analysis]
|
| 298 |
Hawthorne AB, Stenson R, Gillespie D, Swarbrick ET, Dhar A, Kapur KC, Hood K, Probert CS. One-year investigator-blind randomized multicenter trial comparing Asacol 2.4 g once daily with 800 mg three times daily for maintenance of remission in ulcerative colitis. Inflamm Bowel Dis 2012;18:1885-93. [PMID: 22081522 DOI: 10.1002/ibd.21938] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 299 |
Mao R, Xiao YL, Gao X, Chen BL, He Y, Yang L, Hu PJ, Chen MH. Fecal calprotectin in predicting relapse of inflammatory bowel diseases: a meta-analysis of prospective studies. Inflamm Bowel Dis 2012;18:1894-9. [PMID: 22238138 DOI: 10.1002/ibd.22861] [Cited by in Crossref: 205] [Cited by in F6Publishing: 173] [Article Influence: 18.6] [Reference Citation Analysis]
|
| 300 |
Scaldaferri F, Pizzoferrato M, Gerardi V, Lopetuso L, Gasbarrini A. The gut barrier: new acquisitions and therapeutic approaches. J Clin Gastroenterol 2012;46 Suppl:S12-7. [PMID: 22955350 DOI: 10.1097/MCG.0b013e31826ae849] [Cited by in Crossref: 130] [Cited by in F6Publishing: 127] [Article Influence: 11.8] [Reference Citation Analysis]
|
| 301 |
Jena G, Trivedi PP, Sandala B. Oxidative stress in ulcerative colitis: an old concept but a new concern. Free Radic Res. 2012;46:1339-1345. [PMID: 22856328 DOI: 10.3109/10715762.2012.717692] [Cited by in Crossref: 84] [Cited by in F6Publishing: 93] [Article Influence: 7.6] [Reference Citation Analysis]
|
| 302 |
Kiss LS, Papp M, Lovasz BD, Vegh Z, Golovics PA, Janka E, Varga E, Szathmari M, Lakatos PL. High-sensitivity C-reactive protein for identification of disease phenotype, active disease, and clinical relapses in Crohn's disease: a marker for patient classification? Inflamm Bowel Dis 2012;18:1647-54. [PMID: 22081542 DOI: 10.1002/ibd.21933] [Cited by in Crossref: 60] [Cited by in F6Publishing: 52] [Article Influence: 5.5] [Reference Citation Analysis]
|
| 303 |
Teshima CW, Dieleman LA, Meddings JB. Abnormal intestinal permeability in Crohn’s disease pathogenesis. Ann N Y Acad Sci. 2012;1258:159-165. [PMID: 22731729 DOI: 10.1111/j.1749-6632.2012.06612.x] [Cited by in Crossref: 61] [Cited by in F6Publishing: 63] [Article Influence: 5.5] [Reference Citation Analysis]
|
| 304 |
Lee JM, Leach ST, Katz T, Day AS, Jaffe A, Ooi CY. Update of faecal markers of inflammation in children with cystic fibrosis. Mediators Inflamm 2012;2012:948367. [PMID: 22988347 DOI: 10.1155/2012/948367] [Cited by in Crossref: 29] [Cited by in F6Publishing: 36] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 305 |
Parikh A, Leach T, Wyant T, Scholz C, Sankoh S, Mould DR, Ponich T, Fox I, Feagan BG. Vedolizumab for the treatment of active ulcerative colitis: a randomized controlled phase 2 dose-ranging study. Inflamm Bowel Dis 2012;18:1470-9. [PMID: 22147460 DOI: 10.1002/ibd.21896] [Cited by in Crossref: 162] [Cited by in F6Publishing: 151] [Article Influence: 14.7] [Reference Citation Analysis]
|
| 306 |
Alhagamhmad MH, Day AS, Lemberg DA, Leach ST. An update of the role of nutritional therapy in the management of Crohn's disease. J Gastroenterol 2012;47:872-82. [PMID: 22699323 DOI: 10.1007/s00535-012-0617-9] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 307 |
Shaoul R, Sladek M, Turner D, Paeregaard A, Veres G, Wauters GV, Escher J, Dias JA, Lionetti P, Staino A, Kolho KL, de Ridder L, Nuti F, Cucchiara S, Sheva O, Levine A; ESPGHAN Porto IBD Group. Limitations of fecal calprotectin at diagnosis in untreated pediatric Crohn's disease. Inflamm Bowel Dis 2012;18:1493-7. [PMID: 22275268 DOI: 10.1002/ibd.21875] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 308 |
Sherwood RA. Faecal markers of gastrointestinal inflammation. J Clin Pathol 2012;65:981-5. [DOI: 10.1136/jclinpath-2012-200901] [Cited by in Crossref: 44] [Cited by in F6Publishing: 49] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 309 |
Netzel-Arnett S, Buzza MS, Shea-Donohue T, Désilets A, Leduc R, Fasano A, Bugge TH, Antalis TM. Matriptase protects against experimental colitis and promotes intestinal barrier recovery. Inflamm Bowel Dis 2012;18:1303-14. [PMID: 22081509 DOI: 10.1002/ibd.21930] [Cited by in Crossref: 47] [Cited by in F6Publishing: 41] [Article Influence: 4.3] [Reference Citation Analysis]
|
| 310 |
Fukunaga K, Matsumoto T. Current status and future perspectives of leukocytapheresis for inflammatory bowel disease. J Gastroenterol Hepatol 2012;27:997-1003. [PMID: 22414250 DOI: 10.1111/j.1440-1746.2012.07119.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 311 |
Abraham BP, Kane S. Fecal markers: calprotectin and lactoferrin. Gastroenterol Clin North Am 2012;41:483-95. [PMID: 22500530 DOI: 10.1016/j.gtc.2012.01.007] [Cited by in Crossref: 73] [Cited by in F6Publishing: 76] [Article Influence: 6.6] [Reference Citation Analysis]
|
| 312 |
Gecse K, Róka R, Séra T, Rosztóczy A, Annaházi A, Izbéki F, Nagy F, Molnár T, Szepes Z, Pávics L, Bueno L, Wittmann T. Leaky gut in patients with diarrhea-predominant irritable bowel syndrome and inactive ulcerative colitis. Digestion 2012;85:40-6. [PMID: 22179430 DOI: 10.1159/000333083] [Cited by in Crossref: 55] [Cited by in F6Publishing: 58] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 313 |
Cabriada JL, Domènech E, Ibargoyen N, Hernández V, Clofent J, Ginard D, Gutiérrez-Ibarluzea I, Hinojosa J. Leukocytapheresis for steroid-dependent ulcerative colitis in clinical practice: results of a nationwide Spanish registry. J Gastroenterol 2012;47:359-65. [PMID: 22105230 DOI: 10.1007/s00535-011-0499-2] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 314 |
Iskandar HN, Ciorba MA. Biomarkers in inflammatory bowel disease: current practices and recent advances. Transl Res 2012;159:313-25. [PMID: 22424434 DOI: 10.1016/j.trsl.2012.01.001] [Cited by in Crossref: 128] [Cited by in F6Publishing: 135] [Article Influence: 11.6] [Reference Citation Analysis]
|
| 315 |
Vilela EG, Torres HODG, Martins FP, Ferrari MLA, Andrade MM, Cunha ASD. Evaluation of inflammatory activity in Crohn’s disease and ulcerative colitis. World J Gastroenterol 2012; 18(9): 872-881 [PMID: 22408345 DOI: 10.3748/wjg.v18.i9.872] [Cited by in CrossRef: 64] [Cited by in F6Publishing: 71] [Article Influence: 5.8] [Reference Citation Analysis]
|
| 316 |
Sydora MJ, Sydora BC, Fedorak RN. Validation of a point-of-care desk top device to quantitate fecal calprotectin and distinguish inflammatory bowel disease from irritable bowel syndrome. J Crohns Colitis 2012;6:207-14. [PMID: 22325175 DOI: 10.1016/j.crohns.2011.08.008] [Cited by in Crossref: 37] [Cited by in F6Publishing: 46] [Article Influence: 3.4] [Reference Citation Analysis]
|
| 317 |
Denizot J, Sivignon A, Barreau F, Darcha C, Chan HF, Stanners CP, Hofman P, Darfeuille-Michaud A, Barnich N. Adherent-invasive Escherichia coli induce claudin-2 expression and barrier defect in CEABAC10 mice and Crohn's disease patients. Inflamm Bowel Dis 2012;18:294-304. [PMID: 21688348 DOI: 10.1002/ibd.21787] [Cited by in Crossref: 63] [Cited by in F6Publishing: 56] [Article Influence: 5.7] [Reference Citation Analysis]
|
| 318 |
Panaccione R, Hibi T, Peyrin-Biroulet L, Schreiber S. Implementing changes in clinical practice to improve the management of Crohn's disease. J Crohns Colitis 2012;6 Suppl 2:S235-42. [PMID: 22463930 DOI: 10.1016/S1873-9946(12)60503-0] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 319 |
Louis E, Baumgart DC, Ghosh S, Gomollón F, Hanauer S, Hart A, Irving P. What changes in inflammatory bowel disease management can be implemented today? J Crohns Colitis 2012;6 Suppl 2:S260-7. [PMID: 22463933 DOI: 10.1016/S1873-9946(12)60506-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 320 |
Cabriada JL. Aféresis en enfermedad inflamatoria intestinal. ¿Una opción válida? Gastroenterología y Hepatología 2012;35:22-31. [DOI: 10.1016/j.gastrohep.2011.10.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 321 |
Mills AM, Huckins DS, Kwok H, Baumann BM, Ruddy RM, Rothman RE, Schrock JW, Lovecchio F, Krief WI, Hexdall A, Caspari R, Cohen B, Lewis RJ. Diagnostic characteristics of S100A8/A9 in a multicenter study of patients with acute right lower quadrant abdominal pain. Acad Emerg Med 2012;19:48-55. [PMID: 22221415 DOI: 10.1111/j.1553-2712.2011.01259.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 322 |
Ma TY, Anderson JM, Turner JR. Tight Junctions and the Intestinal Barrier. Physiology of the Gastrointestinal Tract 2012. [DOI: 10.1016/b978-0-12-382026-6.00038-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 323 |
Yoshimura N, Tadami T, Kawaguchi T, Sako M, Yoshimoto H, Yamaka T, Takazoe M. Processed blood volume impacts clinical efficacy in patients with ulcerative colitis undergoing adsorptive depletion of myeloid lineage leucocytes. J Gastroenterol 2012;47:49-55. [PMID: 21915624 DOI: 10.1007/s00535-011-0464-0] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 324 |
Dotan I. Laboratory Evaluation Including Novel Diagnostic Markers of Inflammatory Bowel Disease. Crohn's Disease and Ulcerative Colitis 2012. [DOI: 10.1007/978-1-4614-0998-4_21] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 325 |
Ayling RM. New faecal tests in gastroenterology. Ann Clin Biochem. 2012;49:44-54. [PMID: 22113956 DOI: 10.1258/acb.2011.011150] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 326 |
Yeşil A, Senateş E, Bayoğlu IV, Erdem ED, Demirtunç R, Kurdaş Övünç AO. Red cell distribution width: a novel marker of activity in inflammatory bowel disease. Gut Liver 2011;5:460-7. [PMID: 22195244 DOI: 10.5009/gnl.2011.5.4.460] [Cited by in Crossref: 79] [Cited by in F6Publishing: 85] [Article Influence: 6.6] [Reference Citation Analysis]
|
| 327 |
Kaneda K, Saitoh F, Shibusawa H, Maegawa H, Saniabadi AR, Kashiwagi N, Matsukawa A. Correlation of neutrophil and monocyte derived interleukin-1 receptor antagonist and interleukin-8 with colitis severity in the rabbit. Cytokine 2011;56:508-14. [DOI: 10.1016/j.cyto.2011.07.008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 328 |
Mindemark M, Larsson A. Ruling out IBD: estimation of the possible economic effects of pre-endoscopic screening with F-calprotectin. Clin Biochem. 2012;45:552-555. [PMID: 22056737 DOI: 10.1016/j.clinbiochem.2011.10.015] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 329 |
Judd TA, Day AS, Lemberg DA, Turner D, Leach ST. Update of fecal markers of inflammation in inflammatory bowel disease. J Gastroenterol Hepatol 2011;26:1493-9. [PMID: 21777275 DOI: 10.1111/j.1440-1746.2011.06846.x] [Cited by in Crossref: 57] [Cited by in F6Publishing: 53] [Article Influence: 4.8] [Reference Citation Analysis]
|
| 330 |
Laharie D, Mesli S, El Hajbi F, Chabrun E, Chanteloup E, Capdepont M, Razaire S, de Lédinghen V, Zerbib F. Prediction of Crohn's disease relapse with faecal calprotectin in infliximab responders: a prospective study. Aliment Pharmacol Ther 2011;34:462-9. [PMID: 21671970 DOI: 10.1111/j.1365-2036.2011.04743.x] [Cited by in Crossref: 66] [Cited by in F6Publishing: 44] [Article Influence: 5.5] [Reference Citation Analysis]
|
| 331 |
Travis SP, Higgins PD, Orchard T, Van Der Woude CJ, Panaccione R, Bitton A, O'Morain C, Panés J, Sturm A, Reinisch W, Kamm MA, D'Haens G. Review article: defining remission in ulcerative colitis. Aliment Pharmacol Ther 2011;34:113-24. [PMID: 21615435 DOI: 10.1111/j.1365-2036.2011.04701.x] [Cited by in Crossref: 124] [Cited by in F6Publishing: 125] [Article Influence: 10.3] [Reference Citation Analysis]
|
| 332 |
Wagner M, Peterson CG, Stolt I, Sangfelt P, Agnarsdottir M, Lampinen M, Carlson M. Fecal eosinophil cationic protein as a marker of active disease and treatment outcome in collagenous colitis: a pilot study. Scand J Gastroenterol 2011;46:849-54. [PMID: 21557718 DOI: 10.3109/00365521.2011.571707] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 333 |
Manolakis AC, Kapsoritakis AN, Tiaka EK, Potamianos SP. Calprotectin, calgranulin C, and other members of the s100 protein family in inflammatory bowel disease. Dig Dis Sci 2011;56:1601-11. [PMID: 21203903 DOI: 10.1007/s10620-010-1494-9] [Cited by in Crossref: 62] [Cited by in F6Publishing: 58] [Article Influence: 5.2] [Reference Citation Analysis]
|
| 334 |
Lewis JD. The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease. Gastroenterology 2011;140:1817-1826.e2. [PMID: 21530748 DOI: 10.1053/j.gastro.2010.11.058] [Cited by in Crossref: 300] [Cited by in F6Publishing: 316] [Article Influence: 25.0] [Reference Citation Analysis]
|
| 335 |
Koulaouzidis A, Douglas S, Rogers MA, Arnott ID, Plevris JN. Fecal calprotectin: a selection tool for small bowel capsule endoscopy in suspected IBD with prior negative bi-directional endoscopy. Scand J Gastroenterol 2011;46:561-6. [PMID: 21269246 DOI: 10.3109/00365521.2011.551835] [Cited by in Crossref: 62] [Cited by in F6Publishing: 69] [Article Influence: 5.2] [Reference Citation Analysis]
|
| 336 |
Kaner D, Bernimoulin J, Dietrich T, Kleber B, Friedmann A. Calprotectin levels in gingival crevicular fluid predict disease activity in patients treated for generalized aggressive periodontitis: Calprotectin predicts periodontal disease activity. Journal of Periodontal Research 2011;46:417-26. [DOI: 10.1111/j.1600-0765.2011.01355.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
|
| 337 |
Lakatos PL, Kiss LS, Palatka K, Altorjay I, Antal-Szalmas P, Palyu E, Udvardy M, Molnar T, Farkas K, Veres G, Harsfalvi J, Papp J, Papp M. Serum lipopolysaccharide-binding protein and soluble CD14 are markers of disease activity in patients with Crohn's disease. Inflamm Bowel Dis 2011;17:767-77. [PMID: 20865702 DOI: 10.1002/ibd.21402] [Cited by in Crossref: 55] [Cited by in F6Publishing: 55] [Article Influence: 4.6] [Reference Citation Analysis]
|
| 338 |
Masoodi I, Tijjani BM, Wani H, Hassan NS, Khan AB, Hussain S. Biomarkers in the management of ulcerative colitis: a brief review. Ger Med Sci. 2011;9:Doc03. [PMID: 21394194 DOI: 10.3205/000126] [Cited by in F6Publishing: 19] [Reference Citation Analysis]
|
| 339 |
Rosh JR. Assessing disease risk in pediatric ulcerative colitis. Inflamm Bowel Dis 2011;17:13-4. [PMID: 20629182 DOI: 10.1002/ibd.21392] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 340 |
Lamb CA, Mansfield JC. Measurement of faecal calprotectin and lactoferrin in inflammatory bowel disease. Frontline Gastroenterol 2011;2:13-8. [PMID: 23904968 DOI: 10.1136/fg.2010.001362] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 2.9] [Reference Citation Analysis]
|
| 341 |
Sprakes MB, Hamlin PJ, Ford AC. Utility of fecal calprotectin in differentiating active inflammatory bowel disease from coexistent irritable bowel syndrome. Am J Gastroenterol 2011;106:166; author reply 166-7. [PMID: 21212757 DOI: 10.1038/ajg.2010.355] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 342 |
Hanauer SB, Kornbluth AA, Messick J, Rubin DT, Sandborn WJ, Sands BE. Clinical scenarios in IBD: optimizing the use of conventional and biologic agents. Inflamm Bowel Dis 2010;16 Suppl 1:S1-11. [PMID: 21104734 DOI: 10.1002/ibd.21529] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 343 |
Pham M, Leach ST, Lemberg DA, Day AS. Subclinical intestinal inflammation in siblings of children with Crohn's disease. Dig Dis Sci 2010;55:3502-7. [PMID: 20931283 DOI: 10.1007/s10620-010-1434-8] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 344 |
Hanai H, Takeda Y, Eberhardson M, Gruber R, Saniabadi AR, Winqvist O, Lofberg R. The mode of actions of the Adacolumn therapeutic leucocytapheresis in patients with inflammatory bowel disease: a concise review. Clin Exp Immunol. 2011;163:50-58. [PMID: 21078086 DOI: 10.1111/j.1365-2249.2010.04279.x] [Cited by in Crossref: 65] [Cited by in F6Publishing: 72] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 345 |
Hanai H, Takeda Y, Eberhardson M, Gruber R, Saniabadi AR, Winqvist O, Lofberg R. The mode of actions of the Adacolumn therapeutic leucocytapheresis in patients with inflammatory bowel disease: a concise review. Clin Exp Immunol 2011;163:50-8. [PMID: 21078086 DOI: 10.1111/j.1365-2249.2010.04279.x] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 346 |
Caccaro R, D’Incá R, Sturniolo GC. Clinical utility of calprotectin and lactoferrin as markers of inflammation in patients with inflammatory bowel disease. Expert Rev Clin Immunol. 2010;6:551-558. [PMID: 20594128 DOI: 10.1586/eci.10.26] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 347 |
Tanaka T, Okanobu H, Kuga Y, Yoshifuku Y, Fujino H, Miwata T, Moriya T, Nishida T, Oya T. Clinical and endoscopic features of responders and non-responders to adsorptive leucocytapheresis: a report based on 120 patients with active ulcerative colitis. Gastroenterol Clin Biol. 2010;34:687-695. [PMID: 20934287 DOI: 10.1016/j.gcb.2010.08.007] [Cited by in Crossref: 21] [Cited by in F6Publishing: 25] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 348 |
Song WB, Wang YY, Meng FS, Zhang QH, Zeng JY, Xiao LP, Yu XP, Peng DD, Su L, Xiao B. Curcumin protects intestinal mucosal barrier function of rat enteritis via activation of MKP-1 and attenuation of p38 and NF-κB activation. PLoS One. 2010;5:e12969. [PMID: 20885979 DOI: 10.1371/journal.pone.0012969] [Cited by in Crossref: 60] [Cited by in F6Publishing: 66] [Article Influence: 4.6] [Reference Citation Analysis]
|
| 349 |
Lakatos PL, Kiss LS. Is the disease course predictable in inflammatory bowel diseases? World J Gastroenterol. 2010;16:2591-2599. [PMID: 20518079 DOI: 10.3748/wjg.v16.i21.2591.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 350 |
Onali S, Calabrese E, Petruzziello C, Zorzi F, Sica GS, Lolli E, Ascolani M, Condino G, Pallone F, Biancone L. Endoscopic vs ultrasonographic findings related to Crohn's disease recurrence: a prospective longitudinal study at 3 years. J Crohns Colitis 2010;4:319-28. [PMID: 21122521 DOI: 10.1016/j.crohns.2009.12.010] [Cited by in Crossref: 43] [Cited by in F6Publishing: 45] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 351 |
Keohane J, O'Mahony C, O'Mahony L, O'Mahony S, Quigley EM, Shanahan F. Irritable bowel syndrome-type symptoms in patients with inflammatory bowel disease: a real association or reflection of occult inflammation? Am J Gastroenterol 2010;105:1788, 1789-94; quiz 1795. [PMID: 20389294 DOI: 10.1038/ajg.2010.156] [Cited by in Crossref: 140] [Cited by in F6Publishing: 156] [Article Influence: 10.8] [Reference Citation Analysis]
|
| 352 |
Sipponen T, Kolho KL. Faecal calprotectin in children with clinically quiescent inflammatory bowel disease. Scand J Gastroenterol 2010;45:872-7. [PMID: 20377469 DOI: 10.3109/00365521003782389] [Cited by in Crossref: 71] [Cited by in F6Publishing: 71] [Article Influence: 5.5] [Reference Citation Analysis]
|
| 353 |
Montalto M, Gallo A, Ianiro G, Santoro L, D’Onofrio F, Ricci R, Cammarota G, Covino M, Vastola M, Gasbarrini A, Gasbarrini G. Can chronic gastritis cause an increase in fecal calprotectin concentrations? World J Gastroenterol 2010; 16(27): 3406-3410 [PMID: 20632443 DOI: 10.3748/wjg.v16.i27.3406] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 18] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 354 |
van Rheenen PF, Van de Vijver E, Fidler V. Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis. BMJ 2010;341:c3369. [PMID: 20634346 DOI: 10.1136/bmj.c3369] [Cited by in Crossref: 452] [Cited by in F6Publishing: 472] [Article Influence: 34.8] [Reference Citation Analysis]
|
| 355 |
Lakatos PL, Kiss LS. Is the disease course predictable in inflammatory bowel diseases? World J Gastroenterol 2010; 16(21): 2591-2599 [PMID: 20518079 DOI: 10.3748/wjg.v16.i21.2591] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 16] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 356 |
Dubinsky MC. Serologic and laboratory markers in prediction of the disease course in inflammatory bowel disease. World J Gastroenterol 2010; 16(21): 2604-2608 [PMID: 20518081 DOI: 10.3748/wjg.v16.i21.2604] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 357 |
Engel MA, Neurath MF. New pathophysiological insights and modern treatment of IBD. J Gastroenterol 2010;45:571-83. [PMID: 20213337 DOI: 10.1007/s00535-010-0219-3] [Cited by in Crossref: 130] [Cited by in F6Publishing: 143] [Article Influence: 10.0] [Reference Citation Analysis]
|
| 358 |
García-Sánchez V, Iglesias-Flores E, González R, Gisbert JP, Gallardo-Valverde JM, González-Galilea A, Naranjo-Rodríguez A, de Dios-Vega JF, Muntané J, Gómez-Camacho F. Does fecal calprotectin predict relapse in patients with Crohn's disease and ulcerative colitis? J Crohns Colitis 2010;4:144-52. [PMID: 21122498 DOI: 10.1016/j.crohns.2009.09.008] [Cited by in Crossref: 115] [Cited by in F6Publishing: 119] [Article Influence: 8.8] [Reference Citation Analysis]
|
| 359 |
El-badry A, Sedrak H, Rashed L. Faecal calprotectin in differentiating between functional and organic bowel diseases. Arab Journal of Gastroenterology 2010;11:70-3. [DOI: 10.1016/j.ajg.2010.04.009] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 360 |
Cabriada JL, Ibargoyen N, Hernández A, Bernal A, Castiella A. Sustained remission after steroids and leukocytapheresis induced response in steroid-dependent ulcerative colitis: results at 1 year. Dig Liver Dis 2010;42:432-5. [PMID: 19833566 DOI: 10.1016/j.dld.2009.09.001] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 361 |
Bueno L. Mécanismes régulateurs de la perméabilité des jonctions serrées épithéliales du tube digestif. Cahiers de Nutrition et de Diététique 2010;45:72-77. [DOI: 10.1016/j.cnd.2010.02.003] [Reference Citation Analysis]
|
| 362 |
Grootjans J, Thuijls G, Verdam F, Derikx JP, Lenaerts K, Buurman WA. Non-invasive assessment of barrier integrity and function of the human gut. World J Gastrointest Surg 2010; 2(3): 61-69 [PMID: 21160852 DOI: 10.4240/wjgs.v2.i3.61] [Cited by in CrossRef: 135] [Cited by in F6Publishing: 146] [Article Influence: 10.4] [Reference Citation Analysis]
|
| 363 |
Kuriyama M, Kato J, Takemoto K, Hiraoka S, Okada H, Yamamoto K. Prediction of flare-ups of ulcerative colitis using quantitative immunochemical fecal occult blood test. World J Gastroenterol 2010; 16(9): 1110-1114 [PMID: 20205282 DOI: 10.3748/wjg.v16.i9.1110] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 364 |
Bealer JF, Colgin M. S100A8/A9: a potential new diagnostic aid for acute appendicitis. Acad Emerg Med 2010;17:333-6. [PMID: 20370768 DOI: 10.1111/j.1553-2712.2010.00663.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 365 |
Powell N, Walker MM, Talley NJ. Gastrointestinal eosinophils in health, disease and functional disorders. Nat Rev Gastroenterol Hepatol 2010;7:146-56. [PMID: 20125092 DOI: 10.1038/nrgastro.2010.5] [Cited by in Crossref: 80] [Cited by in F6Publishing: 69] [Article Influence: 6.2] [Reference Citation Analysis]
|
| 366 |
Meucci G, D'Incà R, Maieron R, Orzes N, Vecchi M, Visentini D, Minoli G, Dal Pont E, Zilli M, Benedetti E, Virgilio T, Tonutti E. Diagnostic value of faecal calprotectin in unselected outpatients referred for colonoscopy: A multicenter prospective study. Dig Liver Dis 2010;42:191-5. [PMID: 19695969 DOI: 10.1016/j.dld.2009.07.002] [Cited by in Crossref: 33] [Cited by in F6Publishing: 39] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 367 |
Kallel L, Ayadi I, Matri S, Fekih M, Mahmoud NB, Feki M, Karoui S, Zouari B, Boubaker J, Kaabachi N, Filali A. Fecal calprotectin is a predictive marker of relapse in Crohn's disease involving the colon: a prospective study. Eur J Gastroenterol Hepatol 2010;22:340-5. [PMID: 19581809 DOI: 10.1097/MEG.0b013e32832bab49] [Cited by in Crossref: 82] [Cited by in F6Publishing: 89] [Article Influence: 6.3] [Reference Citation Analysis]
|
| 368 |
Kiss LS, Lakatos PL. Prediction of the disease course in inflammatory bowel diseases. Orvosi Hetilap 2010;151:293-301. [DOI: 10.1556/oh.2010.28813] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 369 |
Van Assche G, Dignass A, Panes J, Beaugerie L, Karagiannis J, Allez M, Ochsenkühn T, Orchard T, Rogler G, Louis E, Kupcinskas L, Mantzaris G, Travis S, Stange E; European Crohn's and Colitis Organisation (ECCO). The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Definitions and diagnosis. J Crohns Colitis 2010;4:7-27. [PMID: 21122488 DOI: 10.1016/j.crohns.2009.12.003] [Cited by in Crossref: 818] [Cited by in F6Publishing: 838] [Article Influence: 62.9] [Reference Citation Analysis]
|
| 370 |
Sands BE, Siegel CA. Crohn's Disease. Sleisenger and Fordtran's Gastrointestinal and Liver Disease 2010. [DOI: 10.1016/b978-1-4160-6189-2.00111-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 371 |
Famularo G, Minisola G. Laboratory Tests. Crohn’s Disease 2010. [DOI: 10.1007/978-88-470-1472-5_7] [Reference Citation Analysis]
|
| 372 |
Abraham BP, Thirumurthi S. Clinical significance of inflammatory markers. Curr Gastroenterol Rep 2009;11:360-7. [PMID: 19765363 DOI: 10.1007/s11894-009-0055-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 373 |
Zisman TL, Rubin DT. Novel diagnostic and prognostic modalities in inflammatory bowel disease. Med Clin North Am 2010;94:155-78. [PMID: 19944803 DOI: 10.1016/j.mcna.2009.10.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 374 |
Zisman TL, Rubin DT. Novel diagnostic and prognostic modalities in inflammatory bowel disease. Gastroenterol Clin North Am 2009;38:729-52. [PMID: 19913211 DOI: 10.1016/j.gtc.2009.08.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 375 |
Schoepfer AM, Beglinger C, Straumann A, Trummler M, Renzulli P, Seibold F. Ulcerative colitis: correlation of the Rachmilewitz endoscopic activity index with fecal calprotectin, clinical activity, C-reactive protein, and blood leukocytes. Inflamm Bowel Dis 2009;15:1851-8. [PMID: 19462421 DOI: 10.1002/ibd.20986] [Cited by in Crossref: 217] [Cited by in F6Publishing: 190] [Article Influence: 15.5] [Reference Citation Analysis]
|
| 376 |
Gisbert JP, McNicholl AG, Gomollon F. Questions and answers on the role of fecal lactoferrin as a biological marker in inflammatory bowel disease. Inflamm Bowel Dis 2009;15:1746-54. [PMID: 19363798 DOI: 10.1002/ibd.20920] [Cited by in Crossref: 73] [Cited by in F6Publishing: 73] [Article Influence: 5.2] [Reference Citation Analysis]
|
| 377 |
Jeffery J, Lewis SJ, Ayling RM. Fecal dimeric M2-pyruvate kinase (tumor M2-PK) in the differential diagnosis of functional and organic bowel disorders. Inflamm Bowel Dis 2009;15:1630-4. [PMID: 19462434 DOI: 10.1002/ibd.20946] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 2.1] [Reference Citation Analysis]
|
| 378 |
Calabrese E, Petruzziello C, Onali S, Condino G, Zorzi F, Pallone F, Biancone L. Severity of postoperative recurrence in Crohn's disease: correlation between endoscopic and sonographic findings. Inflamm Bowel Dis 2009;15:1635-42. [PMID: 19408327 DOI: 10.1002/ibd.20948] [Cited by in Crossref: 99] [Cited by in F6Publishing: 79] [Article Influence: 7.1] [Reference Citation Analysis]
|
| 379 |
Masoodi I, Kochhar R, Dutta U, Vaishnavi C, Prasad KK, Vaiphei K, Kaur S, Singh K. Fecal lactoferrin, myeloperoxidase and serum C-reactive are effective biomarkers in the assessment of disease activity and severity in patients with idiopathic ulcerative colitis. J Gastroenterol Hepatol 2009;24:1768-74. [PMID: 20136960 DOI: 10.1111/j.1440-1746.2009.06048.x] [Cited by in Crossref: 42] [Cited by in F6Publishing: 41] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 380 |
Helmy A, Abdulla M, Kagevi I, Al Kahtani K. Leukocyte apheresis in the management of ulcerative colitis. Saudi J Gastroenterol 2009;15:283-7. [PMID: 19794281 DOI: 10.4103/1319-3767.56093] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 381 |
Navaneethan U, Shen B. Laboratory tests for patients with ileal pouch-anal anastomosis: clinical utility in predicting, diagnosing, and monitoring pouch disorders. Am J Gastroenterol 2009;104:2606-15. [PMID: 19603012 DOI: 10.1038/ajg.2009.392] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 382 |
Frizelle FA, Ing A, Gearry RB, Whitehead M, Faragher IG, Dobbs B. Immunomodulation does not alter histology in resected Crohn’s disease. Tech Coloproctol. 2009;13:295-300. [PMID: 19774438 DOI: 10.1007/s10151-009-0538-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 383 |
Song WB, Lv YH, Zhang ZS, Li YN, Xiao LP, Yu XP, Wang YY, Ji HL, Ma L. Soluble intercellular adhesion molecule-1, D-lactate and diamine oxidase in patients with inflammatory bowel disease. World J Gastroenterol 2009; 15(31): 3916-3919 [PMID: 19701972 DOI: 10.3748/wjg.15.3916] [Cited by in CrossRef: 58] [Cited by in F6Publishing: 63] [Article Influence: 4.1] [Reference Citation Analysis]
|
| 384 |
Nos P, Domènech E. Tratamiento con aféresis en la enfermedad inflamatoria intestinal. Gastroenterología y Hepatología 2009;32:509-18. [DOI: 10.1016/j.gastrohep.2009.01.183] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 385 |
Hibi T, Sameshima Y, Sekiguchi Y, Hisatome Y, Maruyama F, Moriwaki K, Shima C, Saniabadi AR, Matsumoto T. Treating ulcerative colitis by Adacolumn therapeutic leucocytapheresis: clinical efficacy and safety based on surveillance of 656 patients in 53 centres in Japan. Dig Liver Dis 2009;41:570-7. [PMID: 19211314 DOI: 10.1016/j.dld.2008.11.020] [Cited by in Crossref: 50] [Cited by in F6Publishing: 51] [Article Influence: 3.6] [Reference Citation Analysis]
|
| 386 |
Gisbert JP, Bermejo F, Pérez-Calle JL, Taxonera C, Vera I, McNicholl AG, Algaba A, López P, López-Palacios N, Calvo M, González-Lama Y, Carneros JA, Velasco M, Maté J. Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse. Inflamm Bowel Dis 2009;15:1190-8. [PMID: 19291780 DOI: 10.1002/ibd.20933] [Cited by in Crossref: 217] [Cited by in F6Publishing: 182] [Article Influence: 15.5] [Reference Citation Analysis]
|
| 387 |
Varela E, Antolín M, Guarner F, Verges R, Giralt J, Malagelada JR. Faecal DNA and calprotectin as biomarkers of acute intestinal toxicity in patients undergoing pelvic radiotherapy. Aliment Pharmacol Ther 2009;30:175-85. [PMID: 19392859 DOI: 10.1111/j.1365-2036.2009.04019.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 388 |
Clara I, Lix LM, Walker JR, Graff LA, Miller N, Rogala L, Rawsthorne P, Bernstein CN. The Manitoba IBD Index: evidence for a new and simple indicator of IBD activity. Am J Gastroenterol 2009;104:1754-63. [PMID: 19455122 DOI: 10.1038/ajg.2009.197] [Cited by in Crossref: 81] [Cited by in F6Publishing: 76] [Article Influence: 5.8] [Reference Citation Analysis]
|
| 389 |
Lamb CA, Mohiuddin MK, Gicquel J, Neely D, Bergin FG, Hanson JM, Mansfield JC. Faecal calprotectin or lactoferrin can identify postoperative recurrence in Crohn's disease. Br J Surg. 2009;96:663-674. [PMID: 19384912 DOI: 10.1002/bjs.6593] [Cited by in Crossref: 106] [Cited by in F6Publishing: 113] [Article Influence: 7.6] [Reference Citation Analysis]
|
| 390 |
Mendoza J, Abreu M. Biological markers in inflammatory bowel disease: Practical consideration for clinicians. Gastroentérologie Clinique et Biologique 2009;33:S158-73. [DOI: 10.1016/s0399-8320(09)73151-3] [Cited by in Crossref: 74] [Cited by in F6Publishing: 83] [Article Influence: 5.3] [Reference Citation Analysis]
|
| 391 |
Dal Pont E, D’Incà R, Caruso A, Sturniolo GC. Non-invasive investigation in patients with inflammatory joint disease. World J Gastroenterol 2009; 15(20): 2463-2468 [PMID: 19468995 DOI: 10.3748/wjg.15.2463] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 392 |
Johnson MW, Maestranzi S, Duffy AM, Dewar DH, Ciclitira PJ, Sherwood RA, Nicholls JR. Faecal M2-pyruvate kinase: a novel, noninvasive marker of ileal pouch inflammation. Eur J Gastroenterol Hepatol 2009;21:544-50. [PMID: 19300275 DOI: 10.1097/MEG.0b013e3283040cb3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 393 |
Pimentel-Nunes P, Dinis-Ribeiro M, Magro F. Systematic review on drug and diet-induced endoscopic remission in Crohn's disease. Eur J Gastroenterol Hepatol 2009;21:491-503. [PMID: 19293722 DOI: 10.1097/MEG.0b013e3283196b03] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 394 |
Kudo T, Matsumoto T, Esaki M, Yao T, Iida M. Mucosal vascular pattern in ulcerative colitis: observations using narrow band imaging colonoscopy with special reference to histologic inflammation. Int J Colorectal Dis 2009;24:495-501. [PMID: 19145441 DOI: 10.1007/s00384-008-0631-9] [Cited by in Crossref: 48] [Cited by in F6Publishing: 53] [Article Influence: 3.4] [Reference Citation Analysis]
|
| 395 |
Demaude J, Levêque M, Chaumaz G, Eutamène H, Fioramonti J, Bueno L, Ferrier L. Acute stress increases colonic paracellular permeability in mice through a mast cell-independent mechanism: involvement of pancreatic trypsin. Life Sci 2009;84:847-52. [PMID: 19345697 DOI: 10.1016/j.lfs.2009.03.016] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 1.9] [Reference Citation Analysis]
|
| 396 |
Cakal B, Akoz AG, Ustundag Y, Yalinkilic M, Ulker A, Ankarali H. Red cell distribution width for assessment of activity of inflammatory bowel disease. Dig Dis Sci 2009;54:842-7. [PMID: 18716874 DOI: 10.1007/s10620-008-0436-2] [Cited by in Crossref: 76] [Cited by in F6Publishing: 76] [Article Influence: 5.4] [Reference Citation Analysis]
|
| 397 |
Fukunaga K, Nagase K, Kusaka T, Hida N, Ohda Y, Yoshida K, Tozawa K, Kamikozuru K, Iimuro M, Nakamura S, Miwa H, Matsumoto T. Cytapheresis in patients with severe ulcerative colitis after failure of intravenous corticosteroid: a long-term retrospective cohort study. Gut Liver 2009;3:41-7. [PMID: 20479900 DOI: 10.5009/gnl.2009.3.1.41] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 398 |
Matsuda R, Koide T, Tokoro C, Yamamoto T, Godai T, Morohashi T, Fujita Y, Takahashi D, Kawana I, Suzuki S, Umemura S. Quantitive cytokine mRNA expression profiles in the colonic mucosa of patients with steroid naïve ulcerative colitis during active and quiescent disease. Inflamm Bowel Dis 2009;15:328-34. [PMID: 18942752 DOI: 10.1002/ibd.20759] [Cited by in Crossref: 62] [Cited by in F6Publishing: 56] [Article Influence: 4.4] [Reference Citation Analysis]
|
| 399 |
Ho GT, Lee HM, Brydon G, Ting T, Hare N, Drummond H, Shand AG, Bartolo DC, Wilson RG, Dunlop MG, Arnott ID, Satsangi J. Fecal calprotectin predicts the clinical course of acute severe ulcerative colitis. Am J Gastroenterol 2009;104:673-8. [PMID: 19262524 DOI: 10.1038/ajg.2008.119] [Cited by in Crossref: 98] [Cited by in F6Publishing: 109] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 400 |
Ulitsky A. Comment On: Omega-3 Free Fatty Acids for the Maintenance of Remission in Crohn Disease: The EPIC Randomized Controlled Trials. Nutr Clin Pract 2009;24:102-3. [DOI: 10.1177/0884533608329707] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 401 |
Miele E, Pascarella F, Giannetti E, Quaglietta L, Baldassano RN, Staiano A. Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. Am J Gastroenterol 2009;104:437-43. [PMID: 19174792 DOI: 10.1038/ajg.2008.118] [Cited by in Crossref: 350] [Cited by in F6Publishing: 358] [Article Influence: 25.0] [Reference Citation Analysis]
|
| 402 |
Ashorn S, Honkanen T, Kolho KL, Ashorn M, Välineva T, Wei B, Braun J, Rantala I, Luukkaala T, Iltanen S. Fecal calprotectin levels and serological responses to microbial antigens among children and adolescents with inflammatory bowel disease. Inflamm Bowel Dis 2009;15:199-205. [PMID: 18618670 DOI: 10.1002/ibd.20535] [Cited by in Crossref: 45] [Cited by in F6Publishing: 44] [Article Influence: 3.2] [Reference Citation Analysis]
|
| 403 |
Gisbert JP, McNicholl AG. Questions and answers on the role of faecal calprotectin as a biological marker in inflammatory bowel disease. Dig Liver Dis 2009;41:56-66. [PMID: 18602356 DOI: 10.1016/j.dld.2008.05.008] [Cited by in Crossref: 155] [Cited by in F6Publishing: 168] [Article Influence: 11.1] [Reference Citation Analysis]
|
| 404 |
McGuckin MA, Eri R, Simms LA, Florin TH, Radford-Smith G. Intestinal barrier dysfunction in inflammatory bowel diseases. Inflamm Bowel Dis 2009;15:100-13. [PMID: 18623167 DOI: 10.1002/ibd.20539] [Cited by in Crossref: 387] [Cited by in F6Publishing: 388] [Article Influence: 27.6] [Reference Citation Analysis]
|
| 405 |
Joishy M, Davies I, Ahmed M, Wassel J, Davies K, Sayers A, Jenkins H. Fecal calprotectin and lactoferrin as noninvasive markers of pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2009;48:48-54. [PMID: 19172123 DOI: 10.1097/MPG.0b013e31816533d3] [Cited by in Crossref: 55] [Cited by in F6Publishing: 54] [Article Influence: 3.9] [Reference Citation Analysis]
|
| 406 |
Otten CM, Kok L, Witteman BJ, Baumgarten R, Kampman E, Moons KG, de Wit NJ. Diagnostic performance of rapid tests for detection of fecal calprotectin and lactoferrin and their ability to discriminate inflammatory from irritable bowel syndrome. Clin Chem Lab Med. 2008;46:1275-1280. [PMID: 18597588 DOI: 10.1515/cclm.2008.246] [Cited by in Crossref: 32] [Cited by in F6Publishing: 44] [Article Influence: 2.1] [Reference Citation Analysis]
|
| 407 |
Wagner M, Peterson CG, Ridefelt P, Sangfelt P, Carlson M. Fecal markers of inflammation used as surrogate markers for treatment outcome in relapsing inflammatory bowel disease. World J Gastroenterol. 2008;14:5584-559; discussion 5588. [PMID: 18810778 DOI: 10.3784/wjg.14.5584] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 408 |
Shastri YM, Bergis D, Povse N, Schäfer V, Shastri S, Weindel M, Ackermann H, Stein J. Prospective multicenter study evaluating fecal calprotectin in adult acute bacterial diarrhea. Am J Med 2008;121:1099-106. [PMID: 19028207 DOI: 10.1016/j.amjmed.2008.06.034] [Cited by in Crossref: 74] [Cited by in F6Publishing: 78] [Article Influence: 4.9] [Reference Citation Analysis]
|
| 409 |
Jones J, Loftus EV Jr, Panaccione R, Chen LS, Peterson S, McConnell J, Baudhuin L, Hanson K, Feagan BG, Harmsen SW, Zinsmeister AR, Helou E, Sandborn WJ. Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease. Clin Gastroenterol Hepatol 2008;6:1218-24. [PMID: 18799360 DOI: 10.1016/j.cgh.2008.06.010] [Cited by in Crossref: 298] [Cited by in F6Publishing: 308] [Article Influence: 19.9] [Reference Citation Analysis]
|
| 410 |
Lakatos PL. Genetics, Immunology and biomarkers in clinical practice: do they assist in clinical management? Pathogenesis and Clinical Practice in Gastroenterology. [DOI: 10.1007/978-1-4020-8767-7_6] [Reference Citation Analysis]
|
| 411 |
Amati L, Passeri M, Selicato F, Mastronardi M, Penna A, Jirillo E, Covelli V. New Insights into the Biological and Clinical Significance of Fecal Calprotectin in Inflammatory Bowel Disease. Immunopharmacology and Immunotoxicology 2008;28:665-81. [DOI: 10.1080/08923970601067326] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 412 |
Maiden L, Takeuchi K, Baur R, Bjarnason I, O'Donohue J, Forgacs I, Chung-Faye G, Sanderson J, Bjarnason I. Selective white cell apheresis reduces relapse rates in patients with IBD at significant risk of clinical relapse. Inflamm Bowel Dis 2008;14:1413-8. [PMID: 18521900 DOI: 10.1002/ibd.20505] [Cited by in Crossref: 40] [Cited by in F6Publishing: 42] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 413 |
Vogelsang H. Do changes in intestinal permeability predict disease relapse in Crohn's disease? Inflamm Bowel Dis 2008;14 Suppl 2:S162-3. [PMID: 18816766 DOI: 10.1002/ibd.20617] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 414 |
Sipponen T, Savilahti E, Kärkkäinen P, Kolho KL, Nuutinen H, Turunen U, Färkkilä M. Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti-TNF-alpha therapy for Crohn's disease. Inflamm Bowel Dis 2008;14:1392-8. [PMID: 18484671 DOI: 10.1002/ibd.20490] [Cited by in Crossref: 170] [Cited by in F6Publishing: 145] [Article Influence: 11.3] [Reference Citation Analysis]
|
| 415 |
Foell D, Wittkowski H, Ren Z, Turton J, Pang G, Daebritz J, Ehrchen J, Heidemann J, Borody T, Roth J, Clancy R. Phagocyte-specific S100 proteins are released from affected mucosa and promote immune responses during inflammatory bowel disease. J Pathol 2008;216:183-92. [DOI: 10.1002/path.2394] [Cited by in Crossref: 121] [Cited by in F6Publishing: 125] [Article Influence: 8.1] [Reference Citation Analysis]
|
| 416 |
Damms A, Bischoff SC. Validation and clinical significance of a new calprotectin rapid test for the diagnosis of gastrointestinal diseases. Int J Colorectal Dis 2008;23:985-92. [PMID: 18629518 DOI: 10.1007/s00384-008-0506-0] [Cited by in Crossref: 50] [Cited by in F6Publishing: 58] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 417 |
Vestergaard TA, Nielsen SL, Dahlerup JF, Hornung N. Fecal calprotectin: assessment of a rapid test. Scand J Clin Lab Invest 2008;68:343-7. [PMID: 17852834 DOI: 10.1080/00365510701576198] [Cited by in Crossref: 26] [Cited by in F6Publishing: 30] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 418 |
Wagner M, Peterson CG, Ridefelt P, Sangfelt P, Carlson M. Fecal markers of inflammation used as surrogate markers for treatment outcome in relapsing inflammatory bowel disease. World J Gastroenterol 2008; 14(36): 5584-5589 [PMID: 18810778 DOI: 10.3748/wjg.14.5584] [Cited by in CrossRef: 100] [Cited by in F6Publishing: 113] [Article Influence: 6.7] [Reference Citation Analysis]
|
| 419 |
Grip O, Janciauskiene S, Bredberg A. Use of atorvastatin as an anti-inflammatory treatment in Crohn's disease. Br J Pharmacol 2008;155:1085-92. [PMID: 18806816 DOI: 10.1038/bjp.2008.369] [Cited by in Crossref: 48] [Cited by in F6Publishing: 53] [Article Influence: 3.2] [Reference Citation Analysis]
|
| 420 |
Heilmann R, Suchodolski J, Steiner J. Purification and partial characterization of canine calprotectin. Biochimie 2008;90:1306-15. [DOI: 10.1016/j.biochi.2008.03.008] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 421 |
Diamanti A, Colistro F, Basso MS, Papadatou B, Francalanci P, Bracci F, Muraca M, Knafelz D, De Angelis P, Castro M. Clinical role of calprotectin assay in determining histological relapses in children affected by inflammatory bowel diseases. Inflamm Bowel Dis 2008;14:1229-35. [PMID: 18398894 DOI: 10.1002/ibd.20472] [Cited by in Crossref: 52] [Cited by in F6Publishing: 50] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 422 |
Tanaka T, Okanobu H, Yoshimi S, Murakami E, Kogame A, Imagawa H, Numata Y, Kuga Y, Moriya T, Ohya T, Kajiyama G. In patients with ulcerative colitis, adsorptive depletion of granulocytes and monocytes impacts mucosal level of neutrophils and clinically is most effective in steroid naïve patients. Dig Liver Dis 2008;40:731-6. [PMID: 18387860 DOI: 10.1016/j.dld.2008.02.012] [Cited by in Crossref: 49] [Cited by in F6Publishing: 52] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 423 |
D'Incà R, Dal Pont E, Di Leo V, Benazzato L, Martinato M, Lamboglia F, Oliva L, Sturniolo GC. Can calprotectin predict relapse risk in inflammatory bowel disease? Am J Gastroenterol 2008;103:2007-14. [PMID: 18802997 DOI: 10.1111/j.1572-0241.2008.01870.x] [Cited by in Crossref: 139] [Cited by in F6Publishing: 140] [Article Influence: 9.3] [Reference Citation Analysis]
|
| 424 |
Sutherland AD, Gearry RB, Frizelle FA. Review of fecal biomarkers in inflammatory bowel disease. Dis Colon Rectum 2008;51:1283-91. [PMID: 18543035 DOI: 10.1007/s10350-008-9310-8] [Cited by in Crossref: 72] [Cited by in F6Publishing: 76] [Article Influence: 4.8] [Reference Citation Analysis]
|
| 425 |
Sigurbjörnsson FT, Bjarnason I. Leukocytapheresis for the treatment of IBD. Nat Clin Pract Gastroenterol Hepatol. 2008;5:509-516. [PMID: 18665138 DOI: 10.1038/ncpgasthep1209] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 426 |
Hanai H. Leucocytapheresis for inflammatory bowel disease in the era of biologic therapy. Eur J Gastroenterol Hepatol 2008;20:596-600. [PMID: 18679059 DOI: 10.1097/MEG.0b013e3282f5e9f3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 427 |
Biancone L, Onali S, Calabrese E, Petruzziello C, Zorzi F, Condino G, Sica GS, Pallone F. Non-invasive techniques for assessing postoperative recurrence in Crohn's disease. Dig Liver Dis 2008;40 Suppl 2:S265-70. [PMID: 18598999 DOI: 10.1016/S1590-8658(08)60536-8] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 428 |
Canani RB, Terrin G, Rapacciuolo L, Miele E, Siani MC, Puzone C, Cosenza L, Staiano A, Troncone R. Faecal calprotectin as reliable non-invasive marker to assess the severity of mucosal inflammation in children with inflammatory bowel disease. Dig Liver Dis 2008;40:547-53. [PMID: 18358796 DOI: 10.1016/j.dld.2008.01.017] [Cited by in Crossref: 123] [Cited by in F6Publishing: 121] [Article Influence: 8.2] [Reference Citation Analysis]
|
| 429 |
Hanai H, Iida T, Takeuchi K, Watanabe F, Maruyama Y, Kageoka M, Ikeya K, Yamada M, Kikuyama M, Iwaoka Y, Hirayama K, Nagata S, Sato Y, Hosoda Y. Intensive granulocyte and monocyte adsorption versus intravenous prednisolone in patients with severe ulcerative colitis: an unblinded randomised multi-centre controlled study. Dig Liver Dis 2008;40:433-40. [PMID: 18296130 DOI: 10.1016/j.dld.2008.01.007] [Cited by in Crossref: 32] [Cited by in F6Publishing: 35] [Article Influence: 2.1] [Reference Citation Analysis]
|
| 430 |
Karoui S, Serghini M, Boubaker J, Filali A. Moyens d’évaluation de l’activité au cours de la maladie de Crohn : acquis et perspectives. J Afr Hepato Gastroenterol 2008;2:13-17. [DOI: 10.1007/s12157-008-0036-y] [Reference Citation Analysis]
|
| 431 |
Loganayagam A, Bjarnason I. Stool tests: are they useful? Falk Symposium. [DOI: 10.1007/978-1-4020-6987-1_14] [Reference Citation Analysis]
|
| 432 |
Simondi D, Mengozzi G, Betteto S, Bonardi R, Ghignone RP, Fagoonee S, Pellicano R, Sguazzini C, Pagni R, Rizzetto M, Astegiano M. Antiglycan antibodies as serological markers in the differential diagnosis of inflammatory bowel disease. Inflamm Bowel Dis 2008;14:645-51. [PMID: 18240283 DOI: 10.1002/ibd.20368] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 433 |
Walkiewicz D, Werlin SL, Fish D, Scanlon M, Hanaway P, Kugathasan S. Fecal calprotectin is useful in predicting disease relapse in pediatric inflammatory bowel disease. Inflamm Bowel Dis 2008;14:669-73. [PMID: 18240279 DOI: 10.1002/ibd.20376] [Cited by in Crossref: 99] [Cited by in F6Publishing: 77] [Article Influence: 6.6] [Reference Citation Analysis]
|
| 434 |
De Schepper HU, De Man JG, Moreels TG, Pelckmans PA, De Winter BY. Review article: gastrointestinal sensory and motor disturbances in inflammatory bowel disease - clinical relevance and pathophysiological mechanisms. Aliment Pharmacol Ther 2008;27:621-37. [PMID: 18221407 DOI: 10.1111/j.1365-2036.2008.03624.x] [Cited by in Crossref: 44] [Cited by in F6Publishing: 41] [Article Influence: 2.9] [Reference Citation Analysis]
|
| 435 |
Swee M, Wilson CL, Wang Y, McGuire JK, Parks WC. Matrix metalloproteinase-7 (matrilysin) controls neutrophil egress by generating chemokine gradients. J Leukoc Biol 2008;83:1404-12. [PMID: 18334539 DOI: 10.1189/jlb.0108016] [Cited by in Crossref: 51] [Cited by in F6Publishing: 54] [Article Influence: 3.4] [Reference Citation Analysis]
|
| 436 |
Lewis JD, Lichtenstein GR, Deren JJ, Sands BE, Hanauer SB, Katz JA, Lashner B, Present DH, Chuai S, Ellenberg JH, Nessel L, Wu GD; Rosiglitazone for Ulcerative Colitis Study Group. Rosiglitazone for active ulcerative colitis: a randomized placebo-controlled trial. Gastroenterology 2008;134:688-95. [PMID: 18325386 DOI: 10.1053/j.gastro.2007.12.012] [Cited by in Crossref: 158] [Cited by in F6Publishing: 173] [Article Influence: 10.5] [Reference Citation Analysis]
|
| 437 |
Johnson MW, Maestranzi S, Duffy AM, Dewar DH, Forbes A, Bjarnason I, Sherwood RA, Ciclitira P, Nicholls JR. Faecal calprotectin: a noninvasive diagnostic tool and marker of severity in pouchitis. Eur J Gastroenterol Hepatol 2008;20:174-9. [PMID: 18301296 DOI: 10.1097/MEG.0b013e3282f1c9a7] [Cited by in Crossref: 63] [Cited by in F6Publishing: 58] [Article Influence: 4.2] [Reference Citation Analysis]
|
| 438 |
Xiang JY, Ouyang Q, Li GD, Xiao NP. Clinical value of fecal calprotectin in determining disease activity of ulcerative colitis. World J Gastroenterol 2008; 14(1): 53-57 [PMID: 18176961 DOI: 10.3748/wjg.14.53] [Cited by in CrossRef: 73] [Cited by in F6Publishing: 79] [Article Influence: 4.9] [Reference Citation Analysis]
|
| 439 |
Sipponen T, Savilahti E, Kolho KL, Nuutinen H, Turunen U, Färkkilä M. Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings. Inflamm Bowel Dis 2008;14:40-6. [PMID: 18022866 DOI: 10.1002/ibd.20312] [Cited by in Crossref: 326] [Cited by in F6Publishing: 268] [Article Influence: 21.7] [Reference Citation Analysis]
|
| 440 |
Matsumoto T, Fukunaga K, Kamikozuru K, Tozawa K, Yokoyama Y, Kusaka T, Onishi K, Miwa H, Nakamura S. Cytapheresis as a Non-Pharmacological Therapy for Inflammatory Bowel Disease. Transfus Med Hemother. 2008;35:18-23. [PMID: 21547106 DOI: 10.1159/000111763] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 441 |
Brooks AJ, Begg EJ, Zhang M, Frampton CM, Barclay ML. Red blood cell methotrexate polyglutamate concentrations in inflammatory bowel disease. Ther Drug Monit. 2007;29:619-625. [PMID: 17898653 DOI: 10.1097/ftd.0b013e31811f39bb] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 442 |
Kaiser T, Langhorst J, Wittkowski H, Becker K, Friedrich AW, Rueffer A, Dobos GJ, Roth J, Foell D. Faecal S100A12 as a non-invasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome. Gut 2007;56:1706-13. [PMID: 17675327 DOI: 10.1136/gut.2006.113431] [Cited by in Crossref: 143] [Cited by in F6Publishing: 154] [Article Influence: 8.9] [Reference Citation Analysis]
|
| 443 |
Shitrit AB, Braverman D, Stankiewics H, Shitrit D, Peled N, Paz K. Fecal calprotectin as a predictor of abnormal colonic histology. Dis Colon Rectum 2007;50:2188-93. [PMID: 17963005 DOI: 10.1007/s10350-007-9038-x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 444 |
Nikolaus S, Schreiber S. Diagnostics of inflammatory bowel disease. Gastroenterology 2007;133:1670-89. [PMID: 17983810 DOI: 10.1053/j.gastro.2007.09.001] [Cited by in Crossref: 282] [Cited by in F6Publishing: 292] [Article Influence: 17.6] [Reference Citation Analysis]
|
| 445 |
Leach ST, Yang Z, Messina I, Song C, Geczy CL, Cunningham AM, Day AS. Serum and mucosal S100 proteins, calprotectin (S100A8/S100A9) and S100A12, are elevated at diagnosis in children with inflammatory bowel disease. Scand J Gastroenterol 2007;42:1321-31. [PMID: 17852869 DOI: 10.1080/00365520701416709] [Cited by in Crossref: 127] [Cited by in F6Publishing: 132] [Article Influence: 7.9] [Reference Citation Analysis]
|
| 446 |
Abreu MT, Plevy S, Sands BE, Weinstein R. Selective leukocyte apheresis for the treatment of inflammatory bowel disease. J Clin Gastroenterol 2007;41:874-88. [PMID: 18090155 DOI: 10.1097/MCG.0b013e3180479435] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 447 |
Saniabadi AR, Hanai H, Fukunaga K, Sawada K, Shima C, Bjarnason I, Lofberg R. Therapeutic leukocytapheresis for inflammatory bowel disease. Transfus Apher Sci. 2007;37:191-200. [PMID: 17974479 DOI: 10.1016/j.transci.2007.08.003] [Cited by in Crossref: 66] [Cited by in F6Publishing: 68] [Article Influence: 4.1] [Reference Citation Analysis]
|
| 448 |
Yokoyama Y, Fukunaga K, Fukuda Y, Tozawa K, Kamikozuru K, Ohnishi K, Kusaka T, Kosaka T, Hida N, Ohda Y, Miwa H, Matsumoto T. Demonstration of low-regulatory CD25High+CD4+ and high-pro-inflammatory CD28-CD4+ T-Cell subsets in patients with ulcerative colitis: modified by selective granulocyte and monocyte adsorption apheresis. Dig Dis Sci 2007;52:2725-31. [PMID: 17404876 DOI: 10.1007/s10620-006-9560-z] [Cited by in Crossref: 53] [Cited by in F6Publishing: 50] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 449 |
Biancone L, Calabrese E, Petruzziello C, Onali S, Caruso A, Palmieri G, Sica GS, Pallone F. Wireless capsule endoscopy and small intestine contrast ultrasonography in recurrence of Crohn's disease. Inflamm Bowel Dis 2007;13:1256-65. [PMID: 17577246 DOI: 10.1002/ibd.20199] [Cited by in Crossref: 89] [Cited by in F6Publishing: 71] [Article Influence: 5.6] [Reference Citation Analysis]
|
| 450 |
Schoepfer AM, Trummler M, Seeholzer P, Criblez DH, Seibold F. Accuracy of four fecal assays in the diagnosis of colitis. Dis Colon Rectum 2007;50:1697-706. [PMID: 17762964 DOI: 10.1007/s10350-007-0303-9] [Cited by in Crossref: 66] [Cited by in F6Publishing: 73] [Article Influence: 4.1] [Reference Citation Analysis]
|
| 451 |
Fagerberg UL, Lööf L, Lindholm J, Hansson LO, Finkel Y. Fecal calprotectin: a quantitative marker of colonic inflammation in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2007;45:414-20. [PMID: 18030206 DOI: 10.1097/MPG.0b013e31810e75a9] [Cited by in Crossref: 86] [Cited by in F6Publishing: 87] [Article Influence: 5.4] [Reference Citation Analysis]
|
| 452 |
Sasaki M, Sitaraman SV, Babbin BA, Gerner-Smidt P, Ribot EM, Garrett N, Alpern JA, Akyildiz A, Theiss AL, Nusrat A, Klapproth JM. Invasive Escherichia coli are a feature of Crohn's disease. Lab Invest 2007;87:1042-54. [PMID: 17660846 DOI: 10.1038/labinvest.3700661] [Cited by in Crossref: 171] [Cited by in F6Publishing: 182] [Article Influence: 10.7] [Reference Citation Analysis]
|
| 453 |
Denis MA, Reenaers C, Fontaine F, Belaïche J, Louis E. Assessment of endoscopic activity index and biological inflammatory markers in clinically active Crohn's disease with normal C-reactive protein serum level. Inflamm Bowel Dis 2007;13:1100-5. [PMID: 17508418 DOI: 10.1002/ibd.20178] [Cited by in Crossref: 81] [Cited by in F6Publishing: 68] [Article Influence: 5.1] [Reference Citation Analysis]
|
| 454 |
Sudan D, Vargas L, Sun Y, Bok L, Dijkstra G, Langnas A. Calprotectin: a novel noninvasive marker for intestinal allograft monitoring. Ann Surg 2007;246:311-5. [PMID: 17667511 DOI: 10.1097/SLA.0b013e3180f61af4] [Cited by in Crossref: 62] [Cited by in F6Publishing: 64] [Article Influence: 3.9] [Reference Citation Analysis]
|
| 455 |
Irving PM, Gearry RB, Sparrow MP, Gibson PR. Review article: appropriate use of corticosteroids in Crohn's disease. Aliment Pharmacol Ther 2007;26:313-29. [PMID: 17635367 DOI: 10.1111/j.1365-2036.2007.03379.x] [Cited by in Crossref: 62] [Cited by in F6Publishing: 45] [Article Influence: 3.9] [Reference Citation Analysis]
|
| 456 |
Yamamoto T, Saniabadi AR, Maruyama Y, Umegae S, Matsumoto K. Factors affecting clinical and endoscopic efficacies of selective leucocytapheresis for ulcerative colitis. Dig Liver Dis 2007;39:626-33. [PMID: 17532273 DOI: 10.1016/j.dld.2007.04.007] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 457 |
Aoki H, Nakamura K, Yoshimatsu Y, Tsuda Y, Irie M, Fukuda K, Hosoe N, Takada N, Shirai K, Suzuki Y. Adacolumn selective leukocyte adsorption apheresis in patients with active ulcerative colitis: clinical efficacy, effects on plasma IL-8, and expression of Toll-like receptor 2 on granulocytes. Dig Dis Sci 2007;52:1427-33. [PMID: 17394078 DOI: 10.1007/s10620-006-9406-8] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 458 |
Gisbert JP, González-Lama Y, Maté J. [Role of biological markers in inflammatory bowel disease]. Gastroenterol Hepatol. 2007;30:117-129. [PMID: 17374324 DOI: 10.1157/13100073] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 459 |
Casellas F, Borruel N, Torrejón A, Varela E, Antolin M, Guarner F, Malagelada JR. Oral oligofructose-enriched inulin supplementation in acute ulcerative colitis is well tolerated and associated with lowered faecal calprotectin. Aliment Pharmacol Ther 2007;25:1061-7. [PMID: 17439507 DOI: 10.1111/j.1365-2036.2007.03288.x] [Cited by in Crossref: 166] [Cited by in F6Publishing: 157] [Article Influence: 10.4] [Reference Citation Analysis]
|
| 460 |
Vermeire S. Do biomarkers help to optimize therapy in inflammatory bowel disease? Immunoregulation in Inflammatory Bowel Diseases — Current Understanding and Innovation. [DOI: 10.1007/978-1-4020-5889-9_7] [Reference Citation Analysis]
|
| 461 |
Ljung T, Axelsson LG, Herulf M, Lundberg JO, Hellström PM. Early changes in rectal nitric oxide and mucosal inflammatory mediators in Crohn's colitis in response to infliximab treatment. Aliment Pharmacol Ther 2007;25:925-32. [PMID: 17402996 DOI: 10.1111/j.1365-2036.2007.03284.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 462 |
Miele E, Pascarella F, Quaglietta L, Giannetti E, Greco L, Troncone R, Staiano A. Altered intestinal permeability is predictive of early relapse in children with steroid-responsive ulcerative colitis. Aliment Pharmacol Ther 2007;25:933-9. [PMID: 17402997 DOI: 10.1111/j.1365-2036.2007.03291.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 463 |
Casellas F, Borruel N, Antolín M, Varela E, Torrejón A, Armadans L, Guarner F, Malagelada JR. Fecal excretion of deoxyribonucleic acid in long-term follow-up of patients with inactive ulcerative colitis. Inflamm Bowel Dis 2007;13:386-90. [PMID: 17206700 DOI: 10.1002/ibd.20042] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 464 |
Luis Cabriada-nuño J, Bernal-martínez A, Hernández-martín A, Antonio Arévalo-serna J, Fernández-prado E. Aféresis leucocitaria en la inducción de la remisión y retirada de corticoides en la colitis ulcerosa corticodependiente. Diálisis y Trasplante 2007;28:47-55. [DOI: 10.1016/s1886-2845(07)71352-8] [Reference Citation Analysis]
|
| 465 |
von Roon AC, Karamountzos L, Purkayastha S, Reese GE, Darzi AW, Teare JP, Paraskeva P, Tekkis PP. Diagnostic precision of fecal calprotectin for inflammatory bowel disease and colorectal malignancy. Am J Gastroenterol 2007;102:803-13. [PMID: 17324124 DOI: 10.1111/j.1572-0241.2007.01126.x] [Cited by in Crossref: 263] [Cited by in F6Publishing: 267] [Article Influence: 16.4] [Reference Citation Analysis]
|
| 466 |
D'Incà R, Dal Pont E, Di Leo V, Ferronato A, Fries W, Vettorato MG, Martines D, Sturniolo GC. Calprotectin and lactoferrin in the assessment of intestinal inflammation and organic disease. Int J Colorectal Dis 2007;22:429-37. [PMID: 16838143 DOI: 10.1007/s00384-006-0159-9] [Cited by in Crossref: 144] [Cited by in F6Publishing: 157] [Article Influence: 9.0] [Reference Citation Analysis]
|
| 467 |
Bjarnason I, Maiden L, Takeuchi K. Testing the gut and its function — faecal samples — breath tests and more? Falk Symposium. [DOI: 10.1007/1-4020-2916-0_24] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 468 |
Desai D, Faubion WA, Sandborn WJ. Review article: biological activity markers in inflammatory bowel disease. Aliment Pharmacol Ther 2007;25:247-55. [PMID: 17217454 DOI: 10.1111/j.1365-2036.2006.03184.x] [Cited by in Crossref: 103] [Cited by in F6Publishing: 81] [Article Influence: 6.4] [Reference Citation Analysis]
|
| 469 |
Costa F, Mumolo MG, Marchi S, Bellini M. Differential diagnosis between functional and organic intestinal disorders: Is there a role for non-invasive tests? World J Gastroenterol 2007; 13(2): 219-223 [PMID: 17226899 DOI: 10.3748/wjg.v13.i2.219] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 470 |
Montalto M, Curigliano V, Santoro L, Armuzzi A, Cammarota G, Covino M, Mentella MC, Ancarani F, Manna R, Gasbarrini A, Gasbarrini G. Fecal calprotectin in first-degree relatives of patients with ulcerative colitis. Am J Gastroenterol 2007;102:132-6. [PMID: 17100982 DOI: 10.1111/j.1572-0241.2006.00884.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 471 |
Bürk G, Burdelski M, Hemprich A, Kappler M, Lükewille U. Verdauungstrakt. Therapie in der Kinder- und Jugendmedizin 2007. [DOI: 10.1016/b978-343723200-8.50032-9] [Reference Citation Analysis]
|
| 472 |
Hanai H. Positions of selective leukocytapheresis in the medical therapy of ulcerative colitis. World J Gastroenterol 2006; 12(47): 7568-7577 [PMID: 17171783 DOI: 10.3748/wjg.v12.i47.7568] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 38] [Article Influence: 1.9] [Reference Citation Analysis]
|
| 473 |
Meuwis MA, Fillet M, Geurts P, de Seny D, Lutteri L, Chapelle JP, Bours V, Wehenkel L, Belaiche J, Malaise M. Biomarker discovery for inflammatory bowel disease, using proteomic serum profiling. Biochem Pharmacol. 2007;73:1422-1433. [PMID: 17258689 DOI: 10.1016/j.bcp.2006.12.019] [Cited by in Crossref: 79] [Cited by in F6Publishing: 88] [Article Influence: 4.6] [Reference Citation Analysis]
|
| 474 |
Nishio Y, Ando T, Maeda O, Ishiguro K, Watanabe O, Ohmiya N, Niwa Y, Kusugami K, Goto H. Pit patterns in rectal mucosa assessed by magnifying colonoscope are predictive of relapse in patients with quiescent ulcerative colitis. Gut 2006;55:1768-73. [PMID: 16682428 DOI: 10.1136/gut.2005.086900] [Cited by in Crossref: 54] [Cited by in F6Publishing: 55] [Article Influence: 3.2] [Reference Citation Analysis]
|
| 475 |
Suzuki Y, Yoshimura N, Fukuda K, Shirai K, Saito Y, Saniabadi AR. A retrospective search for predictors of clinical response to selective granulocyte and monocyte apheresis in patients with ulcerative colitis. Dig Dis Sci 2006;51:2031-8. [PMID: 17004123 DOI: 10.1007/s10620-006-9199-9] [Cited by in Crossref: 47] [Cited by in F6Publishing: 40] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 476 |
Muratov V, Lundahl J, Ulfgren AK, Elvin K, Fehrman I, Ahlborg N, Ost A, Hittel N, Saniabadi A, Löfberg R. Down-regulation of interferon-gamma parallels clinical response to selective leukocyte apheresis in patients with inflammatory bowel disease: a 12-month follow-up study. Int J Colorectal Dis 2006;21:493-504. [PMID: 16538495 DOI: 10.1007/s00384-005-0069-2] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 477 |
Yamamoto T, Saniabadi AR, Umegae S, Matsumoto K. Impact of selective leukocytapheresis on mucosal inflammation and ulcerative colitis: cytokine profiles and endoscopic findings. Inflamm Bowel Dis 2006;12:719-26. [PMID: 16917227 DOI: 10.1097/00054725-200608000-00008] [Cited by in Crossref: 38] [Cited by in F6Publishing: 31] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 478 |
Sands BE, Sandborn WJ, Wolf DC, Katz S, Safdi M, Schwartz DA, Hanauer SB. Pilot feasibility studies of leukocytapheresis with the Adacolumn Apheresis System in patients with active ulcerative colitis or Crohn disease. J Clin Gastroenterol 2006;40:482-9. [PMID: 16825929 DOI: 10.1097/00004836-200607000-00005] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 479 |
Hanai H, Iida T, Yamada M, Sato Y, Takeuchi K, Tanaka T, Kondo K, Kikuyama M, Maruyama Y, Iwaoka Y, Nakamura A, Hirayama K, Saniabadi AR, Watanabe F. Effects of adacolumn selective leukocytapheresis on plasma cytokines during active disease in patients with active ulcerative colitis. World J Gastroenterol 2006; 12(21): 3393-3399 [PMID: 16733857 DOI: 10.3748/wjg.v12.i21.3393] [Cited by in CrossRef: 37] [Cited by in F6Publishing: 40] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 480 |
Ljung T, Lundberg S, Varsanyi M, Johansson C, Schmidt PT, Herulf M, Lundberg JO, Hellström PM. Rectal nitric oxide as biomarker in the treatment of inflammatory bowel disease: Responders versus nonresponders. World J Gastroenterol 2006; 12(21): 3386-3392 [PMID: 16733856 DOI: 10.3748/wjg.v12.i21.3386] [Cited by in CrossRef: 47] [Cited by in F6Publishing: 51] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 481 |
Konikoff MR, Denson LA. Role of fecal calprotectin as a biomarker of intestinal inflammation in inflammatory bowel disease. Inflamm Bowel Dis 2006;12:524-34. [PMID: 16775498 DOI: 10.1097/00054725-200606000-00013] [Cited by in Crossref: 290] [Cited by in F6Publishing: 286] [Article Influence: 17.1] [Reference Citation Analysis]
|
| 482 |
D'Ovidio V, Aratari A, Viscido A, Marcheggiano A, Papi C, Capurso L, Caprilli R. Mucosal features and granulocyte-monocyte-apheresis in steroid-dependent/refractory ulcerative colitis. Dig Liver Dis 2006;38:389-94. [PMID: 16569521 DOI: 10.1016/j.dld.2005.12.005] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 483 |
Borrelli O, Cordischi L, Cirulli M, Paganelli M, Labalestra V, Uccini S, Russo PM, Cucchiara S. Polymeric diet alone versus corticosteroids in the treatment of active pediatric Crohn's disease: a randomized controlled open-label trial. Clin Gastroenterol Hepatol 2006;4:744-53. [PMID: 16682258 DOI: 10.1016/j.cgh.2006.03.010] [Cited by in Crossref: 313] [Cited by in F6Publishing: 324] [Article Influence: 18.4] [Reference Citation Analysis]
|
| 484 |
Kanai T, Hibi T, Watanabe M. The logics of leukocytapheresis as a natural biological therapy for inflammatory bowel disease. Expert Opinion on Biological Therapy 2006;6:453-66. [DOI: 10.1517/14712598.6.5.453] [Cited by in Crossref: 35] [Cited by in F6Publishing: 37] [Article Influence: 2.1] [Reference Citation Analysis]
|
| 485 |
Greaves ML, Pochapin M. Asymptomatic Ileitis: Past, Present, and Future. Journal of Clinical Gastroenterology 2006;40:281-285. [DOI: 10.1097/01.mcg.0000210104.59370.66] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 486 |
Cabriada JL, Doménech E, Gomollón F, González-Carro P, González-Lara V, Hinojosa J, Jiménez-López CE, Nos P, Obrador A, Panès J, Saro C, Varea V, Lafuente R, Guilera M. [Consensus document on the use of granulocytapheresis in patients with inflammatory bowel disease]. Gastroenterol Hepatol 2006;29:85-92. [PMID: 16448611 DOI: 10.1157/13083905] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 487 |
Stange EF, Travis SP, Vermeire S, Beglinger C, Kupcinkas L, Geboes K, Barakauskiene A, Villanacci V, Von Herbay A, Warren BF, Gasche C, Tilg H, Schreiber SW, Schölmerich J, Reinisch W; European Crohn's and Colitis Organisation. European evidence based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. Gut 2006;55 Suppl 1:i1-15. [PMID: 16481628 DOI: 10.1136/gut.2005.081950a] [Cited by in Crossref: 388] [Cited by in F6Publishing: 449] [Article Influence: 22.8] [Reference Citation Analysis]
|
| 488 |
Schreiber S. Slipping the barrier: how variants in CARD15 could alter permeability of the intestinal wall and population health. Gut 2006;55:308-9. [PMID: 16474103 DOI: 10.1136/gut.2005.076075] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 489 |
Vermeire S, Van Assche G, Rutgeerts P. Laboratory markers in IBD: useful, magic, or unnecessary toys? Gut 2006;55:426-31. [PMID: 16474109 DOI: 10.1136/gut.2005.069476] [Cited by in Crossref: 597] [Cited by in F6Publishing: 626] [Article Influence: 35.1] [Reference Citation Analysis]
|
| 490 |
Weitzman G, Maltz C. What is in store for your Crohn's patient? J Clin Gastroenterol 2006;40:93-5. [PMID: 16394867 DOI: 10.1097/01.mcg.0000196456.84691.09] [Reference Citation Analysis]
|
| 491 |
Pineda AA. Developments in the apheresis procedure for the treatment of inflammatory bowel disease. Inflamm Bowel Dis 2006;12 Suppl 1:S10-4. [PMID: 16378005 DOI: 10.1097/01.mib.0000195386.19268.b3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 492 |
Canani RB, de Horatio LT, Terrin G, Romano MT, Miele E, Staiano A, Rapacciuolo L, Polito G, Bisesti V, Manguso F, Vallone G, Sodano A, Troncone R. Combined use of noninvasive tests is useful in the initial diagnostic approach to a child with suspected inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2006;42:9-15. [PMID: 16385247 DOI: 10.1097/01.mpg.0000187818.76954.9a] [Cited by in Crossref: 89] [Cited by in F6Publishing: 83] [Article Influence: 5.2] [Reference Citation Analysis]
|
| 493 |
Sandborn WJ. Preliminary data on the use of apheresis in inflammatory bowel disease. Inflamm Bowel Dis 2006;12 Suppl 1:S15-21. [PMID: 16378006 DOI: 10.1097/01.mib.0000195387.26892.22] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 494 |
Ma TY, Anderson JM. Tight Junctions and the Intestinal Barrier. Physiology of the Gastrointestinal Tract 2006. [DOI: 10.1016/b978-012088394-3/50064-7] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 495 |
Saniabadi AR, Hanai H, Suzuki Y, Ohmori T, Sawada K, Yoshimura N, Saito Y, Takeda Y, Umemura K, Kondo K, Ikeda Y, Fukunaga K, Nakashima M, Beretta A, Bjarnason I, Lofberg R. Adacolumn for selective leukocytapheresis as a non-pharmacological treatment for patients with disorders of the immune system: an adjunct or an alternative to drug therapy? J Clin Apher. 2005;20:171-184. [PMID: 15892107 DOI: 10.1002/jca.20046] [Cited by in Crossref: 78] [Cited by in F6Publishing: 86] [Article Influence: 4.3] [Reference Citation Analysis]
|
| 496 |
Willemsen LE, Hoetjes JP, van Deventer SJ, van Tol EA. Abrogation of IFN-gamma mediated epithelial barrier disruption by serine protease inhibition. Clin Exp Immunol. 2005;142:275-284. [PMID: 16232214 DOI: 10.1111/j.1365-2249.2005.02906.x] [Cited by in Crossref: 38] [Cited by in F6Publishing: 44] [Article Influence: 2.1] [Reference Citation Analysis]
|
| 497 |
Nagel E, Eser R. Dünndarm. Pichlmayrs Chirurgische Therapie. [DOI: 10.1007/3-540-29184-9_15] [Reference Citation Analysis]
|
| 498 |
Bremner A, Roked S, Robinson R, Phillips I, Beattie M. Faecal calprotectin in children with chronic gastrointestinal symptoms. Acta Paediatr 2005;94:1855-8. [PMID: 16421055 DOI: 10.1111/j.1651-2227.2005.tb01870.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 28] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 499 |
Langhorst J, Elsenbruch S, Mueller T, Rueffer A, Spahn G, Michalsen A, Dobos GJ. Comparison of 4 neutrophil-derived proteins in feces as indicators of disease activity in ulcerative colitis. Inflamm Bowel Dis 2005;11:1085-91. [PMID: 16306771 DOI: 10.1097/01.mib.0000187980.08686.18] [Cited by in Crossref: 95] [Cited by in F6Publishing: 91] [Article Influence: 5.3] [Reference Citation Analysis]
|
| 500 |
Lundberg JO, Hellström PM, Fagerhol MK, Weitzberg E, Roseth AG. Technology insight: calprotectin, lactoferrin and nitric oxide as novel markers of inflammatory bowel disease. Nat Clin Pract Gastroenterol Hepatol. 2005;2:96-102. [PMID: 16265127 DOI: 10.1038/ncpgasthep0094] [Cited by in Crossref: 52] [Cited by in F6Publishing: 56] [Article Influence: 2.9] [Reference Citation Analysis]
|
| 501 |
Loos BG, Tjoa S. Host-derived diagnostic markers for periodontitis: do they exist in gingival crevice fluid? Periodontol 2000 2005;39:53-72. [DOI: 10.1111/j.1600-0757.2005.00129.x] [Cited by in Crossref: 91] [Cited by in F6Publishing: 100] [Article Influence: 5.1] [Reference Citation Analysis]
|
| 502 |
Hanaway P, Roseth A. Inflammatory biomarkers predict relapse in IBD. Gut 2005;54:1346-7. [PMID: 16099806 DOI: 10.1136/gut.2005.070615] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 503 |
Matsushita M, Takakuwa H, Matsubayashi Y, Nishio A, Ikehara S, Okazaki K. Appendix is a priming site in the development of ulcerative colitis. World J Gastroenterol 2005; 11(31): 4869-4874 [PMID: 16097061 DOI: 10.3748/wjg.v11.i31.4869] [Cited by in CrossRef: 39] [Cited by in F6Publishing: 39] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 504 |
Loftus EV. ELEVATED FECAL CALPROTECTIN CONCENTRATIONS PREDICT ULCERATIVE COLITIS RELAPSE. Evidence-Based Gastroenterology 2005;6:87-88. [DOI: 10.1097/01.ebg.0000179720.12234.ae] [Reference Citation Analysis]
|
| 505 |
Markowitz J, Markowitz JE, Bousvaros A, Crandall W, Faubion W, Kirschner BS, Perrault J, Rosh J, Winter H. Workshop report: prevention of postoperative recurrence in Crohn's disease. J Pediatr Gastroenterol Nutr 2005;41:145-51. [PMID: 16056092 DOI: 10.1097/01.mpg.0000172746.86973.ef] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 506 |
Vespasiani Gentilucci U, Caviglia R, Picardi A, Carotti S, Ribolsi M, Galati G, Petitti T, Afeltra A, Cicala M. Infliximab reverses growth hormone resistance associated with inflammatory bowel disease. Aliment Pharmacol Ther 2005;21:1063-71. [PMID: 15854167 DOI: 10.1111/j.1365-2036.2005.02449.x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 25] [Article Influence: 1.9] [Reference Citation Analysis]
|
| 507 |
Fagerberg UL, Lööf L, Myrdal U, Hansson LO, Finkel Y. Colorectal inflammation is well predicted by fecal calprotectin in children with gastrointestinal symptoms. J Pediatr Gastroenterol Nutr 2005;40:450-5. [PMID: 15795593 DOI: 10.1097/01.mpg.0000154657.08994.94] [Cited by in Crossref: 101] [Cited by in F6Publishing: 94] [Article Influence: 5.6] [Reference Citation Analysis]
|
| 508 |
Sawada K, Egashira A, Ohnishi K, Fukunaga K, Kusaka T, Shimoyama T. Leukocytapheresis (LCAP) for management of fulminant ulcerative colitis with toxic megacolon. Dig Dis Sci 2005;50:767-73. [PMID: 15844716 DOI: 10.1007/s10620-005-2571-3] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 509 |
Pardi DS, Sandborn WJ. Predicting relapse in patients with inflammatory bowel disease: what is the role of biomarkers? Gut 2005;54:321-2. [PMID: 15710974 DOI: 10.1136/gut.2004.048850] [Cited by in Crossref: 27] [Cited by in F6Publishing: 33] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 510 |
Costa F, Mumolo MG, Ceccarelli L, Bellini M, Romano MR, Sterpi C, Ricchiuti A, Marchi S, Bottai M. Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease. Gut 2005;54:364-8. [PMID: 15710984 DOI: 10.1136/gut.2004.043406] [Cited by in Crossref: 383] [Cited by in F6Publishing: 417] [Article Influence: 21.3] [Reference Citation Analysis]
|
| 511 |
Foell D, Frosch M, Sorg C, Roth J. Phagocyte-specific calcium-binding S100 proteins as clinical laboratory markers of inflammation. Clin Chim Acta. 2004;344:37-51. [PMID: 15149869 DOI: 10.1016/j.cccn.2004.02.023] [Cited by in Crossref: 227] [Cited by in F6Publishing: 212] [Article Influence: 12.6] [Reference Citation Analysis]
|
| 512 |
Homann N, Klarmann U, Fellermann K, Brüning A, Klingenberg-Noftz R, Witthöft T, Stange EF, Ludwig D. Mesenteric pulsatility index analysis predicts response to azathioprine in patients with Crohn's disease. Inflamm Bowel Dis 2005;11:126-32. [PMID: 15677905 DOI: 10.1097/00054725-200502000-00005] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 513 |
Reimund JM, Bonaz B, Gompel M, Michot F, Moreau J, Veyrac M, Wagner Ballon J. [Induction and maintenance of remission in ulcerative colitis]. Gastroenterol Clin Biol 2004;28:992-1004. [PMID: 15672571 DOI: 10.1016/s0399-8320(04)95177-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 514 |
Plevy SE, Reguiero M. Autoimmunity – Inflammatory Bowel Disease. Measuring Immunity 2005. [DOI: 10.1016/b978-012455900-4/50308-1] [Reference Citation Analysis]
|
| 515 |
Kohno H, Mizuno M, Nasu J, Makidono C, Hiraoka S, Inaba T, Yamamoto K, Okada H, Fujita T, Shiratori Y. Stool decay-accelerating factor as a marker for monitoring the disease activity during leukocyte apheresis therapy in patients with refractory ulcerative colitis. J Gastroenterol Hepatol 2005;20:73-8. [PMID: 15610450 DOI: 10.1111/j.1440-1746.2004.03545.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 516 |
Hanai H, Watanabe F, Yamada M, Sato Y, Takeuchi K, Iida T, Tozawa K, Tanaka T, Maruyama Y, Matsushita I, Iwaoka Y, Kikuch K, Saniabadi AR. Adsorptive granulocyte and monocyte apheresis versus prednisolone in patients with corticosteroid-dependent moderately severe ulcerative colitis. Digestion 2004;70:36-44. [PMID: 15297776 DOI: 10.1159/000080079] [Cited by in Crossref: 104] [Cited by in F6Publishing: 111] [Article Influence: 5.5] [Reference Citation Analysis]
|
| 517 |
Kanke K, Nakano M, Hiraishi H, Terano A. Clinical evaluation of granulocyte/monocyte apheresis therapy for active ulcerative colitis. Dig Liver Dis 2004;36:811-7. [PMID: 15646427 DOI: 10.1016/j.dld.2004.08.004] [Cited by in Crossref: 75] [Cited by in F6Publishing: 73] [Article Influence: 3.9] [Reference Citation Analysis]
|
| 518 |
Johnson MW, Dewar DH, Ciclitira P, Forbes A, Nicholls RJ, Bjarnason I. Use of fecal lactoferrin to diagnose irritable pouch syndrome: a word of caution. Gastroenterology 2004;127:1647-8; author reply 1648. [PMID: 15521043 DOI: 10.1053/j.gastro.2004.09.069] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 519 |
Feagan BG. Endoscopic scoring system for Crohn's disease: viva the evolution! Gastrointest Endosc 2004;60:590-1. [PMID: 15472684 DOI: 10.1016/s0016-5107(04)01961-3] [Reference Citation Analysis]
|
| 520 |
Osterman MT, Lewis JD. The role and importance of endoscopic mucosal healing in ulcerative colitis. Techniques in Gastrointestinal Endoscopy 2004;6:144-153. [DOI: 10.1016/j.tgie.2004.09.002] [Reference Citation Analysis]
|
| 521 |
Røseth AG, Aadland E, Grzyb K. Normalization of faecal calprotectin: a predictor of mucosal healing in patients with inflammatory bowel disease. Scand J Gastroenterol 2004;39:1017-20. [PMID: 15513345 DOI: 10.1080/00365520410007971] [Cited by in Crossref: 189] [Cited by in F6Publishing: 199] [Article Influence: 9.9] [Reference Citation Analysis]
|
| 522 |
Dolwani S, Metzner M, Wassell JJ, Yong A, Hawthorne AB. Diagnostic accuracy of faecal calprotectin estimation in prediction of abnormal small bowel radiology. Aliment Pharmacol Ther 2004;20:615-21. [PMID: 15352909 DOI: 10.1111/j.1365-2036.2004.02128.x] [Cited by in Crossref: 63] [Cited by in F6Publishing: 52] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 523 |
Hanai H, Takeuchi K, Iida T, Kashiwagi N, Saniabadi AR, Matsushita I, Sato Y, Kasuga N, Nakamura T. Relationship between fecal calprotectin, intestinal inflammation, and peripheral blood neutrophils in patients with active ulcerative colitis. Dig Dis Sci 2004;49:1438-43. [PMID: 15481316 DOI: 10.1023/b:ddas.0000042243.47279.87] [Cited by in Crossref: 86] [Cited by in F6Publishing: 77] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 524 |
Bjarnason I, Takeuchi K, Bjarnason A, Adler SN, Teahon K. The G.U.T. of gut. Scandinavian Journal of Gastroenterology 2004;39:807-815. [DOI: 10.1080/00365520410003326] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 525 |
Hanai H, Watanabe F, Yamada M, Sato Y, Takeuchi K, Iida T, Tozawa K, Tanaka T, Maruyama Y, Matsushita I, Iwaoka Y, Saniabadi A. Correlation of serum soluble TNF-alpha receptors I and II levels with disease activity in patients with ulcerative colitis. Am J Gastroenterol 2004;99:1532-8. [PMID: 15307873 DOI: 10.1111/j.1572-0241.2004.30432.x] [Cited by in Crossref: 60] [Cited by in F6Publishing: 61] [Article Influence: 3.2] [Reference Citation Analysis]
|
| 526 |
Naganuma M, Funakoshi S, Sakuraba A, Takagi H, Inoue N, Ogata H, Iwao Y, Ishi H, Hibi T. Granulocytapheresis is useful as an alternative therapy in patients with steroid-refractory or -dependent ulcerative colitis. Inflamm Bowel Dis 2004;10:251-7. [PMID: 15290920 DOI: 10.1097/00054725-200405000-00012] [Cited by in Crossref: 97] [Cited by in F6Publishing: 81] [Article Influence: 5.1] [Reference Citation Analysis]
|
| 527 |
Canani RB, Romano MT, Greco L, Terrin G, Sferlazzas C, Barabino A, Fontana M, Roggero P, Guariso G, De Angelis G, Fecarotta S, Polito G, Cucchiara S. Effects of disease activity on anti-Saccharomyces cerevisiae antibodies: implications for diagnosis and follow-up of children with Crohn's disease. Inflamm Bowel Dis 2004;10:234-9. [PMID: 15290917 DOI: 10.1097/00054725-200405000-00009] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 528 |
Suzuki Y, Yoshimura N, Saniabadi AR, Saito Y. Selective granulocyte and monocyte adsorptive apheresis as a first-line treatment for steroid naïve patients with active ulcerative colitis: a prospective uncontrolled study. Dig Dis Sci 2004;49:565-71. [PMID: 15185858 DOI: 10.1023/b:ddas.0000026299.43792.ae] [Cited by in Crossref: 117] [Cited by in F6Publishing: 97] [Article Influence: 6.2] [Reference Citation Analysis]
|
| 529 |
Yamamoto T, Umegae S, Kitagawa T, Matsumoto K. Mucosal cytokine production during remission after resection for Crohn's disease and its relationship to future relapse. Aliment Pharmacol Ther 2004;19:671-8. [PMID: 15023169 DOI: 10.1111/j.1365-2036.2004.01899.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 530 |
Leal Berral J, Benita Len V, Gonzlez de Canales Simn P, Manzano Espinosa L. Colitis ulcerosa. Medicine - Programa de Formaci?n M?dica Continuada Acreditado 2004;9:349-357. [DOI: 10.1016/s0211-3449(04)70040-5] [Reference Citation Analysis]
|
| 531 |
Waetzig GH, Schreiber S. Mechanisms of infliximab: the reverse side of a drug effect. Inflamm Bowel Dis 2004;10 Suppl 1:S38-43. [PMID: 15168830 DOI: 10.1097/00054725-200402001-00009] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 532 |
Furrie E, Macfarlane S, Cummings JH, Macfarlane GT. Systemic antibodies towards mucosal bacteria in ulcerative colitis and Crohn's disease differentially activate the innate immune response. Gut 2004;53:91-8. [PMID: 14684582 DOI: 10.1136/gut.53.1.91] [Cited by in Crossref: 62] [Cited by in F6Publishing: 66] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 533 |
Brookes MJ, Green JRB. Maintenance of Remission in Crohn???s Disease: Current and Emerging Therapeutic Options. Drugs 2004;64:1069-89. [DOI: 10.2165/00003495-200464100-00004] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 534 |
Suzuki Y, Yoshimura N, Saitoh Y, Saniabadi AR. Granulocyte and monocyte adsorptive apheresis in a case with severe ulcerative colitis unresponsive to conventional medication. J Clin Apher 2003;18:40-2. [PMID: 12717793 DOI: 10.1002/jca.10048] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 535 |
Walker MM. Biopsy assessment of drug efficacy in the gastrointestinal tract. Br J Clin Pharmacol 2003;56:483-8. [PMID: 14651720 DOI: 10.1046/j.1365-2125.2003.01981.x] [Reference Citation Analysis]
|
| 536 |
Biancone L, Fiori R, Tosti C, Marinetti A, Catarinacci M, De Nigris F, Simonetti G, Pallone F. Virtual colonoscopy compared with conventional colonoscopy for stricturing postoperative recurrence in Crohn's disease. Inflamm Bowel Dis 2003;9:343-50. [PMID: 14671482 DOI: 10.1097/00054725-200311000-00001] [Cited by in Crossref: 38] [Cited by in F6Publishing: 26] [Article Influence: 1.9] [Reference Citation Analysis]
|
| 537 |
Carty E, Rampton DS. Evaluation of new therapies for inflammatory bowel disease. Br J Clin Pharmacol 2003;56:351-61. [PMID: 12968979 DOI: 10.1046/j.1365-2125.2003.01965.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 538 |
Limburg PJ, Devens ME, Harrington JJ, Diehl NN, Mahoney DW, Ahlquist DA. Prospective evaluation of fecal calprotectin as a screening biomarker for colorectal neoplasia. Am J Gastroenterol 2003;98:2299-305. [PMID: 14572583 DOI: 10.1111/j.1572-0241.2003.07630.x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 43] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 539 |
Costa F, Mumolo MG, Bellini M, Romano MR, Ceccarelli L, Arpe P, Sterpi C, Marchi S, Maltinti G. Role of faecal calprotectin as non-invasive marker of intestinal inflammation. Dig Liver Dis 2003;35:642-7. [PMID: 14563186 DOI: 10.1016/s1590-8658(03)00381-5] [Cited by in Crossref: 199] [Cited by in F6Publishing: 204] [Article Influence: 10.0] [Reference Citation Analysis]
|
| 540 |
Klebl FH, Bataille F, Bertea CR, Herfarth H, Hofstädter F, Schölmerich J, Rogler G. Association of perinuclear antineutrophil cytoplasmic antibodies and anti-Saccharomyces cerevisiae antibodies with Vienna classification subtypes of Crohn's disease. Inflamm Bowel Dis 2003;9:302-7. [PMID: 14555913 DOI: 10.1097/00054725-200309000-00003] [Cited by in Crossref: 42] [Cited by in F6Publishing: 38] [Article Influence: 2.1] [Reference Citation Analysis]
|
| 541 |
Wild GE, Waschke KA, Bitton A, Thomson AB. The mechanisms of prednisone inhibition of inflammation in Crohn's disease involve changes in intestinal permeability, mucosal TNFalpha production and nuclear factor kappa B expression. Aliment Pharmacol Ther 2003;18:309-17. [PMID: 12895215 DOI: 10.1046/j.1365-2036.2003.01611.x] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 1.9] [Reference Citation Analysis]
|
| 542 |
Poullis A, Foster R, Mendall MA, Fagerhol MK. Emerging role of calprotectin in gastroenterology. J Gastroenterol Hepatol 2003;18:756-62. [PMID: 12795745 DOI: 10.1046/j.1440-1746.2003.03014.x] [Cited by in Crossref: 78] [Cited by in F6Publishing: 83] [Article Influence: 3.9] [Reference Citation Analysis]
|
| 543 |
Thomas PD, Forbes A, Green J, Howdle P, Long R, Playford R, Sheridan M, Stevens R, Valori R, Walters J, Addison GM, Hill P, Brydon G. Guidelines for the investigation of chronic diarrhoea, 2nd edition. Gut 2003;52 Suppl 5:v1-15. [PMID: 12801941 DOI: 10.1136/gut.52.suppl_5.v1] [Cited by in Crossref: 150] [Cited by in F6Publishing: 162] [Article Influence: 7.5] [Reference Citation Analysis]
|
| 544 |
Sostegni R, Daperno M, Scaglione N, Lavagna A, Rocca R, Pera A. Review article: Crohn's disease: monitoring disease activity. Aliment Pharmacol Ther 2003;17 Suppl 2:11-7. [PMID: 12786607 DOI: 10.1046/j.1365-2036.17.s2.17.x] [Cited by in Crossref: 160] [Cited by in F6Publishing: 168] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 545 |
Biancone L, Tosti C, Fina D, Fantini M, De Nigris F, Geremia A, Pallone F. Review article: maintenance treatment of Crohn's disease. Aliment Pharmacol Ther 2003;17 Suppl 2:31-7. [PMID: 12786610 DOI: 10.1046/j.1365-2036.17.s2.20.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 546 |
Tamboli CP, Richard F, Colombel JF. Fecal calprotectin in Crohn's disease: new family ties. Gastroenterology 2003;124:1972-4. [PMID: 12806631 DOI: 10.1016/s0016-5085(03)00552-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 547 |
Thjodleifsson B, Sigthorsson G, Cariglia N, Reynisdottir I, Gudbjartsson DF, Kristjansson K, Meddings JB, Gudnason V, Wandall JH, Andersen LP, Sherwood R, Kjeld M, Oddsson E, Gudjonsson H, Bjarnason I. Subclinical intestinal inflammation: an inherited abnormality in Crohn's disease relatives? Gastroenterology 2003;124:1728-37. [PMID: 12806605 DOI: 10.1016/s0016-5085(03)00383-4] [Cited by in Crossref: 117] [Cited by in F6Publishing: 120] [Article Influence: 5.9] [Reference Citation Analysis]
|
| 548 |
Farhadi A, Banan A, Fields J, Keshavarzian A. Intestinal barrier: an interface between health and disease. J Gastroenterol Hepatol 2003;18:479-97. [PMID: 12702039 DOI: 10.1046/j.1440-1746.2003.03032.x] [Cited by in Crossref: 338] [Cited by in F6Publishing: 352] [Article Influence: 16.9] [Reference Citation Analysis]
|
| 549 |
Homann C, Christensen E, Schlichting P, Philipsen EK, Graudal NA, Garred P. Ascites fluid and plasma calprotectin concentrations in liver disease. Scand J Gastroenterol 2003;38:415-20. [PMID: 12739714 DOI: 10.1080/00365520310000870] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 550 |
Annovazzi A, Biancone L, Caviglia R, Chianelli M, Capriotti G, Mather SJ, Caprilli R, Pallone F, Scopinaro F, Signore A. 99mTc-interleukin-2 and (99m)Tc-HMPAO granulocyte scintigraphy in patients with inactive Crohn's disease. Eur J Nucl Med Mol Imaging 2003;30:374-82. [PMID: 12634965 DOI: 10.1007/s00259-002-1069-x] [Cited by in Crossref: 39] [Cited by in F6Publishing: 40] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 551 |
Biancone L, Fantini M, Tosti C, Bozzi R, Vavassori P, Pallone F. Fecal alpha 1-antitrypsin clearance as a marker of clinical relapse in patients with Crohn's disease of the distal ileum. Eur J Gastroenterol Hepatol 2003;15:261-6. [PMID: 12610321 DOI: 10.1097/00042737-200303000-00009] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 552 |
Herndon BL, Abbasi S, Bennett D, Bamberger D. Calcium-binding proteins MRP 8 and 14 in a Staphylococcus aureus infection model: role of therapy, inflammation, and infection persistence. J Lab Clin Med 2003;141:110-20. [PMID: 12577047 DOI: 10.1067/mlc.2003.17] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 553 |
Matsui T, Nishimura T, Matake H, Ohta T, Sakurai T, Yao T. Granulocytapheresis for Crohn's disease: a report on seven refractory patients. Am J Gastroenterol 2003;98:511-2. [PMID: 12591086 DOI: 10.1111/j.1572-0241.2003.07251.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 20] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 554 |
Sawada K, Ohnishi K, Fukunaga K, Shimoyama T. A new treatment for HCV-ulcerative colitis comorbidity intolerant to INF-alpha. Am J Gastroenterol 2003;98:228-9. [PMID: 12526978 DOI: 10.1111/j.1572-0241.2003.07193.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 555 |
Loonen HJ, Griffiths AM, Merkus MP, Derkx HH. A critical assessment of items on the Pediatric Crohn's Disease Activity Index. J Pediatr Gastroenterol Nutr 2003;36:90-5. [PMID: 12500002 DOI: 10.1097/00005176-200301000-00017] [Cited by in Crossref: 59] [Cited by in F6Publishing: 61] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 556 |
Hanai H, Watanabe F, Takeuchi K, Iida T, Yamada M, Iwaoka Y, Saniabadi A, Matsushita I, Sato Y, Tozawa K, Arai H, Furuta T, Sugimoto K, Bjarnason I. Leukocyte adsorptive apheresis for the treatment of active ulcerative colitis: a prospective, uncontrolled, pilot study. Clin Gastroenterol Hepatol 2003;1:28-35. [PMID: 15017514 DOI: 10.1053/jcgh.2003.50005] [Cited by in Crossref: 160] [Cited by in F6Publishing: 162] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 557 |
Thjodleifsson B, Davídsdóttir K, Agnarsson U, Sigthórsson G, Kjeld M, Bjarnason I. Effect of Pentavac and measles-mumps-rubella (MMR) vaccination on the intestine. Gut 2002;51:816-7. [PMID: 12427783 DOI: 10.1136/gut.51.6.816] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 558 |
Hanai H, Watanabe F, Saniabadi AR, Matsushitai I, Takeuchi K, Iida T. Therapeutic efficacy of granulocyte and monocyte adsorption apheresis in severe active ulcerative colitis. Dig Dis Sci 2002;47:2349-53. [PMID: 12395908 DOI: 10.1023/a:1020159932758] [Cited by in Crossref: 67] [Cited by in F6Publishing: 67] [Article Influence: 3.2] [Reference Citation Analysis]
|
| 559 |
Olafsdottir E, Aksnes L, Fluge G, Berstad A. Faecal calprotectin levels in infants with infantile colic, healthy infants, children with inflammatory bowel disease, children with recurrent abdominal pain and healthy children. Acta Paediatrica 2002;91:45-50. [DOI: 10.1111/j.1651-2227.2002.tb01638.x] [Cited by in Crossref: 132] [Cited by in F6Publishing: 132] [Article Influence: 6.3] [Reference Citation Analysis]
|
| 560 |
Tibble JA, Sigthorsson G, Foster R, Forgacs I, Bjarnason I. Use of surrogate markers of inflammation and Rome criteria to distinguish organic from nonorganic intestinal disease. Gastroenterology 2002;123:450-60. [PMID: 12145798 DOI: 10.1053/gast.2002.34755] [Cited by in Crossref: 294] [Cited by in F6Publishing: 313] [Article Influence: 14.0] [Reference Citation Analysis]
|
| 561 |
Aadland E, Fagerhol MK. Faecal calprotectin: a marker of inflammation throughout the intestinal tract. Eur J Gastroenterol Hepatol 2002;14:823-5. [PMID: 12172400 DOI: 10.1097/00042737-200208000-00002] [Cited by in Crossref: 67] [Cited by in F6Publishing: 71] [Article Influence: 3.2] [Reference Citation Analysis]
|
| 562 |
Biancone L, De Nigris F, Del Vecchio Blanco G, Monteleone I, Vavassori P, Geremia A, Pallone F. Review article: monitoring the activity of Crohn's disease. Aliment Pharmacol Ther 2002;16 Suppl 4:29-33. [PMID: 12047257 DOI: 10.1046/j.1365-2036.16.s4.18.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 563 |
Canani RB, Cirillo P, Bruzzese E, Graf M, Terrin G, Gaudiello G, De Curtis M, Cucchiara S, Guarino A. Nitric oxide production in rectal dialysate is a marker of disease activity and location in children with inflammatory bowel disease. Am J Gastroenterol 2002;97:1574-6. [PMID: 12094899 DOI: 10.1111/j.1572-0241.2002.05757.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 564 |
Arnott ID, Williams N, Drummond HE, Ghosh S. Whole gut lavage fluid interleukin-1beta and interleukin-8 in smokers and non-smokers with Crohn's disease in clinical remission. Dig Liver Dis 2002;34:424-9. [PMID: 12132790 DOI: 10.1016/s1590-8658(02)80040-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 565 |
Kashiwagi N, Sugimura K, Koiwai H, Yamamoto H, Yoshikawa T, Saniabadi AR, Adachi M, Shimoyama T. Immunomodulatory effects of granulocyte and monocyte adsorption apheresis as a treatment for patients with ulcerative colitis. Dig Dis Sci 2002;47:1334-41. [PMID: 12064810 DOI: 10.1023/a:1015330816364] [Cited by in Crossref: 127] [Cited by in F6Publishing: 130] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 566 |
Waetzig GH, Seegert D, Rosenstiel P, Nikolaus S, Schreiber S. p38 mitogen-activated protein kinase is activated and linked to TNF-alpha signaling in inflammatory bowel disease. J Immunol 2002;168:5342-51. [PMID: 11994493 DOI: 10.4049/jimmunol.168.10.5342] [Cited by in Crossref: 297] [Cited by in F6Publishing: 311] [Article Influence: 14.1] [Reference Citation Analysis]
|
| 567 |
Wakefield AJ. The gut-brain axis in childhood developmental disorders. J Pediatr Gastroenterol Nutr 2002;34 Suppl 1:S14-7. [PMID: 12082381 DOI: 10.1097/00005176-200205001-00004] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 568 |
Arnott ID, Watts D, Ghosh S. Review article: is clinical remission the optimum therapeutic goal in the treatment of Crohn's disease? Aliment Pharmacol Ther 2002;16:857-67. [PMID: 11966492 DOI: 10.1046/j.1365-2036.2002.01242.x] [Cited by in Crossref: 51] [Cited by in F6Publishing: 52] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 569 |
Demeo MT, Mutlu EA, Keshavarzian A, Tobin MC. Intestinal Permeation and Gastrointestinal Disease. Journal of Clinical Gastroenterology 2002;34:385-396. [DOI: 10.1097/00004836-200204000-00003] [Cited by in Crossref: 187] [Cited by in F6Publishing: 196] [Article Influence: 8.9] [Reference Citation Analysis]
|
| 570 |
Wakefield AJ, Puleston JM, Montgomery SM, Anthony A, O'Leary JJ, Murch SH. Review article: the concept of entero-colonic encephalopathy, autism and opioid receptor ligands. Aliment Pharmacol Ther 2002;16:663-74. [PMID: 11929383 DOI: 10.1046/j.1365-2036.2002.01206.x] [Cited by in Crossref: 62] [Cited by in F6Publishing: 63] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 571 |
Poullis A, Foster R, Northfield TC, Mendall MA. Review article: faecal markers in the assessment of activity in inflammatory bowel disease. Aliment Pharmacol Ther 2002;16:675-81. [PMID: 11929384 DOI: 10.1046/j.1365-2036.2002.01196.x] [Cited by in Crossref: 85] [Cited by in F6Publishing: 85] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 572 |
Kim S, Ferry G. Inflammatory bowel diseases in children. Curr Probl Pediatr Adolesc Health Care 2002;32:108-32. [PMID: 11981533 DOI: 10.1067/mps.2002.122638] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 573 |
Bjarnason I, Cederborg A, åkvist A, Smale S. Chapter 23 Intestinal barrier function. Biology of Growing Animals 2002. [DOI: 10.1016/s1877-1823(09)70139-0] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 574 |
Goodgame RW, Kimball K, Akram S, Ike E, Ou CN, Sutton F, Graham D. Randomized controlled trial of clarithromycin and ethambutol in the treatment of Crohn's disease. Aliment Pharmacol Ther 2001;15:1861-6. [PMID: 11736715 DOI: 10.1046/j.1365-2036.2001.01099.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 575 |
Nemetz A, Tóth M, García-González MA, Zágoni T, Fehér J, Peña AS, Tulassay Z. Allelic variation at the interleukin 1beta gene is associated with decreased bone mass in patients with inflammatory bowel diseases. Gut 2001;49:644-9. [PMID: 11600466 DOI: 10.1136/gut.49.5.644] [Cited by in Crossref: 45] [Cited by in F6Publishing: 50] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 576 |
Arnott ID, Drummond HE, Ghosh S. Frequency of continuing mucosal inflammation in clinically inactive Crohn's disease. Scott Med J 2001;46:136-9. [PMID: 11771492 DOI: 10.1177/003693300104600504] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 577 |
Tibble J, Bjarnason I. Non-invasive investigation of inflammatory bowel disease. World J Gastroenterol 2001; 7(4): 460-465 [PMID: 11819811 DOI: 10.3748/wjg.v7.i4.460] [Cited by in CrossRef: 115] [Cited by in F6Publishing: 119] [Article Influence: 5.2] [Reference Citation Analysis]
|
| 578 |
Wollheim FA. Enteropathic arthritis: how do the joints talk with the gut? Curr Opin Rheumatol 2001;13:305-9. [PMID: 11555733 DOI: 10.1097/00002281-200107000-00011] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 579 |
Shanahan F. Inflammatory bowel disease: immunodiagnostics, immunotherapeutics, and ecotherapeutics. Gastroenterology 2001;120:622-35. [PMID: 11179240 DOI: 10.1053/gast.2001.22122] [Cited by in Crossref: 252] [Cited by in F6Publishing: 266] [Article Influence: 11.5] [Reference Citation Analysis]
|
| 580 |
Fagerhol MK. Calprotectin, a faecal marker of organic gastrointestinal abnormality. Lancet 2000;356:1783-4. [PMID: 11117904 DOI: 10.1016/S0140-6736(00)03224-4] [Cited by in Crossref: 101] [Cited by in F6Publishing: 104] [Article Influence: 4.4] [Reference Citation Analysis]
|
| 581 |
Fixa B, Komárková O, Procházková J. Serum lysozyme in inflammatory gastric and enteric diseases and in functional dyspepsia. Scand J Gastroenterol 1983;18:349-52. [PMID: 6673061 DOI: 10.3109/00365528309181605] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 582 |
Bjarnason I, Bissoli F, Conforti A, Maiden L, Moore N, Moretti U, Rainsford K, Takeuchi K, Velo G. Adverse reactions and their mechanisms from nimesulide. In: Rainsford K, editor. Nimesulide — Actions and Uses. Basel: Birkhäuser-Verlag; 2005. pp. 315-415. [DOI: 10.1007/3-7643-7410-1_6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
|
| 583 |
Gasche C, Vermeire S. Laboratory tests — what do they tell us? In: Kruis W, Forbes A, Kreis ME, Jauch K-, Wexner SD, editors. Diverticular Disease: Emerging Evidence in a Common Condition. Dordrecht: Springer Netherlands; 2006. pp. 55-60. [DOI: 10.1007/1-4020-4318-x_7] [Cited by in Crossref: 2] [Reference Citation Analysis]
|
| 584 |
Gearry RB. Faecal testing in inflammatory bowel disease. In: Fraser A, Hibi T, Gibson PR, Oian J-, Schölmerich J, editors. Emerging Issues in Inflammatory Bowel Diseases. Dordrecht: Springer Netherlands; 2007. pp. 135-48. [DOI: 10.1007/978-1-4020-5702-1_15] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
